pathway_source,pathway,odds_ratio,p_value
k,B cell receptor signaling pathway,131.28920454545454,2.7167699088938223e-06
w,11p11.2 copy number variation syndrome ,124.07246376811594,0.0001536711802491824
w,T-cell receptor signaling,76.10177865612648,0.0003969551739825133
k,Staphylococcus aureus infection,72.78922495274102,0.00043288727819452695
w,B cell receptor signaling,70.4878718535469,0.0004608380223452507
w,Complement system,69.03272075302554,0.00047994796872217213
k,AGE-RAGE signaling pathway in diabetic complications,67.63636363636364,0.0004994382699108863
k,Leukocyte transendothelial migration,58.725400457665906,0.000657692837846609
k,T cell receptor signaling pathway,56.25429302155645,0.0007151594997909879
k,Thyroid hormone signaling pathway,55.78478260869565,0.0007269345373424088
k,Natural killer cell mediated cytotoxicity,51.48695652173913,0.0008498327570528766
w,Wnt signaling,50.705533596837945,0.0008755326033628513
w,Hepatitis B infection,44.61043478260869,0.0011235320106329997
k,Oxytocin signaling pathway,44.31442556867262,0.0011381874213260597
k,Hepatitis B,41.816847826086956,0.0012742197815568087
w,Chemokine signaling,40.794803817603395,0.0013370601243457194
k,Wnt signaling pathway,39.585284280936456,0.001417663904013752
k,Neutrophil extracellular trap formation,37.368957979111,0.0015856893910951638
k,Chemokine signaling pathway,35.387163561076605,0.0017627589696571362
k,Proteoglycans in cancer,33.43608695652174,0.001967915123645931
k,Human immunodeficiency virus 1 infection,32.30245746691872,0.0021040981157124565
r,Defective SLC35C1 causes congenital disorder of glycosylation 2C (CDG2C),535.3958333333334,0.0022668384278020097
k:w,Focal adhesion,30.668129238133226,0.0023268929242326675
k,Calcium signaling pathway,26.947755960729314,0.0029885993996635577
w,IL18 signaling,24.653296967752286,0.0035488019267582633
w,Physiopathology of endothelial dysfunction in coronavirus disease,292.0151515151515,0.0038829876462510575
w,Serotonin and anxiety-related events,267.6770833333333,0.004205915771527831
k,MAPK signaling pathway,22.563748531139836,0.004208948210507859
k:w,Human cytomegalovirus infection,20.670345941580294,0.0049809124050998925
w,Cells and molecules involved in local acute inflammatory response ,200.74739583333334,0.005496623544146111
w,Platelet-mediated interactions with vascular and circulating cells,200.74739583333334,0.005496623544146111
w,Serotonin and anxiety,200.74739583333334,0.005496623544146111
w,Ulcerative colitis signaling,188.93627450980392,0.0058190494549940595
r,Disinhibition of SNARE formation,178.4375,0.006141375012815678
w,Extracellular vesicles in the crosstalk of cardiac cells,152.9404761904762,0.007107749867411919
w,Vitamin D in inflammatory diseases,152.9404761904762,0.007107749867411919
w,Cancer immunotherapy by PD-1 blockade,145.98674242424244,0.007429674312374892
w,Physiological and pathological hypertrophy of the heart,139.63768115942028,0.007751498553892181
w,miR-targeted genes in muscle cell,16.3862835167183,0.007763392489085076
w,VEGFA-VEGFR2 signaling,15.541501976284586,0.008584725626116847
w,Sphingolipid metabolism in senescence,118.94444444444444,0.009037794083187181
w,PDGFR-beta pathway,114.69494047619048,0.009359117755663457
w,T cell receptor and co-stimulatory signaling,114.69494047619048,0.009359117755663457
w,GPR143 in melanocytes and retinal pigment epithelium cells,110.73850574712644,0.009680341403909321
r,FCERI mediated Ca+2 mobilization,14.425183512140034,0.009886665704110637
w,G-protein beta:gamma signaling,103.59139784946237,0.01032248874705891
w,Initiation of transcription and translation elongation at the HIV-1 LTR,103.59139784946237,0.01032248874705891
r,Ciprofloxacin ADME,100.35286458333333,0.010643412501615882
w,16p11.2 distal deletion syndrome,97.31060606060606,0.010964236351248923
w,miR-targeted genes in lymphocytes,13.457707509881423,0.011270952919966862
k,African trypanosomiasis,94.44730392156863,0.011284960325763402
r,GDP-fucose biosynthesis,89.19791666666667,0.011926108768615478
k,Aldosterone-regulated sodium reabsorption,86.78603603603604,0.012246533296521263
w,Kisspeptin/kisspeptin receptor system in the ovary,84.50109649122807,0.012566858068444818
w,Common pathways underlying drug addiction,80.27395833333334,0.01320720846338811
w,miRNA in muscle cell differentiation,80.27395833333334,0.01320720846338811
r,Organic anion transport,80.27395833333334,0.01320720846338811
r,RUNX1 regulates transcription of genes involved in differentiation of myeloid cells,80.27395833333334,0.01320720846338811
w,Inflammatory bowel disease signaling,76.44940476190476,0.013847160191446202
w,Chronic hyperglycemia impairment of neuron function,71.35,0.014806340803416045
w,Envelope proteins and their potential roles in EDMD physiopathology,71.35,0.014806340803416045
w,15q25 copy number variation,69.79800724637681,0.01512586859823084
w,Heart development,69.79800724637681,0.01512586859823084
w,IL26 signaling,69.79800724637681,0.01512586859823084
k,Carbohydrate digestion and absorption,68.31205673758865,0.015445296904623398
k,Malaria,66.88802083333333,0.01576462575228017
r,Downstream signaling events of B Cell Receptor (BCR),11.143543805986454,0.016051592780969914
r,Regulation of Complement cascade,11.031797534068787,0.016355703216717483
k,Endocrine and other factor-regulated calcium reabsorption,62.950980392156865,0.01672201583957356
w,IL1 signaling,59.451388888888886,0.01767851186614503
w,RANKL/RANK signaling,59.451388888888886,0.01767851186614503
w,Proximal tubule transport,57.326636904761905,0.018315679578628802
w,Dengue-2 interactions with complement and coagulation cascades,55.348419540229884,0.0189524505233502
w,Kit receptor signaling,55.348419540229884,0.0189524505233502
k,Long-term depression,54.409604519774014,0.01927068728179931
k,VEGF signaling pathway,54.409604519774014,0.01927068728179931
w,Modulators of TCR signaling and T cell activation,53.50208333333333,0.019588824937090167
w,DYRK1A involvement regarding cell proliferation in brain development,52.62431693989071,0.019906863518799247
r,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,52.62431693989071,0.019906863518799247
r:w,Complement cascade,9.905008747489147,0.019973230661113152
w,T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection,50.95238095238095,0.02054264357973583
k,GnRH secretion,50.155598958333336,0.020860385118074184
k,Inflammatory bowel disease,50.155598958333336,0.020860385118074184
w,Oncostatin M signaling,50.155598958333336,0.020860385118074184
r,Transport of nucleotide sugars,50.155598958333336,0.020860385118074184
w,AGE/RAGE pathway,49.38333333333333,0.021178027701052385
k,Amphetamine addiction,47.907960199004975,0.021813016119057105
w,Th17 cell differentiation pathway,47.20281862745098,0.02213036201312696
k,Gastric acid secretion,43.37218468468468,0.02403236282702918
k,Glioma,43.37218468468468,0.02403236282702918
k,Thyroid hormone synthesis,43.37218468468468,0.02403236282702918
k,Leishmaniasis,42.79333333333334,0.024349017479402546
k,Pancreatic cancer,42.2297149122807,0.02466557350082983
w,Regulatory circuits of STAT3 signaling,41.68073593073593,0.024982030920752726
w,Clock-controlled autophagy in bone metabolism,40.62447257383966,0.025614650073810096
w,G alpha (12/13) signaling events,40.62447257383966,0.025614650073810096
k:w,Non-small cell lung cancer,40.62447257383966,0.025614650073810096
w,Glioblastoma signaling,39.136686991869915,0.026562840027672313
w,EGFR tyrosine kinase inhibitor resistance,38.66465863453815,0.026878706456373844
k,ErbB signaling pathway,38.20386904761905,0.02719447448942756
k,Insulin secretion,38.20386904761905,0.02719447448942756
r,Calcineurin activates NFAT,37.314437984496124,0.02782571548608124
w,T-cell activation SARS-CoV-2,37.314437984496124,0.02782571548608124
k:w,Complement and coagulation cascades,36.88505747126437,0.02814118850840504
w,Hair follicle development: cytodifferentiation - stage 3 of 3,36.88505747126437,0.02814118850840504
k,Bile secretion,36.46543560606061,0.028456563252528745
r,CLEC7A (Dectin-1) induces NFAT activation,36.46543560606061,0.028456563252528745
k,GABAergic synapse,36.46543560606061,0.028456563252528745
k,Gap junction,36.46543560606061,0.028456563252528745
w,Pancreatic adenocarcinoma pathway,36.46543560606061,0.028456563252528745
k,Salivary secretion,36.46543560606061,0.028456563252528745
r,WNT5A-dependent internalization of FZD4,36.46543560606061,0.028456563252528745
k,PD-L1 expression and PD-1 checkpoint pathway in cancer,36.05524344569288,0.028771839747793314
w,G protein signaling,35.65416666666667,0.029087018023531305
k,Morphine addiction,35.65416666666667,0.029087018023531305
w,Corticotropin-releasing hormone signaling,35.26190476190476,0.029402098109066965
w,ErbB signaling,35.26190476190476,0.029402098109066965
k,GnRH signaling pathway,35.26190476190476,0.029402098109066965
k,Th1 and Th2 cell differentiation,35.26190476190476,0.029402098109066965
r,Organic cation/anion/zwitterion transport,34.87817028985507,0.02971708003371617
k,Aldosterone synthesis and secretion,33.77543859649123,0.030661437135377417
k,Circadian entrainment,33.77543859649123,0.030661437135377417
w,p75 NTR receptor-mediated signaling,33.77543859649123,0.030661437135377417
k,Fc gamma R-mediated phagocytosis,33.423177083333336,0.030976026709471492
k,Phosphatidylinositol signaling system,33.423177083333336,0.030976026709471492
w,Hippo signaling regulation,33.078178694158076,0.03129051826913271
k,Inflammatory mediator regulation of TRP channels,33.078178694158076,0.03129051826913271
k,Choline metabolism in cancer,32.740221088435376,0.03160491184362671
k:w,Melanogenesis,32.40909090909091,0.03191920746221074
k,Pancreatic secretion,32.084583333333335,0.03223340515413374
w,Wnt signaling and pluripotency,32.084583333333335,0.03223340515413374
k,Amoebiasis,31.766501650165015,0.032547504948636265
k,NF-kappa B signaling pathway,31.454656862745097,0.032861506874950555
k,C-type lectin receptor signaling pathway,31.148867313915858,0.03317541096230045
w,MicroRNAs in cardiomyocyte hypertrophy,31.148867313915858,0.03317541096230045
w,Complement system in neuronal development and plasticity,30.848958333333332,0.033489217239901496
k,HIF-1 signaling pathway,29.982866043613708,0.03443004950624148
w,Macrophage-stimulating protein (MSP) signaling,29.982866043613708,0.03443004950624148
k,Th17 cell differentiation,29.982866043613708,0.03443004950624148
k,Insulin resistance,29.70486111111111,0.03474346483683541
r,Depolymerization of the Nuclear Lamina,29.16401515151515,0.035370002535799555
r,Trafficking of GluR2-containing AMPA receptors,29.16401515151515,0.035370002535799555
k,Serotonergic synapse,28.64248511904762,0.03599614981286036
w,7q11.23 copy number variation syndrome,28.13925438596491,0.03662190690117513
k,Cholinergic synapse,28.13925438596491,0.03662190690117513
k,Glutamatergic synapse,28.13925438596491,0.03662190690117513
k,"Parathyroid hormone synthesis, secretion and action",28.13925438596491,0.03662190690117513
w,Response to elevated platelet cytosolic Ca ions,27.894202898550724,0.03693463919737798
w,Osteoblast differentiation and related diseases,27.416666666666668,0.037559811439452306
k,"Growth hormone synthesis, secretion and action",26.508953168044076,0.03880898733698637
k,Sphingolipid signaling pathway,26.508953168044076,0.03880898733698637
r:w,Beta-catenin independent WNT signaling,6.6513436748962205,0.04115405959923713
r:w,RHO GTPases Activate NADPH Oxidases,24.862403100775193,0.041302671296305535
k,Dopaminergic synapse,24.670833333333334,0.041613944747792474
k,Lysosome,24.670833333333334,0.041613944747792474
k,Vascular smooth muscle contraction,24.670833333333334,0.041613944747792474
r,HSF1 activation,24.296401515151516,0.04223620060751895
k,Osteoclast differentiation,23.933146766169155,0.042858068602758884
k,Yersinia infection,23.580575980392158,0.04347954896520847
w,C-type lectin receptors,23.40815085158151,0.04379014385650574
w,Neuroinflammation and glutamatergic signaling,23.070743405275778,0.0444110432039107
w,NF1 copy number variation syndrome ,23.070743405275778,0.0444110432039107
w,Ectoderm differentiation,22.74290780141844,0.045031555497186695
k,Spinocerebellar ataxia,22.424242424242426,0.04565168096756704
r:w,Signaling by the B Cell Receptor (BCR),6.179032913449817,0.04688933468658279
k,Retrograde endocannabinoid signaling,21.812925170068027,0.04689077236391233
r,Attenuation phase,21.51957494407159,0.04750973875168324
w,Calcium regulation in cardiac cells,21.375833333333333,0.04781907721892326
k,Cell adhesion molecules,20.81953463203463,0.04905546691608641
k,mTOR signaling pathway,20.81953463203463,0.04905546691608641
k,Efferocytosis,20.68494623655914,0.0493643234414537
w,Immunoregulatory interactions between lymphoid and non-lymphoid cells,20.552083333333332,0.049673083664833154
w,Myometrial relaxation and contraction pathways,20.552083333333332,0.049673083664833154
k,Hepatitis C,20.42091295116773,0.049981747615001126
w,Insulin signaling,20.163522012578618,0.05059878681076698
k,cGMP-PKG signaling pathway,20.037239583333335,0.05090716211387645
r,CDC42 GTPase cycle,5.883309458360757,0.05111088191729458
w,EGF/EGFR signaling,19.912525879917183,0.0512154412587977
k,Hepatocellular carcinoma,19.311495983935743,0.05275539561602702
k,Influenza A,18.96794871794872,0.053678216169898145
r,G beta:gamma signalling through CDC42,18.316190476190478,0.055521268754737896
r,VEGFR2 mediated cell proliferation,18.316190476190478,0.055521268754737896
w,Ras signaling,17.51366120218579,0.05797331249842863
k,Kaposi sarcoma-associated herpesvirus infection,16.60405872193437,0.06102977394440321
r,Cell-extracellular matrix interactions,16.266074450084602,0.0622496909280996
w,Orexin receptor pathway,16.18371212121212,0.06255443235181982
r:w,Fc epsilon receptor (FCERI) signaling,5.188109328498615,0.06358864344399652
k,Diabetic cardiomyopathy,15.78407224958949,0.06407671395873842
k,Rap1 signaling pathway,15.25654761904762,0.06620392194383497
k,Chemical carcinogenesis - receptor activation,15.184044233807267,0.06650742964631173
k,Lipid and atherosclerosis,15.184044233807267,0.06650742964631173
w,Network map of SARS-CoV-2 signaling,14.695145259938839,0.06862933346171354
k,Human T-cell leukemia virus 1 infection,14.429617117117116,0.06983977019412652
r,RAC1 GTPase cycle,4.909026112875008,0.06991009192088177
k,cAMP signaling pathway,14.36472346786248,0.07014214332649957
k,Coronavirus disease - COVID-19,14.048793859649123,0.0716525940953936
k,Cytoskeleton in muscle cells,13.865800865800866,0.0725577336576241
k,Ras signaling pathway,13.6875,0.07346202597539173
r:w,"Transport of vitamins, nucleosides, and related molecules",13.179012345679013,0.0761698270590394
w,MAPK signaling,13.071088435374149,0.0767705281023707
k:w,Regulation of actin cytoskeleton,12.606463254593177,0.07946904566754313
r:w,"Glutamate binding, activation of AMPA receptors and synaptic plasticity",12.127367424242424,0.08245851759361726
r,Trafficking of AMPA receptors,12.127367424242424,0.08245851759361726
r,HSF1-dependent transactivation,11.901177199504337,0.08394975631218116
r,G-protein beta:gamma signalling,11.270393192488262,0.08840952529049768
k:r,Long-term potentiation,10.99828178694158,0.09048361052342392
r,RHOU GTPase cycle,10.491530054644809,0.09461819840973666
k,MicroRNAs in cancer,10.288317256162916,0.09638463565618538
r,Generation of second messenger molecules,9.873842592592593,0.10020057327748001
r,G alpha (z) signalling events,9.634914658634537,0.10254114821846431
w,miR-targeted genes in epithelium,9.24337668593449,0.10662309723810555
r,SLC-mediated transmembrane transport,3.7333333333333334,0.1103107602191395
r,Nuclear Envelope Breakdown,8.78422619047619,0.11184513352569292
w,ADHD and autism (ASD) pathways,8.735997267759563,0.11242354762075052
r,Innate Immune System,2.104721475690203,0.1190721352079363
r,Ca2+ pathway,7.019047619047619,0.13780002522402215
r,Activation of NF-kappaB in B cells,6.988147337709701,0.1383622024395399
r:w,Meiotic synapsis,6.942300724637681,0.13920480851360542
r,Regulation of HSF1-mediated heat shock response,6.9120670995671,0.13976610637132403
r,NRAGE signals death through JNK,6.867204301075269,0.14060739439772105
k,Pathways of neurodegeneration - multiple diseases,6.750352360817477,0.14284696942960073
r,Synthesis of substrates in N-glycan biosythesis,6.568672839506172,0.14647433370259128
r,Signaling by WNT,3.114862339603837,0.14708993625134484
r:w,Transcriptional regulation of white adipocyte differentiation,6.370758483033932,0.15064144291346301
w,Cancer pathways,6.294871794871795,0.15230281192599307
k,Pathways in cancer,6.054395951929159,0.15781820725300402
r,Adaptive Immune System,2.0459004981618047,0.159291938570558
r,"Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein",5.72606223818073,0.1660267550155201
r,RSV-host interactions,5.624338624338624,0.16874582865326715
r,PCP/CE pathway,5.55524099883856,0.1706441142008905
r,RAC2 GTPase cycle,5.357703081232493,0.1763140339192752
r,G alpha (12/13) signalling events,5.268457300275482,0.17900089862106902
r,Hemostasis,2.1453302556818183,0.185706583513688
r,Drug ADME,4.954639709694142,0.18913445376930427
r,SLC transporter disorders,4.900833333333333,0.19098801730564902
r,"Cell death signalling via NRAGE, NRIF and NADE",4.870603975535168,0.1920453694874139
r:w,Cellular response to heat stress,4.803921568627451,0.19441956351744427
r:w,"Transport of bile salts and organic acids, metal ions and amine compounds",4.774862568715642,0.19547260969919975
r:w,Signaling by Rho GTPases,2.0659919259626003,0.199525985896991
r,RAC3 GTPase cycle,4.464118747078074,0.20748805395881842
r,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",2.0137479085331846,0.20934239379175837
r,CLEC7A (Dectin-1) signaling,4.40179806362379,0.21007721540311017
r,Meiosis,4.383436639118457,0.2108523790162291
r:w,Adipogenesis,4.2648011617515635,0.2160015054795343
r,p75 NTR receptor-mediated signalling,4.114381198792583,0.22290168623646925
r,Respiratory Syncytial Virus Infection Pathway,4.050849256900213,0.2259496845266037
r,PPARA activates gene expression,3.9541355721393034,0.23075222275745166
r:w,Mitotic Prophase,3.885747758761206,0.23427261729989596
r:w,Regulation of lipid metabolism by PPARalpha,3.8524242424242425,0.23602700955158462
r:w,Cell junction organization,3.6766493055555554,0.24573106136759576
r,Response to elevated platelet cytosolic Ca2+,3.646766169154229,0.2474602420534552
r,VEGFA-VEGFR2 Pathway,3.584320917983446,0.2511528235075679
r:w,TCR signaling,3.5239548649648538,0.25482800744599765
r:w,Signaling by VEGF,3.3651466949452105,0.2650266351624838
r,RHO GTPase cycle,2.040140145663209,0.27257375785187726
r,Reproduction,3.216573698444895,0.27532920357219876
r,C-type lectin receptors (CLRs),3.0987292277614857,0.2840831025308667
r:w,Factors involved in megakaryocyte development and platelet production,3.00347551342812,0.29157209621934527
r,Cell-Cell communication,2.819085782131196,0.30723729606203465
r,Disorders of transmembrane transporters,2.6222014925373136,0.3259076675991428
r,Death Receptor Signaling,2.5681018142431626,0.33143595617721344
r:w,Cell surface interactions at the vascular wall,2.5181938911022574,0.3367021478351696
k:r,Cellular senescence,2.240027225378788,0.36934977356217796
r,GPCR downstream signalling,1.508239456288986,0.398866430453085
r:w,Neurotransmitter receptors and postsynaptic signal transmission,2.0085088279089556,0.4016408692362621
r:w,Transcriptional regulation by RUNX1,1.9865056818181819,0.4049979022522891
r,Immune System,1.1981268223721027,0.42560812297265416
r,Signaling by GPCR,1.3794933242040397,0.44130999679512617
k:r:w,Cell cycle,1.3365272777623927,0.4568080942091756
r,"Platelet activation, signaling and aggregation",1.644750656167979,0.4650941495730337
r,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1.6211827122153208,0.46987423592637856
r:w,Asparagine N-linked glycosylation,1.5193756073858116,0.4916443243345275
r,Transmission across Chemical Synapses,1.4830722986869167,0.49987648786633726
r,Transport of small molecules,1.2256137005890164,0.5002161495471407
r,RHO GTPase Effectors,1.468735307945463,0.5031996437870944
r,M Phase,1.1455561714708056,0.5907164123634702
r,Neuronal System,0.9936620474809325,0.6419520980862425
r:w,Neutrophil degranulation,0.8725692468222349,0.6884838945317919
r,"Cell Cycle, Mitotic",0.834185296255907,0.7043763578128395
r,Signaling by Receptor Tyrosine Kinases,0.764310503428667,0.7347664268000869
r,Metabolism of lipids,0.5939932067009629,0.8163906719291733
r,Cellular responses to stress,0.5542570951585977,0.8366947401404394
r,Cellular responses to stimuli,0.547913990334618,0.8399643431747679
r,Signal Transduction,0.6296201750747206,0.8653836272358474
r,Viral Infection Pathways,0.47641509433962265,0.8770617007927978
r,Infectious disease,0.3760999133073255,0.9276756010940121
r,Disease,0.41507333192258233,0.9462980201593836
r:w,Generic Transcription Pathway,0.32298997351494513,0.9518384991655733
r,Developmental Biology,0.3090565866084425,0.9576432099808027
r,Post-translational protein modification,0.3074178709840994,0.9583082011245683
r:w,RNA Polymerase II Transcription,0.2941009963768116,0.9635632821187613
r,Gene expression (Transcription),0.2553311146035561,0.9771493636131812
r,Metabolism of proteins,0.20193547164088566,0.9908061859724032
r,Metabolism,0.1917411362975879,0.9926679658916691
w,10q11.21q11.23 copy number variation syndrome,0.0,1.0
w,10q22q23 copy number variation,0.0,1.0
w,13q12.12 copy number variation,0.0,1.0
w,13q12 or CRYL1 copy number variation ,0.0,1.0
w,15q11.2 copy number variation syndrome,0.0,1.0
w,15q11q13 copy number variation,0.0,1.0
w,15q13.3 copy number variation syndrome,0.0,1.0
w,15q24 copy number variation,0.0,1.0
w,16p11.2 proximal deletion syndrome,0.0,1.0
w,17p13.3 (YWHAE) copy number variation,0.0,1.0
w,17q12 copy number variation syndrome,0.0,1.0
w,1p36 copy number variation syndrome,0.0,1.0
w,1q21.1 copy number variation syndrome,0.0,1.0
w,22q11.2 copy number variation syndrome,0.0,1.0
r,2-LTR circle formation,0.0,1.0
w,2q11.2 copy number variation syndrome,0.0,1.0
w,2q13 copy number variation syndrome,0.0,1.0
w,2q21.1 copy number variation syndrome,0.0,1.0
w,2q37 copy number variation syndrome,0.0,1.0
w,3q29 copy number variation syndrome,0.0,1.0
w,"4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression",0.0,1.0
w,4p16.3 copy number variation,0.0,1.0
r,5-Phosphoribose 1-diphosphate biosynthesis,0.0,1.0
w,5q35 copy number variation,0.0,1.0
w,6q16 copy number variation,0.0,1.0
w,7-oxo-C and 7-beta-HC pathways,0.0,1.0
w,7q11.23 distal copy number variation,0.0,1.0
w,8p23.1 copy number variation syndrome,0.0,1.0
w,8q11.23 (RB1CC1) copy number variation,0.0,1.0
r,Abacavir ADME,0.0,1.0
r,Abacavir metabolism,0.0,1.0
r,Abacavir transmembrane transport,0.0,1.0
w,Abacavir transport and metabolism,0.0,1.0
r,Abasic sugar-phosphate removal via the single-nucleotide replacement pathway,0.0,1.0
r:w,ABC-family proteins mediated transport,0.0,1.0
r,ABC transporter disorders,0.0,1.0
k,ABC transporters,0.0,1.0
r,ABC transporters in lipid homeostasis,0.0,1.0
r,Aberrant regulation of mitotic cell cycle due to RB1 defects,0.0,1.0
r,Aberrant regulation of mitotic exit in cancer due to RB1 defects,0.0,1.0
r,Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects,0.0,1.0
r:w,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.0,1.0
r,ABO blood group biosynthesis,0.0,1.0
r,Abortive elongation of HIV-1 transcript in the absence of Tat,0.0,1.0
w,ACE inhibitor pathway,0.0,1.0
w,ACE inhibitor pathway - for workshop,0.0,1.0
w,Acetaminophen in analgesia and antipyresis,0.0,1.0
r,Acetylation,0.0,1.0
r:w,Acetylcholine binding and downstream events,0.0,1.0
r,Acetylcholine inhibits contraction of outer hair cells,0.0,1.0
r,Acetylcholine Neurotransmitter Release Cycle,0.0,1.0
r,Acetylcholine regulates insulin secretion,0.0,1.0
w,Acetylcholine synthesis,0.0,1.0
w,Acquired partial lipodystrophy / Barraquer-Simons syndrome,0.0,1.0
r,Acrosome Reaction and Sperm:Oocyte Membrane Binding,0.0,1.0
w,Acrylamide biotransformation and exposure biomarkers,0.0,1.0
r,Activated NOTCH1 Transmits Signal to the Nucleus,0.0,1.0
r,Activated NTRK2 signals through CDK5,0.0,1.0
r,Activated NTRK2 signals through FRS2 and FRS3,0.0,1.0
r,Activated NTRK2 signals through FYN,0.0,1.0
r,Activated NTRK2 signals through PI3K,0.0,1.0
r,Activated NTRK2 signals through PLCG1,0.0,1.0
r,Activated NTRK2 signals through RAS,0.0,1.0
r,Activated NTRK3 signals through PI3K,0.0,1.0
r,Activated NTRK3 signals through PLCG1,0.0,1.0
r,Activated NTRK3 signals through RAS,0.0,1.0
r,Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,0.0,1.0
w,Activated PKN1 stimulates transcription of AR-regulated genes KLK2 and KLK3,0.0,1.0
r,Activated point mutants of FGFR2,0.0,1.0
r,activated TAK1 mediates p38 MAPK activation,0.0,1.0
r,Activation and oligomerization of BAK protein,0.0,1.0
r,"Activation, myristolyation of BID and translocation to mitochondria",0.0,1.0
r,Activation of AKT2,0.0,1.0
r,Activation of AMPA receptors,0.0,1.0
r,Activation of AMPK downstream of NMDARs,0.0,1.0
r:w,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0,1.0
r,Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins,0.0,1.0
r,Activation of ATR in response to replication stress,0.0,1.0
r,Activation of BAD and translocation to mitochondria ,0.0,1.0
r,Activation of BH3-only proteins,0.0,1.0
r,Activation of BIM and translocation to mitochondria ,0.0,1.0
r,Activation of BMF and translocation to mitochondria,0.0,1.0
r,Activation of C3 and C5,0.0,1.0
r,Activation of Ca-permeable Kainate Receptor,0.0,1.0
r,Activation of caspases through apoptosome-mediated cleavage,0.0,1.0
r,Activation of GABAB receptors,0.0,1.0
r:w,Activation of gene expression by SREBF (SREBP),0.0,1.0
r,Activation of G protein gated Potassium channels,0.0,1.0
r,Activation of HOX genes during differentiation,0.0,1.0
r,"Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)",0.0,1.0
r:w,Activation of kainate receptors upon glutamate binding,0.0,1.0
r:w,Activation of Matrix Metalloproteinases,0.0,1.0
r,Activation of Na-permeable kainate receptors,0.0,1.0
r,"Activation of NIMA Kinases NEK9, NEK6, NEK7",0.0,1.0
w,Activation of NLRP3 inflammasome by SARS-CoV-2,0.0,1.0
r,Activation of NMDA receptors and postsynaptic events,0.0,1.0
r,Activation of NOXA and translocation to mitochondria,0.0,1.0
r,Activation of PPARGC1A (PGC-1alpha) by phosphorylation,0.0,1.0
r,Activation of PUMA and translocation to mitochondria,0.0,1.0
r,Activation of RAC1,0.0,1.0
r,Activation of RAC1 downstream of NMDARs,0.0,1.0
r,Activation of RAS in B cells,0.0,1.0
r,Activation of SMO,0.0,1.0
r,Activation of the AP-1 family of transcription factors,0.0,1.0
r,"Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S",0.0,1.0
r,Activation of the phototransduction cascade,0.0,1.0
r,Activation of the pre-replicative complex,0.0,1.0
r,Activation of the TFAP2 (AP-2) family of transcription factors,0.0,1.0
r,Activation of TRKA receptors,0.0,1.0
r,"Activation, translocation and oligomerization of BAX",0.0,1.0
k:w,Acute myeloid leukemia,0.0,1.0
w,Acute viral myocarditis,0.0,1.0
r,Acyl chain remodeling of CL,0.0,1.0
r,Acyl chain remodeling of DAG and TAG,0.0,1.0
r,Acyl chain remodelling of PC,0.0,1.0
r,Acyl chain remodelling of PE,0.0,1.0
r,Acyl chain remodelling of PG,0.0,1.0
r,Acyl chain remodelling of PI,0.0,1.0
r,Acyl chain remodelling of PS,0.0,1.0
r,Adenosine P1 receptors,0.0,1.0
r,Adenylate cyclase activating pathway,0.0,1.0
r,Adenylate cyclase inhibitory pathway,0.0,1.0
k,Adherens junction,0.0,1.0
r,Adherens junctions interactions,0.0,1.0
k,Adipocytokine signaling pathway,0.0,1.0
r,ADORA2B mediated anti-inflammatory cytokines production,0.0,1.0
r,ADP signalling through P2Y purinoceptor 1,0.0,1.0
r,ADP signalling through P2Y purinoceptor 12,0.0,1.0
r,"Adrenaline,noradrenaline inhibits insulin secretion",0.0,1.0
r,Adrenaline signalling through Alpha-2 adrenergic receptor,0.0,1.0
k,Adrenergic signaling in cardiomyocytes,0.0,1.0
r,Adrenoceptors,0.0,1.0
r:w,Advanced glycosylation endproduct receptor signaling,0.0,1.0
w,Aerobic glycolysis,0.0,1.0
w,Aerobic glycolysis - augmented,0.0,1.0
r,Aerobic respiration and respiratory electron transport,0.0,1.0
w,Affected pathways in Duchenne muscular dystrophy,0.0,1.0
r:w,Aflatoxin activation and detoxification,0.0,1.0
w,Aflatoxin B1 metabolism,0.0,1.0
r:w,Aggrephagy,0.0,1.0
r,Agmatine biosynthesis,0.0,1.0
w,Airway smooth muscle cell contraction,0.0,1.0
r,AKT-mediated inactivation of FOXO1A,0.0,1.0
r,AKT phosphorylates targets in the cytosol,0.0,1.0
r,AKT phosphorylates targets in the nucleus,0.0,1.0
w,Alanine and aspartate metabolism,0.0,1.0
k,"Alanine, aspartate and glutamate metabolism",0.0,1.0
r:w,Alanine metabolism,0.0,1.0
w,ALA oxylipin metabolism,0.0,1.0
k,Alcoholic liver disease,0.0,1.0
k,Alcoholism,0.0,1.0
r,alectinib-resistant ALK mutants,0.0,1.0
r,ALKBH2 mediated reversal of alkylation damage,0.0,1.0
r,ALKBH3 mediated reversal of alkylation damage,0.0,1.0
r,ALK mutants bind TKIs,0.0,1.0
k:w,Allograft rejection,0.0,1.0
w,Alpha 6 beta 4 signaling,0.0,1.0
r,Alpha-defensins,0.0,1.0
r,alpha-linolenic acid (ALA) metabolism,0.0,1.0
k,alpha-Linolenic acid metabolism,0.0,1.0
r:w,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,0.0,1.0
r,Alpha-oxidation of phytanate,0.0,1.0
w,Alpha-protein kinase 1 signaling,0.0,1.0
r,Alpha-protein kinase 1 signaling pathway,0.0,1.0
w,Alstrom syndrome,0.0,1.0
w,Altered glycosylation of MUC1 in tumor microenvironment,0.0,1.0
r,Alternative complement activation,0.0,1.0
r,Alternative Lengthening of Telomeres (ALT),0.0,1.0
w,Alternative pathway of fetal androgen synthesis,0.0,1.0
k,Alzheimer disease,0.0,1.0
w,Alzheimer's disease,0.0,1.0
w,Alzheimer's disease and miRNA effects,0.0,1.0
r,Amine ligand-binding receptors,0.0,1.0
r,Amine Oxidase reactions,0.0,1.0
r,Amino Acid conjugation,0.0,1.0
w,Amino acid conjugation of benzoic acid,0.0,1.0
w,Amino acid metabolism,0.0,1.0
w,Amino acid metabolism in triple-negative breast cancer cells,0.0,1.0
w,Amino acid metabolism pathway excerpt: histidine catabolism extension,0.0,1.0
r:w,Amino acids regulate mTORC1,0.0,1.0
r,Amino acid transport across the plasma membrane,0.0,1.0
w,Amino acid transport defects (IEMs),0.0,1.0
k,Aminoacyl-tRNA biosynthesis,0.0,1.0
k,Amino sugar and nucleotide sugar metabolism,0.0,1.0
w,AMP-activated protein kinase signaling,0.0,1.0
r,AMPK inhibits chREBP transcriptional activation activity,0.0,1.0
k,AMPK signaling pathway,0.0,1.0
w,Amplification and expansion of oncogenic pathways as metastatic traits,0.0,1.0
r,Amplification of signal from the kinetochores,0.0,1.0
r,Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal,0.0,1.0
r:w,Amyloid fiber formation,0.0,1.0
k,Amyotrophic lateral sclerosis,0.0,1.0
w,Amyotrophic lateral sclerosis (ALS),0.0,1.0
r,Anchoring fibril formation,0.0,1.0
r,Anchoring of the basal body to the plasma membrane,0.0,1.0
r:w,Androgen biosynthesis,0.0,1.0
w,Androgen receptor network in prostate cancer,0.0,1.0
w,Androgen receptor signaling,0.0,1.0
w,Angiogenesis,0.0,1.0
w,Angiogenesis overview,0.0,1.0
w,Angiopoietin-like protein 8 regulatory pathway,0.0,1.0
w,Angiotensin II receptor type 1 pathway,0.0,1.0
r,Antagonism of Activin by Follistatin,0.0,1.0
r,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0,1.0
r,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0,1.0
k,Antigen processing and presentation,0.0,1.0
r,Antigen processing-Cross presentation,0.0,1.0
r,Antigen processing: Ubiquitination & Proteasome degradation,0.0,1.0
r:w,Anti-inflammatory response favouring Leishmania parasite infection,0.0,1.0
r:w,Antimicrobial peptides,0.0,1.0
w,Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway,0.0,1.0
r,Antiviral mechanism by IFN-stimulated genes,0.0,1.0
r,APC/C:Cdc20 mediated degradation of Cyclin B,0.0,1.0
r,APC/C:Cdc20 mediated degradation of mitotic proteins,0.0,1.0
r,APC/C:Cdc20 mediated degradation of Securin,0.0,1.0
r,APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1,0.0,1.0
r,APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint,0.0,1.0
r,APC-Cdc20 mediated degradation of Nek2A,0.0,1.0
r,APC/C-mediated degradation of cell cycle proteins,0.0,1.0
r,APC truncation mutants are not K63 polyubiquitinated,0.0,1.0
r,APC truncation mutants have impaired AXIN binding,0.0,1.0
k,Apelin signaling pathway,0.0,1.0
r,APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway,0.0,1.0
r,APOBEC3G mediated resistance to HIV-1 infection,0.0,1.0
w,ApoE and miR-146 in inflammation and atherosclerosis,0.0,1.0
k:r:w,Apoptosis,0.0,1.0
r,Apoptosis induced DNA fragmentation,0.0,1.0
w,Apoptosis modulation and signaling,0.0,1.0
w,Apoptosis modulation by HSP70,0.0,1.0
k,Apoptosis - multiple species,0.0,1.0
w,Apoptosis-related network due to altered Notch3 in ovarian cancer,0.0,1.0
r,Apoptotic cleavage of cell adhesion  proteins,0.0,1.0
r,Apoptotic cleavage of cellular proteins,0.0,1.0
r:w,Apoptotic execution phase,0.0,1.0
r,Apoptotic factor-mediated response,0.0,1.0
r,Aquaporin-mediated transport,0.0,1.0
w,Arachidonate epoxygenase / epoxide hydrolase,0.0,1.0
r,Arachidonate production from DAG,0.0,1.0
w,"Arachidonic acid (AA, ARA) oxylipin metabolism",0.0,1.0
k:r:w,Arachidonic acid metabolism,0.0,1.0
k,Arginine and proline metabolism,0.0,1.0
k,Arginine biosynthesis,0.0,1.0
w,Aripiprazole metabolic pathway,0.0,1.0
r,ARL13B-mediated ciliary trafficking of INPP5E,0.0,1.0
r,ARMS-mediated activation,0.0,1.0
r,Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2,0.0,1.0
k:w,Arrhythmogenic right ventricular cardiomyopathy,0.0,1.0
w,Arsenic metabolism and reactive oxygen species generation,0.0,1.0
w,Artemisinin inhibition of uveal melanoma,0.0,1.0
w,Arylamine metabolism,0.0,1.0
w,Aryl hydrocarbon receptor pathway,0.0,1.0
w,Aryl hydrocarbon receptor signaling,0.0,1.0
r,Aryl hydrocarbon receptor signalling,0.0,1.0
k,Ascorbate and aldarate metabolism,0.0,1.0
r,ASP-3026-resistant ALK mutants,0.0,1.0
r:w,Aspartate and asparagine metabolism,0.0,1.0
r,Aspirin ADME,0.0,1.0
w,Aspirin and miRNAs,0.0,1.0
r:w,Assembly and cell surface presentation of NMDA receptors,0.0,1.0
r,Assembly and release of respiratory syncytial virus (RSV) virions,0.0,1.0
r,Assembly of active LPL and LIPC lipase complexes,0.0,1.0
r:w,Assembly of collagen fibrils and other multimeric structures,0.0,1.0
r,Assembly Of The HIV Virion,0.0,1.0
r,Assembly of the ORC complex at the origin of replication,0.0,1.0
r,Assembly of the pre-replicative complex,0.0,1.0
w,Assembly of the primary cilium,0.0,1.0
r,Assembly of Viral Components at the Budding Site,0.0,1.0
r,Association of TriC/CCT with target proteins during biosynthesis,0.0,1.0
k,Asthma,0.0,1.0
r,Astrocytic Glutamate-Glutamine Uptake And Metabolism,0.0,1.0
r,Asymmetric localization of PCP proteins,0.0,1.0
r,A tetrasaccharide linker sequence is required for GAG synthesis,0.0,1.0
r:w,ATF4 activates genes in response to endoplasmic reticulum  stress,0.0,1.0
r:w,ATF6 (ATF6-alpha) activates chaperone genes,0.0,1.0
r,ATF6 (ATF6-alpha) activates chaperones,0.0,1.0
r,ATF6B (ATF6-beta) activates chaperones,0.0,1.0
w,ATM signaling,0.0,1.0
w,ATM signaling in development and disease ,0.0,1.0
r,Atorvastatin ADME,0.0,1.0
k,ATP-dependent chromatin remodeling,0.0,1.0
r,ATP sensitive Potassium channels,0.0,1.0
w,ATR signaling,0.0,1.0
r,Attachment and Entry,0.0,1.0
r,Attachment of GPI anchor to uPAR,0.0,1.0
r,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0,1.0
r,AURKA Activation by TPX2,0.0,1.0
r,Autodegradation of Cdh1 by Cdh1:APC/C,0.0,1.0
r,Autodegradation of the E3 ubiquitin ligase COP1,0.0,1.0
k,Autoimmune thyroid disease,0.0,1.0
r,Autointegration results in viral DNA circles,0.0,1.0
r:w,Autophagy,0.0,1.0
k,Autophagy - animal,0.0,1.0
w,Autophagy in pancreatic ductal adenocarcinoma,0.0,1.0
k,Autophagy - other,0.0,1.0
w,Autosomal recessive osteopetrosis pathways,0.0,1.0
r,AXIN missense mutants destabilize the destruction complex,0.0,1.0
w,AXL signaling,0.0,1.0
r,Axonal growth inhibition (RHOA activation),0.0,1.0
r,Axonal growth stimulation,0.0,1.0
k:r:w,Axon guidance,0.0,1.0
r,Azathioprine ADME,0.0,1.0
r,Bacterial Infection Pathways,0.0,1.0
k,Bacterial invasion of epithelial cells,0.0,1.0
w,Bardet-Biedl syndrome,0.0,1.0
k,Basal cell carcinoma,0.0,1.0
k,Basal transcription factors,0.0,1.0
k:r:w,Base excision repair,0.0,1.0
r:w,"Base-Excision Repair, AP Site Formation",0.0,1.0
r,Basigin interactions,0.0,1.0
r,BBSome-mediated cargo-targeting to cilium,0.0,1.0
r,"BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV",0.0,1.0
r,BDNF activates NTRK2 (TRKB) signaling,0.0,1.0
w,BDNF-TrkB signaling,0.0,1.0
w,Benzene metabolism,0.0,1.0
w,Benzo(a)pyrene metabolism,0.0,1.0
k,beta-Alanine metabolism,0.0,1.0
r,Beta-catenin phosphorylation cascade,0.0,1.0
r,Beta defensins,0.0,1.0
r,betaKlotho-mediated ligand binding,0.0,1.0
r,Beta oxidation of butanoyl-CoA to acetyl-CoA,0.0,1.0
r,Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA,0.0,1.0
r,Beta oxidation of hexanoyl-CoA to butanoyl-CoA,0.0,1.0
r,Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA,0.0,1.0
r,Beta oxidation of myristoyl-CoA to lauroyl-CoA,0.0,1.0
r,Beta oxidation of octanoyl-CoA to hexanoyl-CoA,0.0,1.0
r,Beta oxidation of palmitoyl-CoA to myristoyl-CoA,0.0,1.0
r,Beta-oxidation of pristanoyl-CoA,0.0,1.0
r,Beta-oxidation of very long chain fatty acids,0.0,1.0
r,BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,0.0,1.0
r,Bicarbonate transporters,0.0,1.0
r:w,Bile acid and bile salt metabolism,0.0,1.0
w,Bile acid synthesis and enterohepatic circulation ,0.0,1.0
r,Binding and entry of HIV virion,0.0,1.0
r:w,Binding and Uptake of Ligands by Scavenger Receptors,0.0,1.0
r,Binding of TCF/LEF:CTNNB1 to target gene promoters,0.0,1.0
r,Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB,0.0,1.0
w,Biogenic amine synthesis,0.0,1.0
r,Biological oxidations,0.0,1.0
w,Biomarkers for pyrimidine metabolism disorders,0.0,1.0
w,Biomarkers for urea cycle disorders,0.0,1.0
w,Biosynthesis and regeneration of tetrahydrobiopterin and catabolism of phenylalanine,0.0,1.0
w,Biosynthesis and turnover of 1-deoxy-sphingoid bases,0.0,1.0
r,"Biosynthesis of A2E, implicated in retinal degradation",0.0,1.0
r,Biosynthesis of aspirin-triggered D-series resolvins,0.0,1.0
r:w,Biosynthesis of DHA-derived SPMs,0.0,1.0
r,Biosynthesis of DHA-derived sulfido conjugates,0.0,1.0
r:w,Biosynthesis of DPA-derived SPMs,0.0,1.0
r,Biosynthesis of DPAn-3-derived 13-series resolvins,0.0,1.0
r,Biosynthesis of DPAn-3-derived maresins,0.0,1.0
r,Biosynthesis of DPAn-3-derived protectins and resolvins,0.0,1.0
r,Biosynthesis of DPAn-3 SPMs,0.0,1.0
r,Biosynthesis of DPAn-6 SPMs,0.0,1.0
r,Biosynthesis of D-series resolvins,0.0,1.0
r,Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives,0.0,1.0
w,Biosynthesis of electrophilic omega-3 PUFA oxo-derivatives,0.0,1.0
r:w,Biosynthesis of EPA-derived SPMs,0.0,1.0
r,Biosynthesis of E-series 18(R)-resolvins,0.0,1.0
r,Biosynthesis of E-series 18(S)-resolvins,0.0,1.0
r,Biosynthesis of maresin conjugates in tissue regeneration (MCTR),0.0,1.0
r,Biosynthesis of maresin-like SPMs,0.0,1.0
r,Biosynthesis of maresins,0.0,1.0
r,Biosynthesis of protectin and resolvin conjugates in tissue regeneration (PCTR and RCTR),0.0,1.0
r,Biosynthesis of protectins,0.0,1.0
r,Biosynthesis of specialized proresolving mediators (SPMs),0.0,1.0
k,Biosynthesis of unsaturated fatty acids,0.0,1.0
k,Biotin metabolism,0.0,1.0
w,"Biotin metabolism, including IMDs",0.0,1.0
r,Biotin transport and metabolism,0.0,1.0
k:w,Bladder cancer,0.0,1.0
r,Blockage of phagosome acidification,0.0,1.0
w,Blood clotting cascade,0.0,1.0
r:w,Blood group systems biosynthesis,0.0,1.0
r:w,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0,1.0
w,BMP2-WNT4-FOXO1 pathway in primary endometrial stromal cell differentiation,0.0,1.0
w,BMP signaling in eyelid development,0.0,1.0
w,Bone morphogenic protein signaling and regulation,0.0,1.0
w,Brain-derived neurotrophic factor (BDNF) signaling,0.0,1.0
r:w,Branched-chain amino acid catabolism,0.0,1.0
r,Breakdown of the nuclear lamina,0.0,1.0
k,Breast cancer,0.0,1.0
w,Breast cancer pathway,0.0,1.0
r,brigatinib-resistant ALK mutants,0.0,1.0
r,Budding and maturation of HIV virion,0.0,1.0
w,Burn wound healing,0.0,1.0
k,Butanoate metabolism,0.0,1.0
w,Butyrate-induced histone acetylation,0.0,1.0
r,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.0,1.0
r:w,Butyrophilin (BTN) family interactions,0.0,1.0
r:w,B-WICH complex positively regulates rRNA expression,0.0,1.0
r,C6 deamination of adenosine,0.0,1.0
r,Ca2+ activated K+ channels,0.0,1.0
r,Ca-dependent events,0.0,1.0
w,Caffeine and theobromine metabolism,0.0,1.0
k,Caffeine metabolism,0.0,1.0
r,Calcitonin-like ligand receptors,0.0,1.0
w,Calcium mediated T-cell apoptosis involved in inclusion body myositis,0.0,1.0
r,Calmodulin induced events,0.0,1.0
r,Calnexin/calreticulin cycle,0.0,1.0
w,Caloric restriction and aging,0.0,1.0
r,CaMK IV-mediated phosphorylation of CREB,0.0,1.0
w,CAMKK2 pathway,0.0,1.0
r,CaM pathway,0.0,1.0
r,Cam-PDE 1 activation,0.0,1.0
w,Cancer immunotherapy by CTLA4 blockade,0.0,1.0
w,Cannabinoid receptor signaling,0.0,1.0
w,Canonical and non-canonical Notch signaling,0.0,1.0
w,Canonical and non-canonical TGF-B signaling,0.0,1.0
w,Canonical NF-kB pathway,0.0,1.0
r,Cap-dependent Translation Initiation,0.0,1.0
r:w,Carboxyterminal post-translational modifications of tubulin,0.0,1.0
r:w,Cardiac conduction,0.0,1.0
w,Cardiac hypertrophic response,0.0,1.0
k,Cardiac muscle contraction,0.0,1.0
w,Cardiac progenitor differentiation,0.0,1.0
r,Cardiogenesis,0.0,1.0
w,Cardiomyocyte signaling converging on titin,0.0,1.0
r:w,Cargo concentration in the ER,0.0,1.0
r,Cargo recognition for clathrin-mediated endocytosis,0.0,1.0
r,Cargo trafficking to the periciliary membrane,0.0,1.0
r:w,Carnitine metabolism,0.0,1.0
r:w,Carnitine synthesis,0.0,1.0
w,Carnosine metabolism of glial cells,0.0,1.0
r,CASP8 activity is inhibited,0.0,1.0
r:w,Caspase activation via Death Receptors in the presence of ligand,0.0,1.0
r:w,Caspase activation via Dependence Receptors in the absence of ligand,0.0,1.0
r,Caspase activation via extrinsic apoptotic signalling pathway,0.0,1.0
r,Caspase-mediated cleavage of cytoskeletal proteins,0.0,1.0
w,Catabolism of skeletal muscle in cachexia,0.0,1.0
w,Catalytic cycle of mammalian flavin-containing monooxygenases (FMOs),0.0,1.0
r,Catecholamine biosynthesis,0.0,1.0
r,Cation-coupled Chloride cotransporters,0.0,1.0
w,CCL18 signaling,0.0,1.0
r,CD163 mediating an anti-inflammatory response,0.0,1.0
r,CD209 (DC-SIGN) signaling,0.0,1.0
r,CD22 mediated BCR regulation,0.0,1.0
r,CD28 co-stimulation,0.0,1.0
r,CD28 dependent PI3K/Akt signaling,0.0,1.0
r,CD28 dependent Vav1 pathway,0.0,1.0
r,Cdc20:Phospho-APC/C mediated degradation of Cyclin A,0.0,1.0
r,CDC6 association with the ORC:origin complex,0.0,1.0
r,CDH11 homotypic and heterotypic interactions,0.0,1.0
r,CDK-mediated phosphorylation and removal of Cdc6,0.0,1.0
r,Cell-cell junction organization,0.0,1.0
r:w,Cell Cycle Checkpoints,0.0,1.0
w,Cell differentiation - expanded index,0.0,1.0
w,Cell differentiation - index,0.0,1.0
w,Cell division cycle 27,0.0,1.0
w,Cell interactions of the pancreatic cancer microenvironment,0.0,1.0
w,Cell lineage map for neuronal differentiation,0.0,1.0
r:w,Cell recruitment (pro-inflammatory response),0.0,1.0
w,Cell-type dependent selectivity of CCK2R signaling,0.0,1.0
r:w,Cellular hexose transport,0.0,1.0
w,Cellular proteostasis,0.0,1.0
r,Cellular response to chemical stress,0.0,1.0
r:w,Cellular response to hypoxia,0.0,1.0
r,Cellular response to mitochondrial stress,0.0,1.0
r,Cellular response to starvation,0.0,1.0
k,Central carbon metabolism in cancer,0.0,1.0
r,Centrosome maturation,0.0,1.0
r,Ceramide signalling,0.0,1.0
w,"Cerebral organic acidurias, including diseases",0.0,1.0
r,ceritinib-resistant ALK mutants,0.0,1.0
r,cGMP effects,0.0,1.0
k,Chagas disease,0.0,1.0
r:w,Chaperone Mediated Autophagy,0.0,1.0
r,Chaperonin-mediated protein folding,0.0,1.0
k,Chemical carcinogenesis - DNA adducts,0.0,1.0
k,Chemical carcinogenesis - reactive oxygen species,0.0,1.0
w,Chemical compounds to monitor proteins,0.0,1.0
r,Chemokine receptors bind chemokines,0.0,1.0
r,Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex,0.0,1.0
r,CHL1 interactions,0.0,1.0
w,Cholestasis,0.0,1.0
r:w,Cholesterol biosynthesis,0.0,1.0
w,Cholesterol biosynthesis pathway,0.0,1.0
w,Cholesterol biosynthesis pathway in hepatocytes,0.0,1.0
w,"Cholesterol biosynthesis, regulation and transport",0.0,1.0
r,Cholesterol biosynthesis via desmosterol,0.0,1.0
r,Cholesterol biosynthesis via lathosterol,0.0,1.0
w,Cholesterol biosynthesis with skeletal dysplasias,0.0,1.0
k:w,Cholesterol metabolism,0.0,1.0
w,Cholesterol metabolism with Bloch and Kandutsch-Russell pathways,0.0,1.0
w,Cholesterol synthesis disorders,0.0,1.0
r:w,Choline catabolism,0.0,1.0
r,Chondroitin sulfate biosynthesis,0.0,1.0
r,Chondroitin sulfate/dermatan sulfate metabolism,0.0,1.0
r,ChREBP activates metabolic gene expression,0.0,1.0
r,Chromatin modifications during the maternal to zygotic transition (MZT),0.0,1.0
r,Chromatin modifying enzymes,0.0,1.0
r:w,Chromatin organization,0.0,1.0
w,Chromosomal and microsatellite instability in colorectal cancer ,0.0,1.0
r,Chromosome Maintenance,0.0,1.0
k,Chronic myeloid leukemia,0.0,1.0
r,Chylomicron assembly,0.0,1.0
r,Chylomicron clearance,0.0,1.0
r,Chylomicron remodeling,0.0,1.0
w,Ciliary landscape,0.0,1.0
w,Ciliopathies,0.0,1.0
r:w,Cilium Assembly,0.0,1.0
r:w,Circadian Clock,0.0,1.0
k,Circadian rhythm,0.0,1.0
w,Circadian rhythm genes,0.0,1.0
k,Citrate cycle (TCA cycle),0.0,1.0
w,Citric acid cycle and respiratory electron transport,0.0,1.0
r,Citric acid cycle (TCA cycle),0.0,1.0
r:w,Class A/1 (Rhodopsin-like receptors),0.0,1.0
r:w,Class B/2 (Secretin family receptors),0.0,1.0
r:w,Class C/3 (Metabotropic glutamate/pheromone receptors),0.0,1.0
r,Classical antibody-mediated complement activation,0.0,1.0
r,Classical Kir channels,0.0,1.0
w,Classical pathway of steroidogenesis with glucocorticoid and mineralocorticoid metabolism,0.0,1.0
w,Class I MHC mediated antigen processing and presentation,0.0,1.0
r,Class I MHC mediated antigen processing & presentation,0.0,1.0
r:w,Class I peroxisomal membrane protein import,0.0,1.0
r:w,Clathrin-mediated endocytosis,0.0,1.0
w,Clear cell renal cell carcinoma pathways,0.0,1.0
r,Cleavage of the damaged purine,0.0,1.0
r,Cleavage of the damaged pyrimidine ,0.0,1.0
r,CLEC7A/inflammasome pathway,0.0,1.0
r,Cobalamin (Cbl) metabolism,0.0,1.0
r,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0,1.0
k,Cobalamin transport and metabolism,0.0,1.0
k,Cocaine addiction,0.0,1.0
w,Cocaine metabolism,0.0,1.0
w,Codeine and morphine metabolism,0.0,1.0
r,Coenzyme A biosynthesis,0.0,1.0
w,Cohesin complex - Cornelia de Lange syndrome,0.0,1.0
r,Cohesin Loading onto Chromatin,0.0,1.0
w,Colchicine metabolic pathway,0.0,1.0
r:w,Collagen biosynthesis and modifying enzymes,0.0,1.0
r:w,Collagen chain trimerization,0.0,1.0
r:w,Collagen degradation,0.0,1.0
r,Collagen formation,0.0,1.0
k,Collecting duct acid secretion,0.0,1.0
k,Colorectal cancer,0.0,1.0
r,Common Pathway of Fibrin Clot Formation,0.0,1.0
r,Competing endogenous RNAs (ceRNAs) regulate PTEN translation,0.0,1.0
w,Complement activation,0.0,1.0
w,Complement-mediated inflammation of pulmonary alveolus in COVID-19 (hypothetical pathway),0.0,1.0
r,Complex I biogenesis,0.0,1.0
r,Complex III assembly,0.0,1.0
r,Complex IV assembly,0.0,1.0
r,Condensation of Prometaphase Chromosomes,0.0,1.0
r,Condensation of Prophase Chromosomes,0.0,1.0
w,Congenital generalized lipodystrophy,0.0,1.0
r,Conjugation of benzoate with glycine,0.0,1.0
r,Conjugation of carboxylic acids,0.0,1.0
r,Conjugation of phenylacetate with glutamine,0.0,1.0
r,Conjugation of salicylate with glycine,0.0,1.0
w,Constitutive androstane receptor pathway,0.0,1.0
r,Constitutive Signaling by Aberrant PI3K in Cancer,0.0,1.0
r,Constitutive Signaling by AKT1 E17K in Cancer,0.0,1.0
r,Constitutive Signaling by EGFRvIII,0.0,1.0
r,Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,0.0,1.0
r,Constitutive Signaling by NOTCH1 HD Domain Mutants,0.0,1.0
r,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,0.0,1.0
r,Constitutive Signaling by NOTCH1 PEST Domain Mutants,0.0,1.0
r,Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,0.0,1.0
r,Constitutive Signaling by Overexpressed ERBB2,0.0,1.0
w,Control of immune tolerance by vasoactive intestinal peptide,0.0,1.0
r,Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase,0.0,1.0
w,Conversion of angiotensinogen to angiotensin II ,0.0,1.0
r,Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding,0.0,1.0
r,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0,1.0
r,COPI-dependent Golgi-to-ER retrograde traffic,0.0,1.0
r:w,COPII-mediated vesicle transport,0.0,1.0
r,COPI-independent Golgi-to-ER retrograde traffic,0.0,1.0
r:w,COPI-mediated anterograde transport,0.0,1.0
w,Copper homeostasis,0.0,1.0
w,Copper metabolism,0.0,1.0
w,Cori cycle,0.0,1.0
k,Cortisol synthesis and secretion,0.0,1.0
r:w,Costimulation by the CD28 family,0.0,1.0
w,COVID-19 adverse outcome pathway,0.0,1.0
w,COVID-19 and endothelial cell senescence,0.0,1.0
w,COVID-19 structural coverage map,0.0,1.0
w,"COVID-19, thrombosis and anticoagulation",0.0,1.0
r,COX reactions,0.0,1.0
r:w,Creatine metabolism,0.0,1.0
w,Creatine pathway,0.0,1.0
r,Creation of C4 and C2 activators,0.0,1.0
r,CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling,0.0,1.0
r,CREB1 phosphorylation through the activation of Adenylate Cyclase,0.0,1.0
r,CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde,0.0,1.0
r,CREB3 factors activate genes,0.0,1.0
r,CREB phosphorylation,0.0,1.0
r,crenolanib-resistant FLT3 mutants,0.0,1.0
r:w,Cristae formation,0.0,1.0
r,crizotinib-resistant ALK mutants,0.0,1.0
r,CRMPs in Sema3A signaling,0.0,1.0
r,Crosslinking of collagen fibrils,0.0,1.0
r,Cross-presentation of particulate exogenous antigens (phagosomes),0.0,1.0
r,Cross-presentation of soluble exogenous antigens (endosomes),0.0,1.0
r,CS/DS degradation,0.0,1.0
r,CTLA4 inhibitory signaling,0.0,1.0
r,CTNNB1 S33 mutants aren't phosphorylated,0.0,1.0
r,CTNNB1 S37 mutants aren't phosphorylated,0.0,1.0
r,CTNNB1 S45 mutants aren't phosphorylated,0.0,1.0
r,CTNNB1 T41 mutants aren't phosphorylated,0.0,1.0
k,Cushing syndrome,0.0,1.0
r,Cyclin A/B1/B2 associated events during G2/M transition,0.0,1.0
r,Cyclin A:Cdk2-associated events at S phase entry,0.0,1.0
r,Cyclin D associated events in G1,0.0,1.0
r,Cyclin E associated events during G1/S transition ,0.0,1.0
w,CYP2E1 activation leading to neurodegeneration,0.0,1.0
r,CYP2E1 reactions,0.0,1.0
w,Cysteine and methionine catabolism,0.0,1.0
k,Cysteine and methionine metabolism,0.0,1.0
r,Cysteine formation from homocysteine,0.0,1.0
r,Cytochrome c-mediated apoptotic response,0.0,1.0
r,Cytochrome P450 - arranged by substrate type,0.0,1.0
k:w,Cytokine-cytokine receptor interaction,0.0,1.0
w,Cytokines and inflammatory response,0.0,1.0
r,Cytokine Signaling in Immune system,0.0,1.0
w,Cytokine storm syndrome,0.0,1.0
w,Cytoplasmic ribosomal proteins,0.0,1.0
r,Cytoprotection by HMOX1,0.0,1.0
w,Cytosine methylation,0.0,1.0
k:w,Cytosolic DNA-sensing pathway,0.0,1.0
r:w,Cytosolic iron-sulfur cluster assembly,0.0,1.0
r:w,Cytosolic sensors of pathogen-associated DNA ,0.0,1.0
r,Cytosolic sulfonation of small molecules,0.0,1.0
r,Cytosolic tRNA aminoacylation,0.0,1.0
r:w,DAG and IP3 signaling,0.0,1.0
k,D-Amino acid metabolism,0.0,1.0
r:w,DAP12 interactions,0.0,1.0
r,DAP12 signaling,0.0,1.0
r,DARPP-32 events,0.0,1.0
r,Dasatinib-resistant KIT mutants,0.0,1.0
r,DCC mediated attractive signaling,0.0,1.0
w,DDR1-mediated signaling,0.0,1.0
w,DDX1 as a regulatory component of the Drosha microprocessor,0.0,1.0
r:w,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.0,1.0
r,Deactivation of the beta-catenin transactivating complex,0.0,1.0
r:w,Deadenylation-dependent mRNA decay,0.0,1.0
r,Deadenylation of mRNA,0.0,1.0
r,Dectin-1 mediated noncanonical NF-kB signaling,0.0,1.0
r,Dectin-2 family,0.0,1.0
r,Defective ABCA12 causes ARCI4B,0.0,1.0
r,Defective ABCA1 causes TGD,0.0,1.0
r,Defective ABCA3 causes SMDP3,0.0,1.0
r,Defective ABCB11 causes PFIC2 and BRIC2,0.0,1.0
r,"Defective ABCB4 causes PFIC3, ICP3 and GBD1",0.0,1.0
r,Defective ABCB6 causes MCOPCB7,0.0,1.0
r,Defective ABCC2 causes DJS,0.0,1.0
r,Defective ABCC6 causes PXE,0.0,1.0
r,Defective ABCC8 can cause hypo- and hyper-glycemias,0.0,1.0
r,"Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome",0.0,1.0
r,Defective ABCD1 causes ALD,0.0,1.0
r,Defective ABCD4 causes MAHCJ,0.0,1.0
r,Defective ABCG5 causes sitosterolemia,0.0,1.0
r,Defective ABCG8 causes GBD4 and sitosterolemia,0.0,1.0
r,Defective ACTH causes obesity and POMCD,0.0,1.0
r,Defective ACY1 causes encephalopathy,0.0,1.0
r,Defective ADA disrupts (deoxy)adenosine deamination,0.0,1.0
r,Defective AHCY causes HMAHCHD,0.0,1.0
r,Defective ALG11 causes CDG-1p,0.0,1.0
r,Defective ALG12 causes CDG-1g,0.0,1.0
r,Defective ALG14 causes ALG14-CMS,0.0,1.0
r,Defective ALG1 causes CDG-1k,0.0,1.0
r,Defective ALG2 causes CDG-1i,0.0,1.0
r,Defective ALG3 causes CDG-1d,0.0,1.0
r,Defective ALG6 causes CDG-1c,0.0,1.0
r,Defective ALG8 causes CDG-1h,0.0,1.0
r,Defective ALG9 causes CDG-1l,0.0,1.0
r,Defective AMN causes MGA1,0.0,1.0
r,Defective APRT disrupts adenine salvage,0.0,1.0
r,"Defective AVP does not bind AVPR1A,B and causes neurohypophyseal diabetes insipidus (NDI)",0.0,1.0
r,Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI),0.0,1.0
r,Defective B3GALT6 causes EDSP2 and SEMDJL1,0.0,1.0
r,Defective B3GALTL causes PpS,0.0,1.0
r,Defective B3GAT3 causes JDSSDHD,0.0,1.0
r,Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0
r,Defective B4GALT1 causes CDG-2d,0.0,1.0
r,"Defective B4GALT7 causes EDS, progeroid type",0.0,1.0
r,Defective Base Excision Repair Associated with MUTYH,0.0,1.0
r,Defective Base Excision Repair Associated with NEIL1,0.0,1.0
r,Defective Base Excision Repair Associated with NEIL3,0.0,1.0
r,Defective Base Excision Repair Associated with NTHL1,0.0,1.0
r,Defective Base Excision Repair Associated with OGG1,0.0,1.0
r,"Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)",0.0,1.0
r,Defective binding of VWF variant to GPIb:IX:V,0.0,1.0
r,Defective BTD causes biotidinase deficiency,0.0,1.0
r,Defective C1GALT1C1 causes TNPS,0.0,1.0
r,Defective CBLIF causes IFD,0.0,1.0
r,Defective CD320 causes MMATC,0.0,1.0
r,Defective CFTR causes cystic fibrosis,0.0,1.0
r,"Defective CHST14 causes EDS, musculocontractural type",0.0,1.0
r,Defective CHST3 causes SEDCJD,0.0,1.0
r,Defective CHST6 causes MCDC1,0.0,1.0
r,Defective CHSY1 causes TPBS,0.0,1.0
r,Defective cofactor function of FVIIIa variant,0.0,1.0
r,Defective CP causes aceruloplasminemia (ACERULOP),0.0,1.0
r,Defective CSF2RA causes SMDP4,0.0,1.0
r,Defective CSF2RB causes SMDP5,0.0,1.0
r,Defective CUBN causes MGA1,0.0,1.0
r,Defective CYP11A1 causes AICSR,0.0,1.0
r,Defective CYP11B1 causes AH4,0.0,1.0
r,Defective CYP11B2 causes CMO-1 deficiency,0.0,1.0
r,Defective CYP17A1 causes AH5,0.0,1.0
r,Defective CYP19A1 causes AEXS,0.0,1.0
r,Defective CYP1B1 causes Glaucoma,0.0,1.0
r,Defective CYP21A2 causes AH3,0.0,1.0
r,Defective CYP24A1 causes HCAI,0.0,1.0
r,Defective CYP26B1 causes RHFCA,0.0,1.0
r,Defective CYP26C1 causes FFDD4,0.0,1.0
r,Defective CYP27A1 causes CTX,0.0,1.0
r,Defective CYP27B1 causes VDDR1A,0.0,1.0
r,Defective CYP27B1 causes VDDR1B,0.0,1.0
r,Defective CYP2U1 causes SPG56,0.0,1.0
r,Defective CYP4F22 causes ARCI5,0.0,1.0
r,Defective CYP7B1 causes SPG5A and CBAS3,0.0,1.0
r,Defective DHDDS causes RP59,0.0,1.0
r,Defective DNA double strand break response due to BARD1 loss of function,0.0,1.0
r,Defective DNA double strand break response due to BRCA1 loss of function,0.0,1.0
r,Defective DOLK causes DOLK-CDG,0.0,1.0
r,"Defective DPAGT1 causes CDG-1j, CMSTA2",0.0,1.0
r,Defective DPM1 causes DPM1-CDG,0.0,1.0
r,Defective DPM2 causes DPM2-CDG,0.0,1.0
r,Defective DPM3 causes DPM3-CDG,0.0,1.0
r,"Defective EXT1 causes exostoses 1, TRPS2 and CHDS",0.0,1.0
r,Defective EXT2 causes exostoses 2,0.0,1.0
r,Defective F8 accelerates dissociation of the A2 domain,0.0,1.0
r,Defective F8 binding to the cell membrane,0.0,1.0
r,Defective F8 binding to von Willebrand factor,0.0,1.0
r,Defective F8 cleavage by thrombin,0.0,1.0
r,Defective F8 secretion,0.0,1.0
r,Defective F8 sulfation at Y1699,0.0,1.0
r,Defective F9 activation,0.0,1.0
r,Defective F9 secretion,0.0,1.0
r,Defective F9 variant does not activate FX,0.0,1.0
r,Defective factor IX causes hemophilia B,0.0,1.0
r,Defective factor IX causes thrombophilia,0.0,1.0
r,Defective factor VIII causes hemophilia A,0.0,1.0
r,Defective factor XII causes hereditary angioedema,0.0,1.0
r,Defective FMO3 causes TMAU,0.0,1.0
r,Defective GALE causes EDG,0.0,1.0
r,Defective GALK1 causes GALCT2,0.0,1.0
r,Defective GALNT12 causes CRCS1,0.0,1.0
r,Defective GALNT3 causes HFTC,0.0,1.0
r,Defective GALT can cause GALCT,0.0,1.0
r,Defective gamma-carboxylation of F9,0.0,1.0
r,Defective GCK causes maturity-onset diabetes of the young 2 (MODY2),0.0,1.0
r,Defective GCLC causes HAGGSD,0.0,1.0
r,Defective GFPT1 causes CMSTA1,0.0,1.0
r,Defective GGT1 causes GLUTH,0.0,1.0
r,Defective GGT1 in aflatoxin detoxification causes GLUTH,0.0,1.0
r,"Defective GNE causes sialuria, NK and IBM2",0.0,1.0
r,Defective GSS causes GSS deficiency,0.0,1.0
r,Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function,0.0,1.0
r,Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function,0.0,1.0
r,Defective HEXA causes GM2G1,0.0,1.0
r,Defective HEXB causes GM2G2,0.0,1.0
r,Defective HK1 causes hexokinase deficiency (HK deficiency),0.0,1.0
r,Defective HLCS causes multiple carboxylase deficiency,0.0,1.0
r,Defective homologous recombination repair (HRR) due to BRCA1 loss of function,0.0,1.0
r,Defective homologous recombination repair (HRR) due to BRCA2 loss of function,0.0,1.0
r,Defective homologous recombination repair (HRR) due to PALB2 loss of function,0.0,1.0
r,Defective HPRT1 disrupts guanine and hypoxanthine salvage,0.0,1.0
r,Defective Inhibition of DNA Recombination at Telomere,0.0,1.0
r,Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations,0.0,1.0
r,Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations,0.0,1.0
r,Defective Intrinsic Pathway for Apoptosis,0.0,1.0
r,Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function,0.0,1.0
r,Defective LARGE causes MDDGA6 and MDDGB6,0.0,1.0
r,Defective LFNG causes SCDO3,0.0,1.0
r,Defective MAN1B1 causes MRT15,0.0,1.0
r,Defective MAOA causes BRUNS,0.0,1.0
r,Defective MAT1A causes MATD,0.0,1.0
r,Defective MGAT2 causes CDG-2a,0.0,1.0
r,Defective Mismatch Repair Associated With MLH1,0.0,1.0
r,Defective Mismatch Repair Associated With MSH2,0.0,1.0
r,Defective Mismatch Repair Associated With MSH3,0.0,1.0
r,Defective Mismatch Repair Associated With MSH6,0.0,1.0
r,Defective Mismatch Repair Associated With PMS2,0.0,1.0
r,"Defective MMAA causes MMA, cblA type",0.0,1.0
r,"Defective MMAB causes MMA, cblB type",0.0,1.0
r,Defective MMACHC causes MAHCC,0.0,1.0
r,Defective MMADHC causes MMAHCD,0.0,1.0
r,Defective MOGS causes CDG-2b,0.0,1.0
r,Defective MPDU1 causes CDG-1f,0.0,1.0
r,Defective MPI causes MPI-CDG,0.0,1.0
r,Defective MTR causes HMAG,0.0,1.0
r,Defective MTRR causes HMAE,0.0,1.0
r,Defective MUT causes MMAM,0.0,1.0
r,Defective MUTYH substrate binding,0.0,1.0
r,Defective MUTYH substrate processing,0.0,1.0
r,Defective NEU1 causes sialidosis,0.0,1.0
r,Defective NTHL1 substrate binding,0.0,1.0
r,Defective NTHL1 substrate processing,0.0,1.0
r,Defective OGG1 Localization,0.0,1.0
r,Defective OGG1 Substrate Binding,0.0,1.0
r,Defective OGG1 Substrate Processing,0.0,1.0
r,Defective OPLAH causes OPLAHD,0.0,1.0
r,Defective PAPSS2 causes SEMD-PA,0.0,1.0
r,Defective PGM1 causes PGM1-CDG,0.0,1.0
r,Defective PMM2 causes PMM2-CDG,0.0,1.0
r,Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine,0.0,1.0
r,"Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3",0.0,1.0
r,"Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1",0.0,1.0
r,"Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2",0.0,1.0
r,Defective pro-SFTPB causes SMDP1 and RDS,0.0,1.0
r,Defective pro-SFTPC causes SMDP2 and RDS,0.0,1.0
r,Defective pyroptosis,0.0,1.0
r,Defective regulation of TLR7 by endogenous ligand,0.0,1.0
r,Defective RFT1 causes CDG-1n,0.0,1.0
r,Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN),0.0,1.0
r,Defective RIPK1-mediated regulated necrosis,0.0,1.0
r,Defective SERPING1 causes hereditary angioedema,0.0,1.0
r,Defective SFTPA2 causes IPF,0.0,1.0
r,"Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1)",0.0,1.0
r,Defective SLC12A1 causes Bartter syndrome 1 (BS1),0.0,1.0
r,Defective SLC12A3 causes Gitelman syndrome (GS),0.0,1.0
r,"Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN)",0.0,1.0
r,Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT),0.0,1.0
r,Defective SLC17A5 causes Salla disease (SD) and ISSD,0.0,1.0
r,Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25),0.0,1.0
r,Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA),0.0,1.0
r,Defective SLC1A3 causes episodic ataxia 6 (EA6),0.0,1.0
r,Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1),0.0,1.0
r,Defective SLC22A12 causes renal hypouricemia 1 (RHUC1),0.0,1.0
r,Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1),0.0,1.0
r,Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP),0.0,1.0
r,Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D),0.0,1.0
r,Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI),0.0,1.0
r,Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6),0.0,1.0
r,Defective SLC26A2 causes chondrodysplasias,0.0,1.0
r,Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1),0.0,1.0
r,Defective SLC26A4 causes Pendred syndrome (PDS),0.0,1.0
r,Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS),0.0,1.0
r,Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS),0.0,1.0
r,Defective SLC2A10 causes arterial tortuosity syndrome (ATS),0.0,1.0
r,Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1),0.0,1.0
r,Defective SLC2A2 causes Fanconi-Bickel syndrome (FBS),0.0,1.0
r,Defective SLC2A9 causes hypouricemia renal 2 (RHUC2),0.0,1.0
r,Defective SLC33A1 causes spastic paraplegia 42 (SPG42),0.0,1.0
r,Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1),0.0,1.0
r,Defective SLC34A2 causes PALM,0.0,1.0
r,Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0
r,Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH),0.0,1.0
r,Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0
r,Defective SLC35A2 causes congenital disorder of glycosylation 2M (CDG2M),0.0,1.0
r,"Defective SLC35A3 causes arthrogryposis, mental retardation, and seizures (AMRS)",0.0,1.0
r,Defective SLC35D1 causes SCHBCKD,0.0,1.0
r,Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG),0.0,1.0
r,"Defective SLC39A4 causes acrodermatitis enteropathica, zinc-deficiency type (AEZ)",0.0,1.0
r,Defective SLC3A1 causes cystinuria (CSNU),0.0,1.0
r,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum),0.0,1.0
r,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.0,1.0
r,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0,1.0
r,"Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA)",0.0,1.0
r,Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM),0.0,1.0
r,Defective SLC5A2 causes renal glucosuria (GLYS1),0.0,1.0
r,Defective SLC5A5 causes thyroid dyshormonogenesis 1 (TDH1),0.0,1.0
r,Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0
r,Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0
r,Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0
r,Defective SLC6A2 causes orthostatic intolerance (OI),0.0,1.0
r,Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0
r,Defective SLC6A5 causes hyperekplexia 3 (HKPX3),0.0,1.0
r,Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.0,1.0
r,Defective SLC7A9 causes cystinuria (CSNU),0.0,1.0
r,"Defective SLC9A6 causes  X-linked, syndromic mental retardation,, Christianson type (MRXSCH)",0.0,1.0
r,Defective SLC9A9 causes autism 16 (AUTS16),0.0,1.0
r,"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,1.0
r,"Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,1.0
r,"Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2)",0.0,1.0
r,"Defective SRD5A3 causes SRD5A3-CDG, KHRZ",0.0,1.0
r,Defective ST3GAL3 causes MCT12 and EIEE15,0.0,1.0
r,Defective TBXAS1 causes GHDD,0.0,1.0
r,Defective TCN2 causes TCN2 deficiency,0.0,1.0
r,Defective TPMT causes TPMT deficiency,0.0,1.0
r,Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC),0.0,1.0
r,Defective translocation of RB1 mutants to the nucleus,0.0,1.0
r,Defective UGT1A1 causes hyperbilirubinemia,0.0,1.0
r,Defective UGT1A4 causes hyperbilirubinemia,0.0,1.0
r,Defective VWF binding to collagen type I ,0.0,1.0
r,Defective VWF cleavage by ADAMTS13 variant,0.0,1.0
r,Defects in biotin (Btn) metabolism,0.0,1.0
r,Defects in cobalamin (B12) metabolism,0.0,1.0
r,Defects in vitamin and cofactor metabolism,0.0,1.0
r,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0,1.0
r,Defects of platelet adhesion to exposed collagen,0.0,1.0
r:w,Defensins,0.0,1.0
r,Degradation of AXIN,0.0,1.0
r:w,Degradation of beta-catenin by the destruction complex,0.0,1.0
r,Degradation of cysteine and homocysteine,0.0,1.0
r,Degradation of DVL,0.0,1.0
r,Degradation of GABA,0.0,1.0
r,Degradation of GLI1 by the proteasome,0.0,1.0
r,Degradation of GLI2 by the proteasome,0.0,1.0
r:w,Degradation of the extracellular matrix,0.0,1.0
w,"Degradation pathway of sphingolipids, including diseases",0.0,1.0
r,Deletions in the AMER1 gene destabilize the destruction complex,0.0,1.0
r,Deletions in the AXIN1 gene destabilize the destruction complex,0.0,1.0
w,Demo,0.0,1.0
w,Demo_complete,0.0,1.0
r,Deposition of new CENPA-containing nucleosomes at the centromere,0.0,1.0
r,Depurination,0.0,1.0
r,Depyrimidination,0.0,1.0
r:w,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,0.0,1.0
w,Deregulation of Rab and Rab effector genes in bladder cancer,0.0,1.0
r,Dermatan sulfate biosynthesis,0.0,1.0
r:w,Detoxification of Reactive Oxygen Species,0.0,1.0
r:w,Deubiquitination,0.0,1.0
r,Developmental Cell Lineages,0.0,1.0
w,Development and heterogeneity of the ILC family,0.0,1.0
w,Development of pulmonary dendritic cells and macrophage subsets,0.0,1.0
w,Development of ureteric collection system,0.0,1.0
r,DEx/H-box helicases activate type I IFN and inflammatory cytokines production ,0.0,1.0
w,Diclofenac metabolic pathway,0.0,1.0
w,Diet-dependent trimethylamine/trimethylamine N-oxide metabolism ,0.0,1.0
r,Differentiation of keratinocytes in interfollicular epidermis in mammalian skin,0.0,1.0
w,Differentiation of white and brown adipocyte,0.0,1.0
r:w,Digestion,0.0,1.0
r,Digestion and absorption,0.0,1.0
r,Digestion of dietary carbohydrate,0.0,1.0
r,Digestion of dietary lipid,0.0,1.0
w,Dihomo-gamma-linolenic acid (DGLA) oxylipin metabolism,0.0,1.0
k,Dilated cardiomyopathy,0.0,1.0
r,Dimerization of procaspase-8,0.0,1.0
w,Direct reversal repair,0.0,1.0
r,Disassembly of the destruction complex and recruitment of AXIN to the membrane,0.0,1.0
r,Diseases associated with glycosaminoglycan metabolism,0.0,1.0
r,Diseases associated with glycosylation precursor biosynthesis,0.0,1.0
r,Diseases associated with N-glycosylation of proteins,0.0,1.0
r,Diseases associated with O-glycosylation of proteins,0.0,1.0
r,Diseases associated with surfactant metabolism,0.0,1.0
r,Diseases associated with the TLR signaling cascade,0.0,1.0
r,Diseases associated with visual transduction,0.0,1.0
r,Diseases of Base Excision Repair,0.0,1.0
r,Diseases of carbohydrate metabolism,0.0,1.0
r,Diseases of cellular response to stress,0.0,1.0
r,Diseases of Cellular Senescence,0.0,1.0
r,Diseases of DNA Double-Strand Break Repair,0.0,1.0
r,Diseases of DNA repair,0.0,1.0
r,Diseases of glycosylation,0.0,1.0
r,Diseases of hemostasis,0.0,1.0
r,Diseases of Immune System,0.0,1.0
r,Diseases of metabolism,0.0,1.0
r,Diseases of Mismatch Repair (MMR),0.0,1.0
r,Diseases of mitochondrial beta oxidation,0.0,1.0
r,Diseases of mitotic cell cycle,0.0,1.0
r,Diseases of nucleotide metabolism,0.0,1.0
r,Diseases of programmed cell death,0.0,1.0
r,Diseases of propionyl-CoA catabolism,0.0,1.0
r,Diseases of signal transduction by growth factor receptors and second messengers,0.0,1.0
r,Diseases of Telomere Maintenance,0.0,1.0
r,Diseases of the neuronal system,0.0,1.0
w,Disorders in ketolysis,0.0,1.0
w,Disorders in ketone body synthesis,0.0,1.0
w,Disorders of bile acid synthesis and biliary transport,0.0,1.0
r,Disorders of Developmental Biology,0.0,1.0
w,Disorders of folate metabolism and transport,0.0,1.0
w,Disorders of fructose metabolism,0.0,1.0
w,Disorders of galactose metabolism ,0.0,1.0
r,Disorders of Nervous System Development,0.0,1.0
r,Displacement of DNA glycosylase by APEX1,0.0,1.0
w,Disruption of postsynaptic signaling by CNV,0.0,1.0
r:w,Dissolution of Fibrin Clot,0.0,1.0
r:w,DNA Damage Bypass,0.0,1.0
r,DNA Damage Recognition in GG-NER,0.0,1.0
w,DNA damage response,0.0,1.0
w,DNA damage response (only ATM dependent),0.0,1.0
r:w,DNA Damage Reversal,0.0,1.0
r:w,DNA Damage/Telomere Stress Induced Senescence,0.0,1.0
r,DNA Double-Strand Break Repair,0.0,1.0
r:w,DNA Double Strand Break Response,0.0,1.0
w,DNA IR-damage and cellular response via ATR,0.0,1.0
w,DNA IR-double strand breaks and cellular response via ATM,0.0,1.0
r:w,DNA methylation,0.0,1.0
w,DNA mismatch repair,0.0,1.0
r,DNA Repair,0.0,1.0
w,"DNA repair pathways, full network",0.0,1.0
k:r:w,DNA replication,0.0,1.0
r,DNA replication initiation,0.0,1.0
r:w,DNA Replication Pre-Initiation,0.0,1.0
r,DNA strand elongation,0.0,1.0
w,Docosahexaenoic acid oxylipin metabolism,0.0,1.0
r,Dopamine clearance from the synaptic cleft,0.0,1.0
w,Dopamine metabolism,0.0,1.0
r,Dopamine Neurotransmitter Release Cycle,0.0,1.0
r,Dopamine receptors,0.0,1.0
w,Dopaminergic neurogenesis,0.0,1.0
w,Downregulation of ACE2 by SARS-CoV-2 spike protein,0.0,1.0
r,Downregulation of ERBB2:ERBB3 signaling,0.0,1.0
r,Downregulation of ERBB2 signaling,0.0,1.0
r,Downregulation of ERBB4 signaling,0.0,1.0
r,Downregulation of SMAD2/3:SMAD4 transcriptional activity,0.0,1.0
r,Downregulation of TGF-beta receptor signaling,0.0,1.0
r,Downstream signaling of activated FGFR1,0.0,1.0
r,Downstream signaling of activated FGFR2,0.0,1.0
r,Downstream signaling of activated FGFR3,0.0,1.0
r,Downstream signaling of activated FGFR4,0.0,1.0
r,Downstream signal transduction,0.0,1.0
r,Downstream TCR signaling,0.0,1.0
w,Dravet syndrome,0.0,1.0
w,Drug induction of bile acid pathway,0.0,1.0
r,Drug-mediated inhibition of CDK4/CDK6 activity,0.0,1.0
r,Drug-mediated inhibition of ERBB2 signaling,0.0,1.0
r,Drug-mediated inhibition of MET activation,0.0,1.0
k,Drug metabolism - cytochrome P450,0.0,1.0
k,Drug metabolism - other enzymes,0.0,1.0
r,Drug resistance in ERBB2 KD mutants,0.0,1.0
r,Drug resistance in ERBB2 TMD/JMD mutants,0.0,1.0
r,Drug resistance of ALK mutants,0.0,1.0
r,Drug resistance of FLT3 mutants,0.0,1.0
r,Drug resistance of KIT mutants,0.0,1.0
r,Drug resistance of PDGFR mutants,0.0,1.0
r,DSCAM interactions,0.0,1.0
w,Dual hijack model of Vif in HIV infection,0.0,1.0
r,Dual Incision in GG-NER,0.0,1.0
r,Dual incision in TC-NER,0.0,1.0
r,E2F-enabled inhibition of pre-replication complex formation,0.0,1.0
r,E2F mediated regulation of DNA replication,0.0,1.0
r:w,E3 ubiquitin ligases ubiquitinate target proteins,0.0,1.0
r,Early Phase of HIV Life Cycle,0.0,1.0
r,Early SARS-CoV-2 Infection Events,0.0,1.0
w,Ebola virus infection in host,0.0,1.0
w,Ebstein-Barr virus LMP1 signaling,0.0,1.0
r,ECM proteoglycans,0.0,1.0
k,ECM-receptor interaction,0.0,1.0
w,EDA signaling in hair follicle development,0.0,1.0
w,Effect of intestinal microbiome on anticoagulant response of vitamin K antagonists,0.0,1.0
w,Effect of mutated HTT on cholesterol synthesis in brain,0.0,1.0
w,Effect of omega-3 PUFA on Huntington's disease pathways,0.0,1.0
w,Effect of progerin on genes involved in progeria,0.0,1.0
w,Effects of MFN2 mutation,0.0,1.0
w,Effects of nitric oxide,0.0,1.0
r:w,Effects of PIP2 hydrolysis,0.0,1.0
r,EGFR downregulation,0.0,1.0
r,EGFR interacts with phospholipase C-gamma,0.0,1.0
r,EGFR Transactivation by Gastrin,0.0,1.0
r:w,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0,1.0
r,Eicosanoid ligand-binding receptors,0.0,1.0
w,Eicosanoid metabolism via cyclooxygenases (COX),0.0,1.0
w,Eicosanoid metabolism via cytochrome P450 monooxygenases pathway,0.0,1.0
w,Eicosanoid metabolism via lipooxygenases (LOX),0.0,1.0
r,Eicosanoids,0.0,1.0
w,Eicosanoid synthesis,0.0,1.0
w,eIF5A regulation in response to inhibition of the nuclear export system,0.0,1.0
w,Elabela signaling,0.0,1.0
r:w,Elastic fibre formation,0.0,1.0
r,Electric Transmission Across Gap Junctions,0.0,1.0
w,Electron transport chain: OXPHOS system in mitochondria,0.0,1.0
r,Electron transport from NADPH to Ferredoxin,0.0,1.0
r,Elevation of cytosolic Ca2+ levels,0.0,1.0
w,Embryonic stem cell pluripotency pathways,0.0,1.0
r,EML4 and NUDC in mitotic spindle formation,0.0,1.0
w,Endochondral ossification,0.0,1.0
w,Endochondral ossification with skeletal dysplasias,0.0,1.0
k,Endocytosis,0.0,1.0
w,Endoderm differentiation,0.0,1.0
r,Endogenous sterols,0.0,1.0
k:w,Endometrial cancer,0.0,1.0
w,Endoplasmic reticulum stress response in coronavirus infection,0.0,1.0
w,Endosomal sorting complex required for transport,0.0,1.0
r,Endosomal Sorting Complex Required For Transport (ESCRT),0.0,1.0
r,Endosomal/Vacuolar pathway,0.0,1.0
w,Endothelin pathway,0.0,1.0
w,Endothelin pathways,0.0,1.0
r:w,Energy dependent regulation of mTOR by LKB1-AMPK,0.0,1.0
w,Energy metabolism,0.0,1.0
r,Enhanced binding of GP1BA variant to VWF multimer:collagen ,0.0,1.0
r,Enhanced cleavage of VWF variant by ADAMTS13,0.0,1.0
r,eNOS activation,0.0,1.0
w,Enterocyte cholesterol metabolism,0.0,1.0
w,Enterohepatic circulation of bile acids,0.0,1.0
r,Entry of Influenza Virion into Host Cell via Endocytosis,0.0,1.0
r,Enzymatic degradation of dopamine by COMT,0.0,1.0
r,Enzymatic degradation of Dopamine by monoamine oxidase,0.0,1.0
w,EPAC1 and PKA reduction of retinal inflammation,0.0,1.0
w,EPA oxylipin metabolism,0.0,1.0
r,EPHA-mediated growth cone collapse,0.0,1.0
r,EPHB-mediated forward signaling,0.0,1.0
r,EPH-ephrin mediated repulsion of cells,0.0,1.0
r:w,EPH-Ephrin signaling,0.0,1.0
r,Ephrin signaling,0.0,1.0
r,Epigenetic regulation of gene expression,0.0,1.0
k,Epithelial cell signaling in Helicobacter pylori infection,0.0,1.0
r,Epithelial-Mesenchymal Transition (EMT) during gastrulation,0.0,1.0
w,Epithelial to mesenchymal transition in colorectal cancer,0.0,1.0
w,EPO receptor signaling,0.0,1.0
k,Epstein-Barr virus infection,0.0,1.0
r,ERBB2 Activates PTK6 Signaling,0.0,1.0
r,ERBB2 Regulates Cell Motility,0.0,1.0
r:w,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0,1.0
r,ERK/MAPK targets,0.0,1.0
w,ERK pathway in Huntington's disease,0.0,1.0
r,ERKs are inactivated,0.0,1.0
r,ER-Phagosome pathway,0.0,1.0
r,ER Quality Control Compartment (ERQC),0.0,1.0
r,ER to Golgi Anterograde Transport,0.0,1.0
r:w,Erythrocytes take up carbon dioxide and release oxygen,0.0,1.0
r:w,Erythrocytes take up oxygen and release carbon dioxide,0.0,1.0
r,Erythropoietin activates Phosphoinositide-3-kinase (PI3K),0.0,1.0
r,Erythropoietin activates Phospholipase C gamma (PLCG),0.0,1.0
r,Erythropoietin activates RAS,0.0,1.0
r,Erythropoietin activates STAT5,0.0,1.0
r:w,ESR-mediated signaling,0.0,1.0
r,Essential fructosuria,0.0,1.0
r,Essential pentosuria,0.0,1.0
r,Establishment of Sister Chromatid Cohesion,0.0,1.0
w,Estradiol regulation in porto-sinusoidal vascular disease,0.0,1.0
r,Estrogen biosynthesis,0.0,1.0
r,Estrogen-dependent gene expression,0.0,1.0
r,Estrogen-dependent nuclear events downstream of ESR-membrane signaling,0.0,1.0
w,Estrogen metabolism,0.0,1.0
w,Estrogen receptor pathway,0.0,1.0
w,Estrogen signaling,0.0,1.0
k,Estrogen signaling pathway,0.0,1.0
r,Estrogen-stimulated signaling through PRKCZ,0.0,1.0
w,Ethanol effects on histone modifications,0.0,1.0
w,Ethanol metabolism production of ROS by CYP2E1,0.0,1.0
r,Ethanol oxidation,0.0,1.0
w,Ether lipid biosynthesis,0.0,1.0
k,Ether lipid metabolism,0.0,1.0
w,Ethylmalonic encephalopathy,0.0,1.0
w,Eukaryotic transcription initiation,0.0,1.0
r:w,Eukaryotic Translation Elongation,0.0,1.0
r:w,Eukaryotic Translation Initiation,0.0,1.0
r:w,Eukaryotic Translation Termination,0.0,1.0
r,Evasion by RSV of host interferon responses,0.0,1.0
r,Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4,0.0,1.0
r,Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6,0.0,1.0
r,Evasion of Oncogene Induced Senescence Due to p14ARF Defects,0.0,1.0
r,Evasion of Oncogene Induced Senescence Due to p16INK4A Defects,0.0,1.0
r,Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4,0.0,1.0
r,Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6,0.0,1.0
r,Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects,0.0,1.0
r,Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects,0.0,1.0
r:w,Events associated with phagocytolytic activity of PMN cells,0.0,1.0
w,Evolocumab mechanism to reduce LDL cholesterol,0.0,1.0
w,EV release from cardiac cells and their functional effects,0.0,1.0
w,Exercise-induced circadian regulation,0.0,1.0
r,Export of Viral Ribonucleoproteins from Nucleus,0.0,1.0
r,Expression and Processing of Neurotrophins,0.0,1.0
r,Expression and translocation of olfactory receptors,0.0,1.0
w,exRNA mechanism of action and biogenesis,0.0,1.0
r,Extension of Telomeres,0.0,1.0
r:w,Extracellular matrix organization,0.0,1.0
w,Extracellular vesicle-mediated signaling in recipient cells,0.0,1.0
w,Extrafollicular and follicular B cell activation by SARS-CoV-2,0.0,1.0
r:w,Extra-nuclear estrogen signaling,0.0,1.0
r,Extrinsic Pathway of Fibrin Clot Formation,0.0,1.0
w,FABP4 in ovarian cancer,0.0,1.0
w,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling,0.0,1.0
w,Familial  hyperlipidemia type 1,0.0,1.0
w,Familial hyperlipidemia type 2,0.0,1.0
w,Familial hyperlipidemia type 3,0.0,1.0
w,Familial hyperlipidemia type 4,0.0,1.0
w,Familial hyperlipidemia type 5,0.0,1.0
w,Familial partial lipodystrophy,0.0,1.0
w,Fanconi anemia,0.0,1.0
k:r:w,Fanconi anemia pathway,0.0,1.0
w,Farnesoid X receptor pathway,0.0,1.0
r:w,FasL/ CD95L signaling,0.0,1.0
w,Fas ligand pathway and stress induction of heat shock proteins,0.0,1.0
r,FASTK family proteins regulate processing and stability of mitochondrial RNAs,0.0,1.0
k,Fat digestion and absorption,0.0,1.0
w,Fatty acid beta-oxidation,0.0,1.0
k:w,Fatty acid biosynthesis,0.0,1.0
k,Fatty acid degradation,0.0,1.0
k,Fatty acid elongation,0.0,1.0
r,Fatty acid metabolism,0.0,1.0
w,Fatty acid omega-oxidation,0.0,1.0
r,Fatty acids,0.0,1.0
w,Fatty acids and lipoproteins transport in hepatocytes,0.0,1.0
r,Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion,0.0,1.0
w,Fatty acid transporters,0.0,1.0
r:w,Fatty acyl-CoA biosynthesis,0.0,1.0
w,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma,0.0,1.0
r,FBXL7 down-regulates AURKA during mitotic entry and in early mitosis,0.0,1.0
r,FBXW7 Mutants and NOTCH1 in Cancer,0.0,1.0
k,Fc epsilon RI signaling pathway,0.0,1.0
r,FCERI mediated MAPK activation,0.0,1.0
r,FCERI mediated NF-kB activation,0.0,1.0
r:w,Fcgamma receptor (FCGR) dependent phagocytosis,0.0,1.0
r,FCGR3A-mediated IL10 synthesis,0.0,1.0
r:w,FCGR3A-mediated phagocytosis,0.0,1.0
r,FCGR activation,0.0,1.0
w,Felbamate metabolism,0.0,1.0
w,Female steroid hormones in cardiomyocyte energy metabolism,0.0,1.0
k:w,Ferroptosis,0.0,1.0
r:w,Fertilization,0.0,1.0
w,FGF23 signaling in hypophosphatemic rickets and related disorders,0.0,1.0
r,FGFR1b ligand binding and activation,0.0,1.0
r,FGFR1c and Klotho ligand binding and activation,0.0,1.0
r,FGFR1c ligand binding and activation,0.0,1.0
r,FGFR1 ligand binding and activation,0.0,1.0
r,FGFR1 mutant receptor activation,0.0,1.0
r,FGFR2 alternative splicing,0.0,1.0
r,FGFR2b ligand binding and activation,0.0,1.0
r,FGFR2c ligand binding and activation,0.0,1.0
r,FGFR2 ligand binding and activation,0.0,1.0
r,FGFR2 mutant receptor activation,0.0,1.0
r,FGFR3b ligand binding and activation,0.0,1.0
r,FGFR3c ligand binding and activation,0.0,1.0
r,FGFR3 ligand binding and activation,0.0,1.0
r,FGFR3 mutant receptor activation,0.0,1.0
w,FGFR3 signaling in chondrocyte proliferation and terminal differentiation,0.0,1.0
r,FGFR4 ligand binding and activation,0.0,1.0
r,FGFR4 mutant receptor activation,0.0,1.0
w,FGFR4 p.G388R signaling,0.0,1.0
r,FGFRL1 modulation of FGFR1 signaling,0.0,1.0
w,Fibrin complement receptor 3 signaling,0.0,1.0
r,Fibronectin matrix formation,0.0,1.0
r,Ficolins bind to repetitive carbohydrate structures on the target cell surface,0.0,1.0
w,fig-met-1-last-solution,0.0,1.0
w,Flavan-3-ol metabolic pathway,0.0,1.0
r,FLT3 mutants bind TKIs,0.0,1.0
w,FLT3 p.Gln640SerfsTer8 signaling,0.0,1.0
r:w,FLT3 Signaling,0.0,1.0
r,FLT3 signaling by CBL mutants,0.0,1.0
r,FLT3 signaling in disease,0.0,1.0
r,FLT3 signaling through SRC family kinases,0.0,1.0
k,Fluid shear stress and atherosclerosis,0.0,1.0
w,Fluoroacetic acid toxicity,0.0,1.0
w,Fluoropyrimidine activity,0.0,1.0
r,FMO oxidises nucleophiles,0.0,1.0
w,Focal adhesion: PI3K-Akt-mTOR-signaling,0.0,1.0
w,Folate-alcohol and cancer pathway hypotheses,0.0,1.0
k,Folate biosynthesis,0.0,1.0
w,Folate metabolism,0.0,1.0
r,Folding of actin by CCT/TriC,0.0,1.0
w,Follicle stimulating hormone (FSH) signaling,0.0,1.0
r,Formation of annular gap junctions,0.0,1.0
r,Formation of a pool of free 40S subunits,0.0,1.0
r,Formation of apoptosome,0.0,1.0
r,Formation of ATP by chemiosmotic coupling,0.0,1.0
r,Formation of axial mesoderm,0.0,1.0
r,Formation of definitive endoderm,0.0,1.0
r,Formation of editosomes by ADAR proteins,0.0,1.0
w,Formation of Fibrin Clot and the Clotting Cascade,0.0,1.0
r,Formation of Fibrin Clot (Clotting Cascade),0.0,1.0
r,Formation of HIV-1 elongation complex containing HIV-1 Tat,0.0,1.0
r,Formation of HIV elongation complex in the absence of HIV Tat,0.0,1.0
r,Formation of Incision Complex in GG-NER,0.0,1.0
r,Formation of intermediate mesoderm,0.0,1.0
r,Formation of lateral plate mesoderm,0.0,1.0
r,Formation of paraxial mesoderm,0.0,1.0
r,Formation of RNA Pol II elongation complex ,0.0,1.0
r,Formation of Senescence-Associated Heterochromatin Foci (SAHF),0.0,1.0
r,Formation of TC-NER Pre-Incision Complex,0.0,1.0
r,"Formation of the active cofactor, UDP-glucuronate",0.0,1.0
r,Formation of the anterior neural plate,0.0,1.0
r,Formation of the beta-catenin:TCF transactivating complex,0.0,1.0
r,Formation of the cornified envelope,0.0,1.0
r,Formation of the Early Elongation Complex,0.0,1.0
r,Formation of the Editosome,0.0,1.0
r,Formation of the HIV-1 Early Elongation Complex,0.0,1.0
r,Formation of the nephric duct,0.0,1.0
r,Formation of the posterior neural plate,0.0,1.0
r,"Formation of the ternary complex, and subsequently, the 43S complex",0.0,1.0
r,Formation of the ureteric bud,0.0,1.0
r,Formation of tubulin folding intermediates by CCT/TriC,0.0,1.0
r,Formation of WDR5-containing histone-modifying complexes,0.0,1.0
r:w,Formation of xylulose-5-phosphate,0.0,1.0
r,Formyl peptide receptors bind formyl peptides and many other ligands,0.0,1.0
w,FOXA2 pathway,0.0,1.0
r:w,FOXO-mediated transcription,0.0,1.0
r:w,FOXO-mediated transcription of cell cycle genes,0.0,1.0
r:w,FOXO-mediated transcription of cell death genes,0.0,1.0
r:w,"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",0.0,1.0
k,FoxO signaling pathway,0.0,1.0
w,FOXP3 in COVID-19,0.0,1.0
w,Fragile X syndrome,0.0,1.0
r,Free fatty acid receptors,0.0,1.0
r,Free fatty acids regulate insulin secretion,0.0,1.0
r,Frs2-mediated activation,0.0,1.0
r,FRS-mediated FGFR1 signaling,0.0,1.0
r,FRS-mediated FGFR2 signaling,0.0,1.0
r,FRS-mediated FGFR3 signaling,0.0,1.0
r,FRS-mediated FGFR4 signaling,0.0,1.0
k,Fructose and mannose metabolism,0.0,1.0
r,Fructose biosynthesis,0.0,1.0
r,Fructose catabolism,0.0,1.0
r:w,Fructose metabolism,0.0,1.0
w,FTO obesity variant mechanism,0.0,1.0
r,G0 and Early G1,0.0,1.0
w,G13 signaling,0.0,1.0
r,G1 Phase,0.0,1.0
r,G1/S DNA Damage Checkpoints,0.0,1.0
r,G1/S-Specific Transcription,0.0,1.0
r,G1/S Transition,0.0,1.0
w,G1 to S cell cycle control,0.0,1.0
r,G2/M Checkpoints,0.0,1.0
r,G2/M DNA damage checkpoint,0.0,1.0
r,G2/M DNA replication checkpoint,0.0,1.0
r,G2/M Transition,0.0,1.0
r,G2 Phase,0.0,1.0
r,GAB1 signalosome,0.0,1.0
r,GABA B receptor activation,0.0,1.0
w,GABA metabolism (aka GHB),0.0,1.0
r:w,GABA receptor activation,0.0,1.0
w,GABA receptor signaling,0.0,1.0
r,GABA synthesis,0.0,1.0
r:w,"GABA synthesis, release, reuptake and degradation",0.0,1.0
r,Gain-of-function MRAS complexes activate RAF signaling,0.0,1.0
r:w,Galactose catabolism,0.0,1.0
k,Galactose metabolism,0.0,1.0
w,Galanin receptor pathway,0.0,1.0
w,G alpha (i) signaling events,0.0,1.0
r,G alpha (i) signalling events,0.0,1.0
w,G alpha (q) signaling events,0.0,1.0
r,G alpha (q) signalling events,0.0,1.0
w,G alpha (s) signaling events,0.0,1.0
r,G alpha (s) signalling events,0.0,1.0
w,G alpha (z) signaling events,0.0,1.0
w,"Gamma carboxylation, hypusine formation and arylsulfatase activation",0.0,1.0
r,"Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation",0.0,1.0
r,Gamma-carboxylation of protein precursors,0.0,1.0
r,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0,1.0
w,"Gamma-glutamyl cycle for the biosynthesis and degradation of glutathione, including diseases",0.0,1.0
w,Ganglio series sphingolipid metabolism,0.0,1.0
w,Ganglio sphingolipid metabolism,0.0,1.0
r,Gap-filling DNA repair synthesis and ligation in GG-NER,0.0,1.0
r,Gap-filling DNA repair synthesis and ligation in TC-NER,0.0,1.0
r,Gap junction assembly,0.0,1.0
r,Gap junction degradation,0.0,1.0
r,Gap junction trafficking,0.0,1.0
r:w,Gap junction trafficking and regulation,0.0,1.0
w,Gastric acid production,0.0,1.0
k,Gastric cancer,0.0,1.0
w,Gastric cancer network 1,0.0,1.0
w,Gastric cancer network 2,0.0,1.0
w,Gastrin-CREB signaling via PKC and MAPK,0.0,1.0
r,Gastrin-CREB signalling pathway via PKC and MAPK,0.0,1.0
w,Gastrin signaling,0.0,1.0
r,Gastrulation,0.0,1.0
r,G beta:gamma signalling through BTK,0.0,1.0
r,G beta:gamma signalling through PI3Kgamma,0.0,1.0
r,G beta:gamma signalling through PLC beta,0.0,1.0
w,GDNF/RET signaling axis,0.0,1.0
w,GDNF signaling,0.0,1.0
r:w,Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation,0.0,1.0
w,Gene regulatory network modeling somitogenesis ,0.0,1.0
w,Genes associated with the development of rheumatoid arthritis,0.0,1.0
w,Genes controlling nephrogenesis,0.0,1.0
r:w,Gene Silencing by RNA,0.0,1.0
w,Genes related to primary cilium development (based on CRISPR),0.0,1.0
w,Genes targeted by miRNAs in adipocytes,0.0,1.0
w,Genetic causes of porto-sinusoidal vascular disease,0.0,1.0
w,Genotoxicity pathway,0.0,1.0
r,Germ layer formation at gastrulation,0.0,1.0
r,gilteritinib-resistant FLT3 mutants,0.0,1.0
r,GLI3 is processed to GLI3R by the proteasome,0.0,1.0
w,Glial cell differentiation,0.0,1.0
r,GLI proteins bind promoters of Hh responsive genes to promote transcription,0.0,1.0
r,Global Genome Nucleotide Excision Repair (GG-NER),0.0,1.0
w,Globo sphingolipid metabolism,0.0,1.0
w,GLP-1 from intestine and pancreas and role in glucose homeostasis,0.0,1.0
w,GLP-1 in pancreatic islet cells,0.0,1.0
w,GLP-1 secretion from intestine to portal vein,0.0,1.0
r,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,0.0,1.0
r,Glucagon signaling in metabolic regulation,0.0,1.0
k,Glucagon signaling pathway,0.0,1.0
r,Glucagon-type ligand receptors,0.0,1.0
r:w,Glucocorticoid biosynthesis,0.0,1.0
w,Glucocorticoid receptor pathway,0.0,1.0
r,Gluconeogenesis,0.0,1.0
w,Glucose homeostasis,0.0,1.0
r:w,Glucose metabolism,0.0,1.0
w,Glucose metabolism in triple-negative breast cancer cells,0.0,1.0
r:w,Glucuronidation,0.0,1.0
r:w,Glutamate and glutamine metabolism,0.0,1.0
r,Glutamate Neurotransmitter Release Cycle,0.0,1.0
r,Glutathione conjugation,0.0,1.0
k:w,Glutathione metabolism,0.0,1.0
r,Glutathione synthesis and recycling,0.0,1.0
k,Glycerolipid metabolism,0.0,1.0
w,Glycerolipids and glycerophospholipids,0.0,1.0
r:w,Glycerophospholipid biosynthesis,0.0,1.0
w,Glycerophospholipid biosynthetic pathway,0.0,1.0
r,Glycerophospholipid catabolism,0.0,1.0
k,Glycerophospholipid metabolism,0.0,1.0
r,Glycine degradation,0.0,1.0
w,Glycine metabolism,0.0,1.0
w,"Glycine metabolism, including IMDs",0.0,1.0
k,"Glycine, serine and threonine metabolism",0.0,1.0
r,Glycogen breakdown (glycogenolysis),0.0,1.0
r:w,Glycogen metabolism,0.0,1.0
r,Glycogen storage diseases,0.0,1.0
r,Glycogen storage disease type 0 (liver GYS2),0.0,1.0
r,Glycogen storage disease type 0 (muscle GYS1),0.0,1.0
r,Glycogen storage disease type Ia (G6PC),0.0,1.0
r,Glycogen storage disease type Ib (SLC37A4),0.0,1.0
r,Glycogen storage disease type II (GAA),0.0,1.0
r,Glycogen storage disease type IV (GBE1),0.0,1.0
r,Glycogen storage disease type XV (GYG1),0.0,1.0
r,Glycogen synthesis,0.0,1.0
w,Glycogen synthesis and degradation,0.0,1.0
r,Glycolysis,0.0,1.0
w,Glycolysis and gluconeogenesis,0.0,1.0
w,Glycolysis and gluconeogenesis - for workshop,0.0,1.0
k,Glycolysis / Gluconeogenesis,0.0,1.0
w,Glycolysis in senescence,0.0,1.0
r,Glycoprotein hormones,0.0,1.0
k,Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate,0.0,1.0
k,Glycosaminoglycan biosynthesis - heparan sulfate / heparin,0.0,1.0
k,Glycosaminoglycan biosynthesis - keratan sulfate,0.0,1.0
k:w,Glycosaminoglycan degradation,0.0,1.0
r:w,Glycosaminoglycan metabolism,0.0,1.0
w,Glycosaminoglycan synthesis in fibroblasts,0.0,1.0
r,Glycosphingolipid biosynthesis,0.0,1.0
k,Glycosphingolipid biosynthesis - ganglio series,0.0,1.0
k,Glycosphingolipid biosynthesis - globo and isoglobo series,0.0,1.0
k,Glycosphingolipid biosynthesis - lacto and neolacto series,0.0,1.0
r,Glycosphingolipid catabolism,0.0,1.0
r:w,Glycosphingolipid metabolism,0.0,1.0
r,Glycosphingolipid transport,0.0,1.0
w,Glycosylation and related congenital defects,0.0,1.0
k,Glycosylphosphatidylinositol (GPI)-anchor biosynthesis,0.0,1.0
k,Glyoxylate and dicarboxylate metabolism,0.0,1.0
w,Glyoxylate metabolism,0.0,1.0
r:w,Glyoxylate metabolism and glycine degradation,0.0,1.0
w,GNAQ pathways in port-wine stain,0.0,1.0
r,Golgi Associated Vesicle Biogenesis,0.0,1.0
r,Golgi Cisternae Pericentriolar Stack Reorganization,0.0,1.0
r,Golgi-to-ER retrograde transport,0.0,1.0
w,GP1b-IX-V activation signaling,0.0,1.0
r,GP1b-IX-V activation signalling,0.0,1.0
r,GPCR ligand binding,0.0,1.0
w,"GPCRs, class A rhodopsin-like",0.0,1.0
w,"GPCRs, class B secretin-like",0.0,1.0
w,"GPCRs, class C metabotropic glutamate, pheromone",0.0,1.0
w,"GPCRs, other",0.0,1.0
r,GPER1 signaling,0.0,1.0
w,GPR40 pathway,0.0,1.0
r,G-protein activation,0.0,1.0
r,G protein gated Potassium channels,0.0,1.0
r,G-protein mediated events,0.0,1.0
r:w,GPVI-mediated activation cascade,0.0,1.0
k,Graft-versus-host disease,0.0,1.0
r,GRB2 events in EGFR signaling,0.0,1.0
r,GRB2 events in ERBB2 signaling,0.0,1.0
r,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0,1.0
r,GRB7 events in ERBB2 signaling,0.0,1.0
w,Growth factors and hormones in beta cell proliferation,0.0,1.0
r:w,Growth hormone receptor signaling,0.0,1.0
r,GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2,0.0,1.0
r,GTP hydrolysis and joining of the 60S ribosomal subunit,0.0,1.0
w,Gut-liver indole metabolism ,0.0,1.0
w,"H19, Rb-E2F1, and CDK-beta-catenin in colorectal cancer",0.0,1.0
w,Hair follicle development: induction - stage 1 of 3,0.0,1.0
w,Hair follicle development: organogenesis - stage 2 of 3,0.0,1.0
w,Hallmark of cancer: metastasis and epithelial-to-mesenchymal transition,0.0,1.0
r,HATs acetylate histones,0.0,1.0
r,HCMV Early Events,0.0,1.0
r,HCMV Infection,0.0,1.0
r,HCMV Late Events,0.0,1.0
r,HCN channels,0.0,1.0
r,HDACs deacetylate histones,0.0,1.0
r,HDL assembly,0.0,1.0
r,HDL clearance,0.0,1.0
r,HDL remodeling,0.0,1.0
r,HDMs demethylate histones,0.0,1.0
r,HDR through Homologous Recombination (HRR),0.0,1.0
r,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.0,1.0
w,HDR through Homologous Recombination or Single Strand Annealing,0.0,1.0
r:w,HDR through MMEJ (alt-NHEJ),0.0,1.0
r,HDR through Single Strand Annealing (SSA),0.0,1.0
w,Head and neck squamous cell carcinoma,0.0,1.0
r:w,Hedgehog ligand biogenesis,0.0,1.0
r:w,Hedgehog 'off' state,0.0,1.0
r:w,Hedgehog 'on' state,0.0,1.0
w,Hedgehog signaling,0.0,1.0
k,Hedgehog signaling pathway,0.0,1.0
k,Hematopoietic cell lineage,0.0,1.0
w,Hematopoietic stem cell differentiation,0.0,1.0
w,Hematopoietic stem cell gene regulation by GABP alpha/beta complex,0.0,1.0
r:w,Heme biosynthesis,0.0,1.0
r,Heme degradation,0.0,1.0
r,Heme signaling,0.0,1.0
w,Hemesynthesis defects and porphyrias,0.0,1.0
r,Heparan sulfate/heparin (HS-GAG) metabolism,0.0,1.0
w,Hepatitis C and hepatocellular carcinoma,0.0,1.0
w,Hepatocyte growth factor receptor signaling,0.0,1.0
r,Hereditary fructose intolerance,0.0,1.0
w,Hereditary leiomyomatosis and renal cell carcinoma pathway,0.0,1.0
w,Heroin metabolism,0.0,1.0
k,Herpes simplex virus 1 infection,0.0,1.0
w,Hfe effect on hepcidin production,0.0,1.0
r,HHAT G278V doesn't palmitoylate Hh-Np,0.0,1.0
r,Hh mutants abrogate ligand secretion,0.0,1.0
r,Hh mutants are degraded by ERAD,0.0,1.0
w,HIF1A and PPARG regulation of glycolysis,0.0,1.0
r,Highly calcium permeable nicotinic acetylcholine receptors,0.0,1.0
r,Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,0.0,1.0
r,Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,0.0,1.0
w,Hijack of ubiquitination by SARS-CoV-2,0.0,1.0
w,HIPK2 in kidney fibrosis,0.0,1.0
w,Hippocampal synaptogenesis and neurogenesis,0.0,1.0
w,Hippo-Merlin signaling dysregulation,0.0,1.0
k,Hippo signaling pathway,0.0,1.0
k,Hippo signaling pathway - multiple species,0.0,1.0
w,Hippo-YAP signaling,0.0,1.0
r,Histamine receptors,0.0,1.0
r:w,Histidine catabolism,0.0,1.0
k,Histidine metabolism,0.0,1.0
w,Histone modifications,0.0,1.0
r,HIV elongation arrest and recovery,0.0,1.0
r,HIV Infection,0.0,1.0
r:w,HIV Life Cycle,0.0,1.0
r,HIV Transcription Elongation,0.0,1.0
r,HIV Transcription Initiation,0.0,1.0
w,HoC: Nonmutational epigenetic reprogramming,0.0,1.0
w,HoC: Sustaining proliferative signalling,0.0,1.0
r,Homologous DNA Pairing and Strand Exchange,0.0,1.0
k:w,Homologous recombination,0.0,1.0
r,Homology Directed Repair,0.0,1.0
w,Hormonal control of pubertal growth spurt,0.0,1.0
r,Hormone ligand-binding receptors,0.0,1.0
r:w,Host Interactions of HIV factors,0.0,1.0
w,Host-pathogen interaction of human coronaviruses - apoptosis,0.0,1.0
w,Host-pathogen interaction of human coronaviruses - autophagy,0.0,1.0
w,Host-pathogen interaction of human coronaviruses - interferon induction,0.0,1.0
w,Host-pathogen interaction of human coronaviruses - MAPK signaling,0.0,1.0
r,HS-GAG biosynthesis,0.0,1.0
r,HS-GAG degradation,0.0,1.0
w,HSP90 chaperone cycle for steroid hormone receptors (SHR),0.0,1.0
r,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0,1.0
k,Human papillomavirus infection,0.0,1.0
w,Hunger and satiety,0.0,1.0
k,Huntington disease,0.0,1.0
r,HuR (ELAVL1) binds and stabilizes mRNA,0.0,1.0
r,Hyaluronan biosynthesis and export,0.0,1.0
r,Hyaluronan metabolism,0.0,1.0
r,Hyaluronan uptake and degradation,0.0,1.0
r,Hydrolysis of LPC,0.0,1.0
r,Hydrolysis of LPE,0.0,1.0
r,Hydroxycarboxylic acid-binding receptors,0.0,1.0
k,Hypertrophic cardiomyopathy,0.0,1.0
w,Hypertrophy model,0.0,1.0
w,Hypothesized pathways in pathogenesis of cardiovascular disease,0.0,1.0
w,Hypothetical craniofacial development pathway,0.0,1.0
w,Hypoxia-mediated EMT and stemness,0.0,1.0
r,Hypusine synthesis from eIF5A-lysine,0.0,1.0
w,IDO metabolic pathway,0.0,1.0
w,ID signaling,0.0,1.0
r,IFNG signaling activates MAPKs,0.0,1.0
r,IGF1R signaling cascade,0.0,1.0
r,IkBA variant leads to EDA-ID,0.0,1.0
r,IKBKB deficiency causes SCID,0.0,1.0
r,IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR),0.0,1.0
r,IKK complex recruitment mediated by RIP1,0.0,1.0
w,IL10 anti-inflammatory signaling,0.0,1.0
w,IL11 signaling,0.0,1.0
w,IL17 signaling,0.0,1.0
k,IL-17 signaling pathway,0.0,1.0
w,IL19 signaling,0.0,1.0
w,IL1 and megakaryocytes in obesity,0.0,1.0
w,IL2 signaling,0.0,1.0
w,IL3 signaling,0.0,1.0
w,IL4 signaling,0.0,1.0
w,IL5 signaling,0.0,1.0
w,IL6 signaling,0.0,1.0
r,IL-6-type cytokine receptor ligand interactions,0.0,1.0
w,IL7 signaling,0.0,1.0
w,IL9 signaling,0.0,1.0
w,Imatinib and chronic myeloid leukemia,0.0,1.0
r,Imatinib-resistant KIT mutants,0.0,1.0
r,Imatinib-resistant PDGFR mutants,0.0,1.0
w,Immune infiltration in pancreatic cancer,0.0,1.0
w,Immune response to tuberculosis,0.0,1.0
r,Impaired BRCA2 binding to PALB2,0.0,1.0
r,Impaired BRCA2 binding to RAD51,0.0,1.0
r,Impaired BRCA2 binding to SEM1 (DSS1),0.0,1.0
r,Impaired BRCA2 translocation to the nucleus,0.0,1.0
r,Inactivation of APC/C via direct inhibition of the APC/C complex,0.0,1.0
r,Inactivation of CDC42 and RAC1,0.0,1.0
r,Inactivation of CSF3 (G-CSF) signaling,0.0,1.0
r,"Inactivation, recovery and regulation of the phototransduction cascade",0.0,1.0
w,Inclusion body myositis,0.0,1.0
r:w,"Incretin synthesis, secretion, and inactivation",0.0,1.0
w,Induction of autophagy and toll-like receptor signaling by graphene oxide ,0.0,1.0
r,Induction of Cell-Cell Fusion,0.0,1.0
r,Infection with Mycobacterium tuberculosis,0.0,1.0
r,Inflammasomes,0.0,1.0
w,Inflammatory response pathway,0.0,1.0
w,Influence of laminopathies on Wnt signaling,0.0,1.0
w,Influenza A virus infection,0.0,1.0
r:w,Influenza Infection,0.0,1.0
r,Influenza Viral RNA Transcription and Replication,0.0,1.0
r,Influenza Virus Induced Apoptosis,0.0,1.0
r,Inhibition of DNA recombination at telomere,0.0,1.0
w,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells,0.0,1.0
r,Inhibition of Host mRNA Processing and RNA Silencing,0.0,1.0
r,Inhibition of membrane repair,0.0,1.0
r,Inhibition of nitric oxide production,0.0,1.0
r,Inhibition of PKR,0.0,1.0
r,Inhibition of replication initiation of damaged DNA by RB1/E2F1,0.0,1.0
r,Inhibition of Signaling by Overexpressed EGFR,0.0,1.0
r,Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components,0.0,1.0
r,Inhibition of TSC complex formation by PKB,0.0,1.0
r,Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits,0.0,1.0
r,Initial triggering of complement,0.0,1.0
r,Initiation of Nuclear Envelope (NE) Reformation,0.0,1.0
r,InlA-mediated entry of Listeria monocytogenes into host cells,0.0,1.0
r,InlB-mediated entry of Listeria monocytogenes into host cell,0.0,1.0
k:r:w,Inositol phosphate metabolism,0.0,1.0
r,Inositol transporters,0.0,1.0
r:w,Insertion of tail-anchored proteins into the endoplasmic reticulum membrane,0.0,1.0
r,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0,1.0
w,Insulin-like Growth Factor-2 mRNA Binding Proteins binding to RNA,0.0,1.0
r,Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA,0.0,1.0
r:w,Insulin processing,0.0,1.0
r,Insulin receptor recycling,0.0,1.0
r,Insulin receptor signalling cascade,0.0,1.0
w,Insulin signaling in adipocytes (diabetic condition),0.0,1.0
w,Insulin signaling in adipocytes (normal condition),0.0,1.0
k,Insulin signaling pathway,0.0,1.0
w,Integrated breast cancer pathway,0.0,1.0
w,Integrated cancer pathway,0.0,1.0
r:w,Integration of energy metabolism,0.0,1.0
r,Integration of provirus,0.0,1.0
r,Integration of viral DNA into host genomic DNA,0.0,1.0
r,Integrin cell surface interactions,0.0,1.0
w,Integrin-mediated cell adhesion,0.0,1.0
r:w,Integrin signaling,0.0,1.0
r,Interaction between L1 and Ankyrins,0.0,1.0
r,Interaction between PHLDA1 and AURKA,0.0,1.0
w,Interactions between immune cells and microRNAs in tumor microenvironment,0.0,1.0
w,Interactions between LOXL4 and oxidative stress pathway,0.0,1.0
w,Interactions of natural killer cells in pancreatic cancer,0.0,1.0
r,Interactions of Rev with host cellular proteins,0.0,1.0
r,Interactions of Tat with host cellular proteins,0.0,1.0
r,Interactions of Vpr with host cellular proteins,0.0,1.0
r,Interaction With Cumulus Cells And The Zona Pellucida,0.0,1.0
w,Interactome of polycomb repressive complex 2 (PRC2) ,0.0,1.0
r,Interconversion of 2-oxoglutarate and 2-hydroxyglutarate,0.0,1.0
r:w,Interconversion of nucleotide di- and triphosphates,0.0,1.0
r,Interconversion of polyamines,0.0,1.0
r:w,Interferon alpha/beta signaling,0.0,1.0
r:w,Interferon gamma signaling,0.0,1.0
w,Interferon-mediated signaling,0.0,1.0
r,Interferon Signaling,0.0,1.0
w,Interferon type I signaling,0.0,1.0
r:w,Interleukin-10 signaling,0.0,1.0
r:w,Interleukin-12 family signaling,0.0,1.0
r,Interleukin-12 signaling,0.0,1.0
r:w,Interleukin-15 signaling,0.0,1.0
r:w,Interleukin-17 signaling,0.0,1.0
r,Interleukin-18 signaling,0.0,1.0
r:w,Interleukin-1 family signaling,0.0,1.0
w,Interleukin-1 (IL-1) structural pathway,0.0,1.0
w,Interleukin-1 induced activation of NF-kB,0.0,1.0
r:w,Interleukin-1 processing,0.0,1.0
r,Interleukin-1 signaling,0.0,1.0
r:w,Interleukin-20 family signaling,0.0,1.0
r,Interleukin-21 signaling,0.0,1.0
r,Interleukin-23 signaling,0.0,1.0
r,Interleukin-27 signaling,0.0,1.0
r:w,Interleukin-2 family signaling,0.0,1.0
r,Interleukin-2 signaling,0.0,1.0
r,Interleukin-33 signaling,0.0,1.0
r,Interleukin-35 Signalling,0.0,1.0
r,Interleukin-36 pathway,0.0,1.0
r,Interleukin-37 signaling,0.0,1.0
r,Interleukin-38 signaling,0.0,1.0
r:w,"Interleukin-3, Interleukin-5 and GM-CSF signaling",0.0,1.0
r:w,Interleukin-4 and Interleukin-13 signaling,0.0,1.0
r:w,Interleukin-6 family signaling,0.0,1.0
r,Interleukin-6 signaling,0.0,1.0
r:w,Interleukin-7 signaling,0.0,1.0
r:w,Interleukin-9 signaling,0.0,1.0
r,Interleukin receptor SHC signaling,0.0,1.0
r:w,Intestinal absorption,0.0,1.0
r,Intestinal hexose absorption,0.0,1.0
k,Intestinal immune network for IgA production,0.0,1.0
r:w,Intestinal infectious diseases,0.0,1.0
r,Intestinal lipid absorption,0.0,1.0
r,Intestinal saccharidase deficiencies,0.0,1.0
r,Intracellular metabolism of fatty acids regulates insulin secretion,0.0,1.0
r:w,Intracellular oxygen transport,0.0,1.0
r,Intracellular signaling by second messengers,0.0,1.0
w,Intracellular trafficking proteins involved in CMT neuropathy,0.0,1.0
r,Intraflagellar transport,0.0,1.0
w,Intraflagellar transport proteins binding to dynein,0.0,1.0
r:w,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0,1.0
r,Intra-Golgi traffic,0.0,1.0
r:w,Intrinsic Pathway for Apoptosis,0.0,1.0
r,Intrinsic Pathway of Fibrin Clot Formation,0.0,1.0
r,Invadopodia formation,0.0,1.0
w,Involvement of &delta;-secretase in neurodegenerative diseases,0.0,1.0
r,Inwardly rectifying K+ channels,0.0,1.0
r:w,Ion channel transport,0.0,1.0
r,Ion homeostasis,0.0,1.0
r,Ion influx/efflux at host-pathogen interface,0.0,1.0
r,Ionotropic activity of kainate receptors,0.0,1.0
r,Ion transport by P-type ATPases,0.0,1.0
r,IRAK1 recruits IKK complex,0.0,1.0
r,IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation,0.0,1.0
r,IRAK2 mediated activation of TAK1 complex,0.0,1.0
r,IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation,0.0,1.0
r,IRAK4 deficiency (TLR2/4),0.0,1.0
r,IRAK4 deficiency (TLR5),0.0,1.0
r,IRE1alpha activates chaperones,0.0,1.0
r,IRF3 mediated activation of type 1 IFN,0.0,1.0
r,IRF3-mediated induction of type I IFN,0.0,1.0
w,Irinotecan pathway,0.0,1.0
w,Iron metabolism disorders,0.0,1.0
w,Iron metabolism in placenta,0.0,1.0
w,Iron-sulfur cluster biogenesis,0.0,1.0
r:w,Iron uptake and transport,0.0,1.0
r,IRS activation,0.0,1.0
r,IRS-mediated signalling,0.0,1.0
r,IRS-related events triggered by IGF1R,0.0,1.0
r:w,ISG15 antiviral mechanism,0.0,1.0
w,Isoglobo series sphingolipids,0.0,1.0
w,JAK/STAT pathway,0.0,1.0
w,JAK-STAT signaling in the regulation of beta cells,0.0,1.0
k,JAK-STAT signaling pathway,0.0,1.0
r,JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1,0.0,1.0
r,Josephin domain DUBs,0.0,1.0
w,Joubert syndrome,0.0,1.0
w,Kallmann syndrome,0.0,1.0
w,KCNQ2-related epilepsies,0.0,1.0
r,KEAP1-NFE2L2 pathway,0.0,1.0
w,Kennedy pathway from sphingolipids,0.0,1.0
r,Keratan sulfate biosynthesis,0.0,1.0
r,Keratan sulfate degradation,0.0,1.0
r,Keratan sulfate/keratin metabolism,0.0,1.0
r:w,Keratinization,0.0,1.0
w,Ketogenesis and ketolysis,0.0,1.0
r:w,Ketone body metabolism,0.0,1.0
r,Kidney development,0.0,1.0
r,Killing mechanisms,0.0,1.0
r:w,Kinesins,0.0,1.0
w,Kinin-Kallikrein pathway,0.0,1.0
r,KIT mutants bind TKIs,0.0,1.0
w,Kleefstra syndrome,0.0,1.0
w,Krebs cycle disorders,0.0,1.0
r,KSRP (KHSRP) binds and destabilizes mRNA,0.0,1.0
r,KW2449-resistant FLT3 mutants,0.0,1.0
w,Kynurenine pathway and links to cell senescence,0.0,1.0
r,L13a-mediated translational silencing of Ceruloplasmin expression,0.0,1.0
r:w,L1CAM interactions,0.0,1.0
w,Lac-Phe pathway,0.0,1.0
w,Lactate shuttle in glial cells,0.0,1.0
w,Lacto series sphingolipid metabolism,0.0,1.0
r:w,Lactose synthesis,0.0,1.0
r,Lagging Strand Synthesis,0.0,1.0
w,Lamin A processing pathway,0.0,1.0
r,Laminin interactions,0.0,1.0
r:w,Late endosomal microautophagy,0.0,1.0
r,Latent infection - Other responses of Mtb to phagocytosis,0.0,1.0
w,Latent infection - Other responses of Mycobacterium tuberculosis to phagocytosis,0.0,1.0
r,Late Phase of HIV Life Cycle,0.0,1.0
r,Late SARS-CoV-2 Infection Events,0.0,1.0
r,LDL clearance,0.0,1.0
w,LDL- influence on CD14 and TLR4,0.0,1.0
w,LDLRAD4 and what we know about it,0.0,1.0
r,LDL remodeling,0.0,1.0
r,Leading Strand Synthesis,0.0,1.0
r,Lectin pathway of complement activation,0.0,1.0
k,Legionellosis,0.0,1.0
r,Leishmania infection,0.0,1.0
r,Leishmania parasite growth and survival,0.0,1.0
r,Leishmania phagocytosis,0.0,1.0
w,Leptin and adiponectin,0.0,1.0
w,Leptin-insulin signaling overlap,0.0,1.0
w,Leptin signaling,0.0,1.0
r,lestaurtinib-resistant FLT3 mutants,0.0,1.0
w,let-7 inhibition of ES cell reprogramming,0.0,1.0
w,"Leucine, isoleucine and valine metabolism",0.0,1.0
w,Leukocyte-intrinsic Hippo pathway functions,0.0,1.0
w,Leukotriene metabolic pathway,0.0,1.0
r,Leukotriene receptors,0.0,1.0
r,Lewis blood group biosynthesis,0.0,1.0
r:w,LGI-ADAM interactions,0.0,1.0
r,LGK974 inhibits PORCN,0.0,1.0
w,Lidocaine metabolism,0.0,1.0
r,Ligand-receptor interactions,0.0,1.0
r,linifanib-resistant FLT3 mutants,0.0,1.0
r,Linoleic acid (LA) metabolism,0.0,1.0
k,Linoleic acid metabolism,0.0,1.0
w,Linoleic acid metabolism affected by SARS-CoV-2,0.0,1.0
w,Linoleic acid oxylipin metabolism,0.0,1.0
w,Lipid metabolism in senescent cells,0.0,1.0
w,Lipid metabolism pathway,0.0,1.0
r:w,Lipid particle organization,0.0,1.0
w,Lipid particles composition,0.0,1.0
w,Lipid storage and perilipins in skeletal muscle,0.0,1.0
k,Lipoic acid metabolism,0.0,1.0
r:w,Lipophagy,0.0,1.0
r:w,Listeria monocytogenes entry into host cells,0.0,1.0
w,Liver X receptor pathway,0.0,1.0
w,lncRNA in canonical Wnt signaling and colorectal cancer,0.0,1.0
w,lncRNA-mediated mechanisms of therapeutic resistance,0.0,1.0
r,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,0.0,1.0
k,Longevity regulating pathway,0.0,1.0
k,Longevity regulating pathway - multiple species,0.0,1.0
r,lorlatinib-resistant ALK mutants,0.0,1.0
r,Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling,0.0,1.0
r,Loss of function of MECP2 in Rett syndrome,0.0,1.0
r,Loss of Function of SMAD2/3 in Cancer,0.0,1.0
r,Loss of Function of SMAD4 in Cancer,0.0,1.0
r,Loss of Function of TGFBR1 in Cancer,0.0,1.0
r,Loss of Function of TGFBR2 in Cancer,0.0,1.0
r,Loss of Function of TP53 in Cancer,0.0,1.0
r,Loss of function of TP53 in cancer due to loss of tetramerization ability,0.0,1.0
r,Loss of MECP2 binding ability to 5hmC-DNA,0.0,1.0
r,Loss of MECP2 binding ability to 5mC-DNA,0.0,1.0
r,Loss of MECP2 binding ability to the NCoR/SMRT complex,0.0,1.0
r,Loss of Nlp from mitotic centrosomes,0.0,1.0
r,Loss of phosphorylation of MECP2 at T308,0.0,1.0
r,Loss of proteins required for interphase microtubule organization from the centrosome,0.0,1.0
r,LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production,0.0,1.0
r,LTC4-CYSLTR mediated IL4 production,0.0,1.0
w,LTF danger signal response pathway,0.0,1.0
w,Lung fibrosis,0.0,1.0
w,Lung pathology of COVID-19,0.0,1.0
r:w,Lysine catabolism,0.0,1.0
k,Lysine degradation,0.0,1.0
r:w,Lysosomal oligosaccharide catabolism,0.0,1.0
r,Lysosome Vesicle Biogenesis,0.0,1.0
r,Lysosphingolipid and LPA receptors,0.0,1.0
r:w,Macroautophagy,0.0,1.0
w,Macrophage markers,0.0,1.0
r:w,Major pathway of rRNA processing in the nucleolus and cytosol,0.0,1.0
w,Major receptors targeted by epinephrine and norepinephrine,0.0,1.0
r:w,Malate-aspartate shuttle,0.0,1.0
w,Male infertility,0.0,1.0
w,Male steroid hormones in cardiomyocyte energy metabolism,0.0,1.0
w,Mammalian disorder of sexual development,0.0,1.0
w,Mammary gland development: embryonic development - stage 1 of 4,0.0,1.0
w,Mammary gland development: involution - stage 4 of 4,0.0,1.0
w,Mammary gland development: pregnancy and lactation - stage 3 of 4,0.0,1.0
w,Mammary gland development: puberty - stage 2 of 4,0.0,1.0
r,Manipulation of host energy metabolism,0.0,1.0
k,Mannose type O-glycan biosynthesis,0.0,1.0
r,MAP2K and MAPK activation,0.0,1.0
w,MAP3K1 role in promoting and blocking gonadal determination,0.0,1.0
r,MAP3K8 (TPL2)-dependent MAPK1/3 activation,0.0,1.0
r,MAPK1 (ERK2) activation,0.0,1.0
r,MAPK1/MAPK3 signaling,0.0,1.0
r,MAPK3 (ERK1) activation,0.0,1.0
r:w,MAPK6/MAPK4 signaling,0.0,1.0
w,MAPK and NFkB signaling inhibited by Yersinia YopJ,0.0,1.0
w,MAPK cascade,0.0,1.0
r,MAPK family signaling cascades,0.0,1.0
r:w,MAP kinase activation,0.0,1.0
w,MAPK pathway in congenital thyroid cancer,0.0,1.0
r:w,MAPK targets/ Nuclear events mediated by MAP kinases,0.0,1.0
w,Markers of kidney cell lineage,0.0,1.0
r,Masitinib-resistant KIT mutants,0.0,1.0
r,MASTL Facilitates Mitotic Progression,0.0,1.0
r,Maternal to zygotic transition (MZT),0.0,1.0
w,Matrix metalloproteinases,0.0,1.0
r,Maturation of hRSV A proteins,0.0,1.0
r,Maturation of nucleoprotein,0.0,1.0
r,Maturation of protein 3a,0.0,1.0
r,Maturation of protein E,0.0,1.0
r,Maturation of replicase proteins,0.0,1.0
r,Maturation of spike protein,0.0,1.0
r,Maturation of TCA enzymes and regulation of TCA cycle,0.0,1.0
k,Maturity onset diabetes of the young,0.0,1.0
w,mBDNF and proBDNF regulation of GABA neurotransmission,0.0,1.0
r,M-decay: degradation of maternal mRNAs by maternally stored factors,0.0,1.0
r,MDK and PTN in ALK signaling,0.0,1.0
k,Measles,0.0,1.0
w,Measles virus infection,0.0,1.0
w,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms,0.0,1.0
w,MECP2 and associated Rett syndrome,0.0,1.0
r,MECP2 regulates neuronal receptors and channels,0.0,1.0
r,MECP2 regulates transcription factors,0.0,1.0
r,MECP2 regulates transcription of genes involved in GABA signaling,0.0,1.0
r,MECP2 regulates transcription of neuronal ligands,0.0,1.0
r:w,Meiotic recombination,0.0,1.0
r:w,Melanin biosynthesis,0.0,1.0
k:w,Melanoma,0.0,1.0
w,Melatonin metabolism and effects,0.0,1.0
r,Membrane binding and targetting of GAG proteins,0.0,1.0
r,Membrane Trafficking,0.0,1.0
w,Mesodermal commitment pathway,0.0,1.0
r,Metabolic disorders of biological oxidation enzymes,0.0,1.0
w,Metabolic epileptic disorders,0.0,1.0
w,"Metabolic pathway of LDL, HDL and TG, including diseases",0.0,1.0
w,Metabolic pathways of fibroblasts,0.0,1.0
w,Metabolic reprogramming in colon cancer,0.0,1.0
w,Metabolic reprogramming in pancreatic cancer,0.0,1.0
w,Metabolism of alpha-linolenic acid,0.0,1.0
r:w,Metabolism of amine-derived hormones,0.0,1.0
r,Metabolism of amino acids and derivatives,0.0,1.0
r:w,Metabolism of Angiotensinogen to Angiotensins,0.0,1.0
r,Metabolism of carbohydrates,0.0,1.0
r:w,Metabolism of cofactors,0.0,1.0
w,Metabolism of dichloroethylene by CYP450,0.0,1.0
r,Metabolism of fat-soluble vitamins,0.0,1.0
r:w,Metabolism of folate and pterines,0.0,1.0
r,Metabolism of ingested H2SeO4 and H2SeO3 into H2Se,0.0,1.0
r,Metabolism of ingested MeSeO2H into MeSeH,0.0,1.0
r,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.0,1.0
r:w,Metabolism of nitric oxide: NOS3 activation and regulation,0.0,1.0
r:w,Metabolism of non-coding RNA,0.0,1.0
r,Metabolism of nucleotides,0.0,1.0
r:w,Metabolism of polyamines,0.0,1.0
r:w,Metabolism of porphyrins,0.0,1.0
r,Metabolism of RNA,0.0,1.0
r,Metabolism of serotonin,0.0,1.0
w,Metabolism of sphingolipids in ER and Golgi apparatus,0.0,1.0
r:w,Metabolism of steroid hormones,0.0,1.0
r,Metabolism of steroids,0.0,1.0
w,Metabolism of tetrahydrocannabinol (THC),0.0,1.0
r:w,Metabolism of vitamin K,0.0,1.0
r,Metabolism of vitamins and cofactors,0.0,1.0
r:w,Metabolism of water-soluble vitamins and cofactors,0.0,1.0
k,Metabolism of xenobiotics by cytochrome P450,0.0,1.0
r,MET activates PI3K/AKT signaling,0.0,1.0
r,MET activates PTK2 signaling,0.0,1.0
r,MET activates PTPN11,0.0,1.0
r,MET activates RAP1 and RAC1,0.0,1.0
r,MET activates RAS signaling,0.0,1.0
r,MET activates STAT3,0.0,1.0
r,Metal ion SLC transporters,0.0,1.0
r,Metalloprotease DUBs,0.0,1.0
r:w,Metallothioneins bind metals,0.0,1.0
r,Metal sequestration by antimicrobial proteins,0.0,1.0
w,Metapathway biotransformation Phase I and II,0.0,1.0
w,Metastatic brain tumor,0.0,1.0
w,Methionine de novo and salvage pathway,0.0,1.0
w,Methionine metabolism leading to sulfur amino acids and related disorders,0.0,1.0
r,Methionine salvage pathway,0.0,1.0
r,Methylation,0.0,1.0
r,Methylation of MeSeH for excretion,0.0,1.0
w,Methylation pathways,0.0,1.0
r,MET interacts with TNS proteins,0.0,1.0
w,MET in type 1 papillary renal cell carcinoma,0.0,1.0
r,MET promotes cell motility,0.0,1.0
r,MET Receptor Activation,0.0,1.0
r,MET receptor recycling,0.0,1.0
w,Mevalonate arm of cholesterol biosynthesis pathway,0.0,1.0
w,Mevalonate arm of cholesterol biosynthesis pathway with inhibitors,0.0,1.0
w,Mevalonate pathway,0.0,1.0
w,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement,0.0,1.0
w,MFAP5-mediated ovarian cancer cell motility and invasiveness,0.0,1.0
r,MGMT-mediated DNA damage reversal,0.0,1.0
r:w,MHC class II antigen presentation,0.0,1.0
r,Microbial modulation of RIPK1-mediated regulated necrosis,0.0,1.0
w,Microglia pathogen phagocytosis pathway,0.0,1.0
w,MicroRNA for targeting cancer growth and vascularization in glioblastoma,0.0,1.0
r,MicroRNA (miRNA) biogenesis,0.0,1.0
w,MicroRNA network associated with chronic lymphocytic leukemia,0.0,1.0
w,Microtubule cytoskeleton regulation,0.0,1.0
r,Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,0.0,1.0
r,midostaurin-resistant FLT3 mutants,0.0,1.0
k,Mineral absorption,0.0,1.0
r:w,Mineralocorticoid biosynthesis,0.0,1.0
r,Minus-strand DNA synthesis,0.0,1.0
w,mir-124 predicted interactions with cell cycle and differentiation ,0.0,1.0
w,miR-222 in exercise-induced cardiac growth,0.0,1.0
w,miR-509-3p alteration of YAP1/ECM axis,0.0,1.0
w,miR-517 relationship with ARCN1 and USP1,0.0,1.0
w,miRNA biogenesis,0.0,1.0
w,miRNA degrading enzymes,0.0,1.0
w,miRNA regulation of DNA damage response,0.0,1.0
w,miRNA regulation of p53 pathway in prostate cancer,0.0,1.0
w,miRNA regulation of prostate cancer signaling,0.0,1.0
w,miRNA role in immune response in sepsis,0.0,1.0
w,miRNAs involved in DNA damage response,0.0,1.0
w,miRNA targets in ECM and membrane receptors,0.0,1.0
r,Miro GTPase Cycle,0.0,1.0
w,miR-targeted genes in adipocytes,0.0,1.0
w,miR-targeted genes in leukocytes,0.0,1.0
w,miR-targeted genes in squamous cell,0.0,1.0
r,Miscellaneous substrates,0.0,1.0
r:w,Miscellaneous transport and binding events,0.0,1.0
k:r:w,Mismatch repair,0.0,1.0
r,Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta),0.0,1.0
r,Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha),0.0,1.0
r,MITF-M-dependent gene expression,0.0,1.0
r,MITF-M-regulated melanocyte development,0.0,1.0
r,Mitochondrial ABC transporters,0.0,1.0
w,Mitochondrial beta-oxidation,0.0,1.0
r:w,Mitochondrial biogenesis,0.0,1.0
r:w,Mitochondrial calcium ion transport,0.0,1.0
w,Mitochondrial complex I assembly model OXPHOS system,0.0,1.0
w,Mitochondrial complex II assembly,0.0,1.0
w,Mitochondrial complex III assembly,0.0,1.0
w,Mitochondrial complex IV assembly,0.0,1.0
r:w,Mitochondrial Fatty Acid Beta-Oxidation,0.0,1.0
r,mitochondrial fatty acid beta-oxidation of saturated fatty acids,0.0,1.0
r,mitochondrial fatty acid beta-oxidation of unsaturated fatty acids,0.0,1.0
w,Mitochondrial fatty acid oxidation disorders,0.0,1.0
w,Mitochondrial fatty acid synthesis and respiration,0.0,1.0
w,Mitochondrial fatty acid synthesis pathway,0.0,1.0
w,Mitochondrial gene expression,0.0,1.0
w,Mitochondrial immune response to SARS-CoV-2,0.0,1.0
r:w,Mitochondrial iron-sulfur cluster biogenesis,0.0,1.0
w,Mitochondrial long chain fatty acid beta-oxidation,0.0,1.0
r,Mitochondrial protein degradation,0.0,1.0
r:w,Mitochondrial protein import,0.0,1.0
r,Mitochondrial RNA degradation,0.0,1.0
r,Mitochondrial transcription initiation,0.0,1.0
r,Mitochondrial transcription termination,0.0,1.0
r:w,Mitochondrial translation,0.0,1.0
r,Mitochondrial translation elongation,0.0,1.0
r,Mitochondrial translation initiation,0.0,1.0
r,Mitochondrial translation termination,0.0,1.0
r,Mitochondrial tRNA aminoacylation,0.0,1.0
r,Mitochondrial Uncoupling,0.0,1.0
r:w,Mitophagy,0.0,1.0
k,Mitophagy - animal,0.0,1.0
r,Mitotic Anaphase,0.0,1.0
r:w,Mitotic G1 phase and G1/S transition,0.0,1.0
r:w,Mitotic G2-G2/M phases,0.0,1.0
r,Mitotic Metaphase/Anaphase Transition,0.0,1.0
r:w,Mitotic Metaphase and Anaphase,0.0,1.0
r:w,Mitotic Prometaphase,0.0,1.0
r,Mitotic Spindle Checkpoint,0.0,1.0
r:w,Mitotic Telophase/Cytokinesis,0.0,1.0
w,Model for regulation of MSMP expression in cancer cells and its proangiogenic role in ovarian tumors,0.0,1.0
w,Modular map of bradykinin signaling network,0.0,1.0
r,Modulation by Mtb of host immune system,0.0,1.0
w,Modulation of PI3K-Akt-mTOR signaling by bioactive sphingolipids,0.0,1.0
w,Molecular pathway for oxidative stress 1.0,0.0,1.0
r,Molecules associated with elastic fibres,0.0,1.0
r,Molybdenum cofactor biosynthesis,0.0,1.0
w,Molybdenum cofactor (Moco) biosynthesis,0.0,1.0
w,Monoamine GPCRs,0.0,1.0
w,Monoamine transport,0.0,1.0
k,Motor proteins,0.0,1.0
r,MPS I - Hurler syndrome,0.0,1.0
r,MPS II - Hunter syndrome,0.0,1.0
r,MPS IIIA - Sanfilippo syndrome A,0.0,1.0
r,MPS IIIB - Sanfilippo syndrome B,0.0,1.0
r,MPS IIIC - Sanfilippo syndrome C,0.0,1.0
r,MPS IIID - Sanfilippo syndrome D,0.0,1.0
r,MPS IV - Morquio syndrome A,0.0,1.0
r,MPS IV - Morquio syndrome B,0.0,1.0
r,MPS IX - Natowicz syndrome,0.0,1.0
r,MPS VII - Sly syndrome,0.0,1.0
r,MPS VI - Maroteaux-Lamy syndrome,0.0,1.0
r,mRNA 3'-end processing,0.0,1.0
r:w,mRNA Capping,0.0,1.0
r,mRNA decay by 3' to 5' exoribonuclease,0.0,1.0
r,mRNA decay by 5' to 3' exoribonuclease,0.0,1.0
r:w,mRNA Editing,0.0,1.0
r,mRNA Editing: A to I Conversion,0.0,1.0
r,mRNA Editing: C to U Conversion,0.0,1.0
w,mRNA processing,0.0,1.0
w,"mRNA, protein, and metabolite inducation pathway by cyclosporin A",0.0,1.0
r,mRNA Splicing,0.0,1.0
r,mRNA Splicing - Major Pathway,0.0,1.0
r,mRNA Splicing - Minor Pathway,0.0,1.0
k,mRNA surveillance pathway,0.0,1.0
w,mRNA vaccine activation of dendritic cell and induction of IFN-1,0.0,1.0
r,Mtb iron assimilation by chelation,0.0,1.0
r:w,MTF1 activates gene expression,0.0,1.0
w,MTHFR deficiency,0.0,1.0
r,mTORC1-mediated signalling,0.0,1.0
w,MTOR signaling,0.0,1.0
r,MTOR signalling,0.0,1.0
k,Mucin type O-glycan biosynthesis,0.0,1.0
r,Mucopolysaccharidoses,0.0,1.0
w,Multi-drug resistance protein 1 (glycoprotein 1) regulation,0.0,1.0
r,Multifunctional anion exchangers,0.0,1.0
w,Multiple epiphyseal dysplasia and pseudoachondroplasia genes,0.0,1.0
r,Muscarinic acetylcholine receptors,0.0,1.0
r,Muscle contraction,0.0,1.0
r:w,MyD88 cascade initiated on plasma membrane,0.0,1.0
r,MyD88 deficiency (TLR2/4),0.0,1.0
r,MyD88 deficiency (TLR5),0.0,1.0
r:w,MyD88 dependent cascade initiated on endosome,0.0,1.0
w,MYD88 distinct input-output pathway,0.0,1.0
r:w,MyD88-independent TLR4 cascade ,0.0,1.0
r:w,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,0.0,1.0
r,Myoclonic epilepsy of Lafora,0.0,1.0
r:w,Myogenesis,0.0,1.0
r,Na+/Cl- dependent neurotransmitter transporters,0.0,1.0
w,NAD biosynthesis II (from tryptophan),0.0,1.0
w,NAD+ biosynthetic pathways,0.0,1.0
r,NADE modulates death signalling,0.0,1.0
w,NAD+ metabolism,0.0,1.0
w,NAD metabolism in oncogene-induced senescence and mitochondrial dysfunction-associated senescence,0.0,1.0
w,"NAD metabolism, sirtuins and aging",0.0,1.0
r,NADPH regeneration,0.0,1.0
w,Nanomaterial induced apoptosis,0.0,1.0
w,Nanomaterial-induced inflammasome activation,0.0,1.0
w,Nanoparticle-mediated activation of receptor signaling,0.0,1.0
w,Nanoparticle triggered autophagic cell death,0.0,1.0
w,Nanoparticle triggered regulated necrosis,0.0,1.0
r,NCAM1 interactions,0.0,1.0
r:w,NCAM signaling for neurite out-growth,0.0,1.0
w,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,0.0,1.0
w,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,0.0,1.0
k,Necroptosis,0.0,1.0
r,Nectin/Necl  trans heterodimerization,0.0,1.0
r:w,Neddylation,0.0,1.0
r,Nef and signal transduction,0.0,1.0
r,Nef Mediated CD4 Down-regulation,0.0,1.0
r,Nef Mediated CD8 Down-regulation,0.0,1.0
r,Nef mediated downregulation of CD28 cell surface expression,0.0,1.0
r,Nef mediated downregulation of MHC class I complex cell surface expression,0.0,1.0
r,Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,0.0,1.0
r,Negative epigenetic regulation of rRNA expression,0.0,1.0
r,Negative feedback regulation of MAPK pathway,0.0,1.0
r,Negative regulation of activity of TFAP2 (AP-2) family transcription factors,0.0,1.0
r,Negative regulation of FGFR1 signaling,0.0,1.0
r,Negative regulation of FGFR2 signaling,0.0,1.0
r,Negative regulation of FGFR3 signaling,0.0,1.0
r,Negative regulation of FGFR4 signaling,0.0,1.0
r,Negative regulation of FLT3,0.0,1.0
r,Negative regulation of MAPK pathway,0.0,1.0
r,Negative regulation of MET activity,0.0,1.0
r,Negative regulation of NMDA receptor-mediated neuronal transmission,0.0,1.0
r,Negative regulation of NOTCH4 signaling,0.0,1.0
r,Negative regulation of TCF-dependent signaling by DVL-interacting proteins,0.0,1.0
r,Negative regulation of TCF-dependent signaling by WNT ligand antagonists,0.0,1.0
r,Negative regulation of the PI3K/AKT network,0.0,1.0
r,Negative regulators of DDX58/IFIH1 signaling,0.0,1.0
r,NEIL3-mediated resolution of ICLs,0.0,1.0
w,Neolacto series sphingolipid metabolism,0.0,1.0
k,"Neomycin, kanamycin and gentamicin biosynthesis",0.0,1.0
w,Neovascularization processes,0.0,1.0
r:w,Nephrin family interactions,0.0,1.0
w,Nephrogenesis,0.0,1.0
r,Nephron development,0.0,1.0
w,Nephrotic syndrome,0.0,1.0
w,Nephrotoxcicity adverse outcome pathway,0.0,1.0
r,NEP/NS2 Interacts with the Cellular Export Machinery,0.0,1.0
r,Nervous system development,0.0,1.0
r:w,Netrin-1 signaling,0.0,1.0
r,Netrin mediated repulsion signals,0.0,1.0
w,Netrin-UNC5B signaling,0.0,1.0
w,Neural crest cell migration during development,0.0,1.0
w,Neural crest cell migration in cancer,0.0,1.0
w,Neural crest differentiation,0.0,1.0
r:w,Neurexins and neuroligins,0.0,1.0
k,Neuroactive ligand-receptor interaction,0.0,1.0
w,Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway,0.0,1.0
r,Neurodegenerative Diseases,0.0,1.0
r,Neurofascin interactions,0.0,1.0
w,Neurogenesis regulation in the olfactory epithelium,0.0,1.0
w,Neuroinflammation,0.0,1.0
r,Neurophilin interactions with VEGF and VEGFR,0.0,1.0
r:w,Neurotoxicity of clostridium toxins,0.0,1.0
r:w,Neurotransmitter clearance,0.0,1.0
w,Neurotransmitter disorders,0.0,1.0
r:w,Neurotransmitter release cycle,0.0,1.0
r:w,Neurotransmitter uptake and metabolism In glial cells,0.0,1.0
k,Neurotrophin signaling pathway,0.0,1.0
r,NFE2L2 regulates pentose phosphate pathway genes,0.0,1.0
r,NFE2L2 regulating anti-oxidant/detoxification enzymes,0.0,1.0
r,NFE2L2 regulating ER-stress associated genes,0.0,1.0
r,NFE2L2 regulating inflammation associated genes,0.0,1.0
r,NFE2L2 regulating MDR associated enzymes,0.0,1.0
r,NFE2L2 regulating TCA cycle genes,0.0,1.0
r,NFE2L2 regulating tumorigenic genes,0.0,1.0
r,NFG and proNGF binds to p75NTR,0.0,1.0
r,NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,0.0,1.0
r,NF-kB is activated and signals survival,0.0,1.0
r,NGF-independant TRKA activation,0.0,1.0
r:w,NGF processing,0.0,1.0
r:w,NGF-stimulated transcription,0.0,1.0
r,N-Glycan antennae elongation,0.0,1.0
r,N-glycan antennae elongation in the medial/trans-Golgi,0.0,1.0
k:w,N-Glycan biosynthesis,0.0,1.0
r,N-glycan trimming and elongation in the cis-Golgi,0.0,1.0
r,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0,1.0
r,Nicotinamide salvaging,0.0,1.0
k,Nicotinate and nicotinamide metabolism,0.0,1.0
r:w,Nicotinate metabolism,0.0,1.0
k,Nicotine addiction,0.0,1.0
w,Nicotine effect on chromaffin cells,0.0,1.0
w,Nicotine effect on dopaminergic neurons,0.0,1.0
w,Nicotine metabolism in liver cells,0.0,1.0
w,Nifedipine activity,0.0,1.0
w,NIK -&gt;non-canonical NF-kB signaling,0.0,1.0
r,NIK-->noncanonical NF-kB signaling,0.0,1.0
r,Nilotinib-resistant KIT mutants,0.0,1.0
w,NIPBL role in DNA damage - Cornelia de Lange syndrome,0.0,1.0
w,Nitric oxide metabolism in cystic fibrosis,0.0,1.0
r,Nitric oxide stimulates guanylate cyclase,0.0,1.0
k,Nitrogen metabolism,0.0,1.0
w,NO/cGMP/PKG mediated neuroprotection,0.0,1.0
r,NOD1/2 Signaling Pathway,0.0,1.0
w,Nod-like receptor (NLR) signaling,0.0,1.0
k,NOD-like receptor signaling pathway,0.0,1.0
k:w,Non-alcoholic fatty liver disease,0.0,1.0
r,Noncanonical activation of NOTCH3,0.0,1.0
w,Non-classical role of vitamin D,0.0,1.0
k:w,Non-homologous end-joining,0.0,1.0
r,Nonhomologous End-Joining (NHEJ),0.0,1.0
r,Non-integrin membrane-ECM interactions,0.0,1.0
r:w,Nonsense-Mediated Decay (NMD),0.0,1.0
r,Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC),0.0,1.0
r,Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC),0.0,1.0
r:w,NoRC negatively regulates rRNA expression,0.0,1.0
r,Norepinephrine Neurotransmitter Release Cycle,0.0,1.0
r,NOSIP mediated eNOS trafficking,0.0,1.0
r,NOSTRIN mediated eNOS trafficking,0.0,1.0
r,NOTCH1 Intracellular Domain Regulates Transcription,0.0,1.0
w,NOTCH1 regulation of endothelial cell calcification,0.0,1.0
r,NOTCH2 Activation and Transmission of Signal to the Nucleus,0.0,1.0
r,NOTCH2 intracellular domain regulates transcription,0.0,1.0
r,NOTCH3 Activation and Transmission of Signal to the Nucleus,0.0,1.0
r,NOTCH3 Intracellular Domain Regulates Transcription,0.0,1.0
r,NOTCH4 Activation and Transmission of Signal to the Nucleus,0.0,1.0
r,NOTCH4 Intracellular Domain Regulates Transcription,0.0,1.0
r,Notch-HLH transcription pathway,0.0,1.0
w,Notch signaling,0.0,1.0
k,Notch signaling pathway,0.0,1.0
w,Novel intracellular components of RIG-I-like receptor pathway,0.0,1.0
r,NPAS4 regulates expression of target genes,0.0,1.0
w,NPHP1 deletion syndrome,0.0,1.0
r:w,NR1D1 (REV-ERBA) represses gene expression,0.0,1.0
r:w,NR1H2 and NR1H3-mediated signaling,0.0,1.0
r,NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis ,0.0,1.0
r,NR1H2 & NR1H3 regulate gene expression linked to lipogenesis,0.0,1.0
r,NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose,0.0,1.0
r,NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis,0.0,1.0
r,NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake ,0.0,1.0
r,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0,1.0
r,NrCAM interactions,0.0,1.0
w,NRF2-ARE regulation,0.0,1.0
w,NRF2 pathway,0.0,1.0
r,NRIF signals cell death from the nucleus,0.0,1.0
w,NRP1-triggered signaling in pancreatic cancer ,0.0,1.0
w,NRXN1 deletion syndrome,0.0,1.0
r,NS1 Mediated Effects on Host Pathways,0.0,1.0
w,nsp1 from SARS-CoV-2 inhibits translation initiation in the host cell,0.0,1.0
r,NTF3 activates NTRK2 (TRKB) signaling,0.0,1.0
r,NTF3 activates NTRK3 signaling,0.0,1.0
r,NTF4 activates NTRK2 (TRKB) signaling,0.0,1.0
r,NTRK2 activates RAC1,0.0,1.0
r,NTRK3 as a dependence receptor,0.0,1.0
r,Nuclear Envelope (NE) Reassembly,0.0,1.0
r,Nuclear Events (kinase and transcription factor activation),0.0,1.0
r,Nuclear events mediated by NFE2L2,0.0,1.0
r,Nuclear events stimulated by ALK signaling in cancer,0.0,1.0
r,Nuclear import of Rev protein,0.0,1.0
r,Nuclear Pore Complex (NPC) Disassembly,0.0,1.0
w,Nuclear receptors,0.0,1.0
w,Nuclear receptors in lipid metabolism and toxicity,0.0,1.0
w,Nuclear receptors meta-pathway,0.0,1.0
r,Nuclear Receptor transcription pathway,0.0,1.0
r,Nuclear signaling by ERBB4,0.0,1.0
w,Nucleobase biosynthesis,0.0,1.0
w,Nucleobase catabolism,0.0,1.0
k,Nucleocytoplasmic transport,0.0,1.0
r:w,Nucleosome assembly,0.0,1.0
w,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling",0.0,1.0
r,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",0.0,1.0
w,Nucleotide-binding oligomerization domain (NOD) pathway,0.0,1.0
r,Nucleotide biosynthesis,0.0,1.0
r,Nucleotide catabolism,0.0,1.0
r,Nucleotide catabolism defects,0.0,1.0
k:r:w,Nucleotide excision repair,0.0,1.0
w,Nucleotide excision repair in xeroderma pigmentosum ,0.0,1.0
w,Nucleotide GPCRs,0.0,1.0
r,Nucleotide-like (purinergic) receptors,0.0,1.0
w,Nucleotide metabolism,0.0,1.0
r:w,Nucleotide salvage,0.0,1.0
r,Nucleotide salvage defects,0.0,1.0
r,NVP-TAE684-resistant ALK mutants,0.0,1.0
r,O2/CO2 exchange in erythrocytes,0.0,1.0
r,OADH complex synthesizes glutaryl-CoA from 2-OA,0.0,1.0
r:w,OAS antiviral response,0.0,1.0
w,Octadecanoid formation from linoleic acid,0.0,1.0
r,OGDH complex synthesizes succinyl-CoA from 2-OG,0.0,1.0
r,O-glycosylation of TSR domain-containing proteins,0.0,1.0
r,Oleoyl-phe metabolism,0.0,1.0
w,Olfactory bulb development and olfactory learning,0.0,1.0
w,Olfactory receptor activity,0.0,1.0
r,Olfactory Signaling Pathway,0.0,1.0
k,Olfactory transduction,0.0,1.0
w,"Oligodendrocyte specification and differentiation, leading to myelin components for CNS",0.0,1.0
r,Oligomerization of connexins into connexons,0.0,1.0
r:w,O-linked glycosylation,0.0,1.0
r,O-linked glycosylation of mucins,0.0,1.0
w,Omega-3-fatty acids in senescence,0.0,1.0
w,Omega-3 / omega-6 fatty acid synthesis,0.0,1.0
w,Omega-6-fatty acids in senescence,0.0,1.0
w,Omega-9 fatty acid synthesis,0.0,1.0
r:w,Oncogene Induced Senescence,0.0,1.0
r,Oncogenic MAPK signaling,0.0,1.0
w,One-carbon metabolism,0.0,1.0
k,One carbon pool by folate,0.0,1.0
k,Oocyte meiosis,0.0,1.0
w,Opioid receptor pathways,0.0,1.0
w,Opioid signaling,0.0,1.0
r,Opioid Signalling,0.0,1.0
r,Opsins,0.0,1.0
r,Orc1 removal from chromatin,0.0,1.0
r,Orexin and neuropeptides FF and QRFP bind to their respective receptors,0.0,1.0
r,Organelle biogenesis and maintenance,0.0,1.0
r,Organic anion transporters,0.0,1.0
r,Organic cation transport,0.0,1.0
w,Osteoarthritic chondrocyte hypertrophy,0.0,1.0
w,Osteoblast signaling,0.0,1.0
w,Osteoclast signaling,0.0,1.0
w,Osteopontin signaling,0.0,1.0
w,OSX and miRNAs in tooth development,0.0,1.0
k,Other glycan degradation,0.0,1.0
r:w,Other interleukin signaling,0.0,1.0
r,Other semaphorin interactions,0.0,1.0
k,Other types of O-glycan biosynthesis,0.0,1.0
w,Ovarian infertility,0.0,1.0
k,Ovarian steroidogenesis,0.0,1.0
r,Ovarian tumor domain proteases,0.0,1.0
w,Overlap between signal transduction pathways contributing to LMNA laminopathies,0.0,1.0
w,Overview of nanoparticle effects,0.0,1.0
w,Overview of proinflammatory and profibrotic mediators,0.0,1.0
w,Oxidation by cytochrome P450,0.0,1.0
w,Oxidative damage response,0.0,1.0
k:w,Oxidative phosphorylation,0.0,1.0
r:w,Oxidative Stress Induced Senescence,0.0,1.0
w,Oxidative stress response,0.0,1.0
r,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0,1.0
w,Oxysterols derived from cholesterol,0.0,1.0
w,Oxytocin signaling,0.0,1.0
r,p130Cas linkage to MAPK signaling for integrins,0.0,1.0
r,P2Y receptors,0.0,1.0
r,p38MAPK events,0.0,1.0
w,p38 MAPK signaling,0.0,1.0
r,p53-Dependent G1 DNA Damage Response,0.0,1.0
r,p53-Dependent G1/S DNA damage checkpoint,0.0,1.0
r,p53-Independent DNA Damage Response,0.0,1.0
r,p53-Independent G1/S DNA damage checkpoint,0.0,1.0
k,p53 signaling pathway,0.0,1.0
w,p53 transcriptional gene network,0.0,1.0
r,p75NTR negatively regulates cell cycle via SC1,0.0,1.0
r,p75NTR recruits signalling complexes,0.0,1.0
r,p75NTR regulates axonogenesis,0.0,1.0
r,p75NTR signals via NF-kB,0.0,1.0
r,Packaging Of Telomere Ends,0.0,1.0
w,PAFAH1B1 copy number variation,0.0,1.0
w,Pancreatic cancer subtypes,0.0,1.0
k,Pantothenate and CoA biosynthesis,0.0,1.0
r,PAOs oxidise polyamines to amines,0.0,1.0
r,Paracetamol ADME,0.0,1.0
r,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0,1.0
r,Parasite infection,0.0,1.0
r,Parasitic Infection Pathways,0.0,1.0
k,Parkinson disease,0.0,1.0
w,Parkinson's disease pathway,0.0,1.0
w,Parkin-ubiquitin proteasomal system pathway,0.0,1.0
r:w,Passive transport by Aquaporins,0.0,1.0
w,Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex,0.0,1.0
k:w,Pathogenic Escherichia coli infection,0.0,1.0
w,Pathophysiological roles of DUX4 in FSHD1,0.0,1.0
w,Pathways affected in adenoid cystic carcinoma,0.0,1.0
w,Pathways of nucleic acid metabolism and innate immune sensing,0.0,1.0
r,Pausing and recovery of HIV elongation,0.0,1.0
r,Pausing and recovery of Tat-mediated HIV elongation,0.0,1.0
r,PCNA-Dependent Long Patch Base Excision Repair,0.0,1.0
w,PCSK9-mediated LDL receptor degradation,0.0,1.0
r,PD-1 signaling,0.0,1.0
r,PDE3B signalling,0.0,1.0
w,PDGF pathway,0.0,1.0
r,PDGFR mutants bind TKIs,0.0,1.0
r,PDH complex synthesizes acetyl-CoA from PYR,0.0,1.0
r,PECAM1 interactions,0.0,1.0
k,Pentose and glucuronate interconversions,0.0,1.0
w,Pentose phosphate metabolism,0.0,1.0
k:r:w,Pentose phosphate pathway,0.0,1.0
r,Pentose phosphate pathway disease,0.0,1.0
w,Pentose phosphate pathway in senescent cells,0.0,1.0
r,Peptide chain elongation,0.0,1.0
w,Peptide GPCRs,0.0,1.0
r:w,Peptide hormone biosynthesis,0.0,1.0
r,Peptide hormone metabolism,0.0,1.0
r,Peptide ligand-binding receptors,0.0,1.0
r,PERK regulates gene expression,0.0,1.0
w,Peroxiredoxin 2 induced ovarian failure,0.0,1.0
w,Peroxisomal beta-oxidation of tetracosanoyl-CoA,0.0,1.0
r:w,Peroxisomal lipid metabolism,0.0,1.0
r:w,Peroxisomal protein import,0.0,1.0
k,Peroxisome,0.0,1.0
w,"Perturbations to host-cell autophagy, induced by SARS-CoV-2 proteins",0.0,1.0
k,Pertussis,0.0,1.0
r,Pervasive developmental disorders,0.0,1.0
r,pexidartinib-resistant FLT3 mutants,0.0,1.0
r:w,Pexophagy,0.0,1.0
w,"PGK1, PKM2, KHKC/KHKA acting as protein kinases",0.0,1.0
k,Phagosome,0.0,1.0
r,Phase 0 - rapid depolarisation,0.0,1.0
r,Phase 1 - inactivation of fast Na+ channels,0.0,1.0
r,Phase 2 - plateau phase,0.0,1.0
r,Phase 3 - rapid repolarisation,0.0,1.0
r,Phase 4 - resting membrane potential,0.0,1.0
w,"Phase I biotransformations, non-P450",0.0,1.0
r:w,Phase I - Functionalization of compounds,0.0,1.0
r:w,Phase II - Conjugation of compounds,0.0,1.0
r:w,Phenylalanine and tyrosine metabolism,0.0,1.0
k:r,Phenylalanine metabolism,0.0,1.0
k,"Phenylalanine, tyrosine and tryptophan biosynthesis",0.0,1.0
r,Phenylketonuria,0.0,1.0
r,Phosphate bond hydrolysis by NTPDase proteins,0.0,1.0
r,Phosphate bond hydrolysis by NUDT proteins,0.0,1.0
w,Phosphatidyl inositol phosphate pathway,0.0,1.0
w,Phosphodiesterases in neuronal function,0.0,1.0
w,Phosphoinositides metabolism,0.0,1.0
r,Phospholipase C-mediated cascade: FGFR1,0.0,1.0
r,Phospholipase C-mediated cascade; FGFR2,0.0,1.0
r,Phospholipase C-mediated cascade; FGFR3,0.0,1.0
r,Phospholipase C-mediated cascade; FGFR4,0.0,1.0
k,Phospholipase D signaling pathway,0.0,1.0
r,Phospholipid metabolism,0.0,1.0
k,Phosphonate and phosphinate metabolism,0.0,1.0
r,phospho-PLA2 pathway,0.0,1.0
r,Phosphorylation of CD3 and TCR zeta chains,0.0,1.0
r,Phosphorylation of Emi1,0.0,1.0
r,Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes,0.0,1.0
r,Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes,0.0,1.0
r,Phosphorylation of the APC/C,0.0,1.0
w,Photodynamic therapy-induced AP-1 survival signaling,0.0,1.0
w,Photodynamic therapy-induced HIF-1 survival signaling,0.0,1.0
w,Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling,0.0,1.0
w,Photodynamic therapy-induced NF-kB survival signaling,0.0,1.0
w,Photodynamic therapy-induced unfolded protein response,0.0,1.0
k,Phototransduction,0.0,1.0
w,Physico-chemical features and toxicity-associated pathways,0.0,1.0
r,Physiological factors,0.0,1.0
w,Physiopathology of endothelial dysfunction in COVID-19,0.0,1.0
r,PI3K/AKT activation,0.0,1.0
w,PI3K-AKT-mTOR signaling and therapeutic opportunities in prostate cancer,0.0,1.0
w,PI3K/AKT/mTOR - vitamin D3 signaling,0.0,1.0
w,PI3K-Akt signaling,0.0,1.0
r,PI3K/AKT Signaling in Cancer,0.0,1.0
k,PI3K-Akt signaling pathway,0.0,1.0
r:w,PI3K Cascade,0.0,1.0
r,PI-3K cascade:FGFR1,0.0,1.0
r,PI-3K cascade:FGFR2,0.0,1.0
r,PI-3K cascade:FGFR3,0.0,1.0
r,PI-3K cascade:FGFR4,0.0,1.0
r,PI3K events in ERBB2 signaling,0.0,1.0
r,PI3K events in ERBB4 signaling,0.0,1.0
r,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",0.0,1.0
r,PI5P Regulates TP53 Acetylation,0.0,1.0
r,PI and PC transport between ER and Golgi membranes,0.0,1.0
w,Pilocytic astrocytoma,0.0,1.0
r:w,PI Metabolism,0.0,1.0
r,PINK1-PRKN Mediated Mitophagy,0.0,1.0
r:w,PIP3 activates AKT signaling,0.0,1.0
r,PIWI-interacting RNA (piRNA) biogenesis,0.0,1.0
r,PKA activation,0.0,1.0
r,PKA activation in glucagon signalling,0.0,1.0
r,PKA-mediated phosphorylation of CREB,0.0,1.0
r,PKA-mediated phosphorylation of key metabolic factors,0.0,1.0
r,PKB-mediated events,0.0,1.0
w,PKC-gamma calcium signaling in ataxia,0.0,1.0
r,PKMTs methylate histone lysines,0.0,1.0
r,PKR-mediated signaling,0.0,1.0
r,Plasma lipoprotein assembly,0.0,1.0
r:w,"Plasma lipoprotein assembly, remodeling, and clearance",0.0,1.0
r,Plasma lipoprotein clearance,0.0,1.0
r,Plasma lipoprotein remodeling,0.0,1.0
r,Plasmalogen biosynthesis,0.0,1.0
k,Platelet activation,0.0,1.0
r:w,Platelet Adhesion to exposed collagen,0.0,1.0
r:w,Platelet Aggregation (Plug Formation),0.0,1.0
r,Platelet calcium homeostasis,0.0,1.0
r,Platelet degranulation ,0.0,1.0
r:w,Platelet homeostasis,0.0,1.0
r,Platelet sensitization by LDL,0.0,1.0
r,PLC beta mediated events,0.0,1.0
r,PLCG1 events in ERBB2 signaling,0.0,1.0
r,PLC-gamma1 signalling,0.0,1.0
w,Pleural mesothelioma,0.0,1.0
w,Pluripotent stem cell differentiation pathway,0.0,1.0
r,Plus-strand DNA synthesis,0.0,1.0
w,PodNet: protein-protein interactions in the podocyte,0.0,1.0
r,POLB-Dependent Long Patch Base Excision Repair,0.0,1.0
r,Polo-like kinase mediated events,0.0,1.0
k,Polycomb repressive complex,0.0,1.0
w,Polycystic kidney disease pathway,0.0,1.0
r,Polymerase switching,0.0,1.0
r,Polymerase switching on the C-strand of the telomere,0.0,1.0
w,Polyol pathway,0.0,1.0
r,ponatinib-resistant FLT3 mutants,0.0,1.0
k,Porphyrin metabolism,0.0,1.0
r,Positive epigenetic regulation of rRNA expression,0.0,1.0
r,Post-chaperonin tubulin folding pathway,0.0,1.0
w,Post-COVID Neuroinflammation,0.0,1.0
r,Postmitotic nuclear pore complex (NPC) reformation,0.0,1.0
r,Post NMDA receptor activation events,0.0,1.0
r,Postsynaptic nicotinic acetylcholine receptors,0.0,1.0
r,Post-transcriptional silencing by small RNAs,0.0,1.0
r:w,Post-translational modification: synthesis of GPI-anchored proteins,0.0,1.0
r:w,Post-translational protein phosphorylation,0.0,1.0
r:w,Potassium Channels,0.0,1.0
r,Potassium transport channels,0.0,1.0
r,Potential therapeutics for SARS,0.0,1.0
r:w,"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",0.0,1.0
r:w,"POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation",0.0,1.0
r,PP2A-mediated dephosphorylation of key metabolic factors,0.0,1.0
w,PPAR-alpha pathway,0.0,1.0
w,PPAR Beta/Delta pathway,0.0,1.0
w,PPAR-gamma pathway,0.0,1.0
w,PPAR signaling,0.0,1.0
k,PPAR signaling pathway,0.0,1.0
w,Prader-Willi and Angelman syndrome,0.0,1.0
r:w,PRC2 methylates histones and DNA,0.0,1.0
r,Prednisone ADME,0.0,1.0
r,Prefoldin mediated transfer of substrate  to CCT/TriC,0.0,1.0
w,Pregnane X receptor pathway,0.0,1.0
r,Pregnenolone biosynthesis,0.0,1.0
w,Pre-implantation embryo,0.0,1.0
r:w,Pre-NOTCH Expression and Processing,0.0,1.0
r,Pre-NOTCH Processing in Golgi,0.0,1.0
r,Pre-NOTCH Processing in the Endoplasmic Reticulum,0.0,1.0
r,Pre-NOTCH Transcription and Translation,0.0,1.0
r:w,Presynaptic depolarization and calcium channel opening,0.0,1.0
r,Presynaptic function of Kainate receptors,0.0,1.0
r,Presynaptic nicotinic acetylcholine receptors,0.0,1.0
r,Presynaptic phase of homologous DNA pairing and strand exchange,0.0,1.0
r,Prevention of phagosomal-lysosomal fusion,0.0,1.0
k,Primary bile acid biosynthesis,0.0,1.0
w,Primary focal segmental glomerulosclerosis (FSGS),0.0,1.0
k,Primary immunodeficiency,0.0,1.0
w,Primary ovarian insufficiency,0.0,1.0
k,Prion disease,0.0,1.0
w,Prion disease pathway,0.0,1.0
r,Processing and activation of SUMO,0.0,1.0
r:w,Processing of Capped Intron-Containing Pre-mRNA,0.0,1.0
r:w,Processing of Capped Intronless Pre-mRNA,0.0,1.0
r,Processing of DNA double-strand break ends,0.0,1.0
r,Processing of Intronless Pre-mRNAs,0.0,1.0
r:w,Processing of SMDT1,0.0,1.0
r,Processive synthesis on the C-strand of the telomere,0.0,1.0
r,Processive synthesis on the lagging strand,0.0,1.0
w,Progeria-associated lipodystrophy,0.0,1.0
k,Progesterone-mediated oocyte maturation,0.0,1.0
r,Programmed Cell Death,0.0,1.0
r,"Progressive trimming of alpha-1,2-linked mannose residues from Man9/8/7GlcNAc2 to produce Man5GlcNAc2",0.0,1.0
w,Pro-inflammatory cytokines,0.0,1.0
r:w,Prolactin receptor signaling,0.0,1.0
w,Prolactin signaling,0.0,1.0
k,Prolactin signaling pathway,0.0,1.0
w,Proline and hydroxyproline pathways,0.0,1.0
r:w,Proline catabolism,0.0,1.0
r,Prolonged ERK activation events,0.0,1.0
k,Propanoate metabolism,0.0,1.0
r,Propionyl-CoA catabolism,0.0,1.0
r,Prostacyclin signalling through prostacyclin receptor,0.0,1.0
w,Prostaglandin and leukotriene metabolism in senescence ,0.0,1.0
w,Prostaglandin signaling,0.0,1.0
w,Prostaglandin synthesis and regulation,0.0,1.0
r,Prostanoid ligand receptors,0.0,1.0
k,Prostate cancer,0.0,1.0
w,Pro-survival signaling of neuroprotectin D1,0.0,1.0
k,Proteasome,0.0,1.0
w,Proteasome degradation,0.0,1.0
k,Protein digestion and absorption,0.0,1.0
k,Protein export,0.0,1.0
r:w,Protein folding,0.0,1.0
r,Protein hydroxylation,0.0,1.0
r,Protein lipoylation,0.0,1.0
r,Protein localization,0.0,1.0
r:w,Protein methylation,0.0,1.0
k,Protein processing in endoplasmic reticulum,0.0,1.0
r,Protein-protein interactions at synapses,0.0,1.0
r:w,Protein repair,0.0,1.0
r:w,Protein ubiquitination,0.0,1.0
w,Proteoglycan biosynthesis,0.0,1.0
r,Proton-coupled monocarboxylate transport,0.0,1.0
r,Proton-coupled neutral amino acid transporters,0.0,1.0
r,Proton/oligopeptide cotransporters,0.0,1.0
k,Proximal tubule bicarbonate reclamation,0.0,1.0
w,pruebaVia,0.0,1.0
w,"PtdIns(4,5)P2 in cytokinesis pathway",0.0,1.0
r,PTEN Loss of Function in Cancer,0.0,1.0
r:w,PTEN Regulation,0.0,1.0
w,PTF1A related regulatory pathway,0.0,1.0
r,PTK6 Activates STAT3,0.0,1.0
r,PTK6 Down-Regulation,0.0,1.0
r,PTK6 Expression,0.0,1.0
r,PTK6 promotes HIF1A stabilization,0.0,1.0
r,PTK6 Regulates Cell Cycle,0.0,1.0
r,PTK6 Regulates Proteins Involved in RNA Processing,0.0,1.0
r,"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases",0.0,1.0
r,PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1,0.0,1.0
r,Purine catabolism,0.0,1.0
k:w,Purine metabolism,0.0,1.0
w,Purine metabolism and related disorders,0.0,1.0
w,Purinergic signaling,0.0,1.0
w,Purinergic signaling elements and coagulation in COVID-19,0.0,1.0
r,Purinergic signaling in leishmaniasis infection,0.0,1.0
r,Purine ribonucleoside monophosphate biosynthesis,0.0,1.0
r,Purine salvage,0.0,1.0
r,Pyrimidine biosynthesis,0.0,1.0
r,Pyrimidine catabolism,0.0,1.0
k:w,Pyrimidine metabolism,0.0,1.0
w,Pyrimidine metabolism and related diseases,0.0,1.0
r,Pyrimidine salvage,0.0,1.0
r:w,Pyrophosphate hydrolysis,0.0,1.0
r,Pyroptosis,0.0,1.0
k:r,Pyruvate metabolism,0.0,1.0
w,Quercetin and Nf-kB / AP-1 induced apoptosis,0.0,1.0
r,quizartinib-resistant FLT3 mutants,0.0,1.0
r:w,RAB GEFs exchange GTP for GDP on RABs,0.0,1.0
r:w,RAB geranylgeranylation,0.0,1.0
r,RA biosynthesis pathway,0.0,1.0
r,Rab regulation of trafficking,0.0,1.0
w,RAC1/PAK1/p38/MMP2 pathway,0.0,1.0
r,RAF activation,0.0,1.0
r:w,RAF-independent MAPK1/3 activation,0.0,1.0
r:w,RAF/MAP kinase cascade,0.0,1.0
w,RalA downstream regulated genes,0.0,1.0
w,Rap1 signaling,0.0,1.0
r,Rap1 signalling,0.0,1.0
r,Ras activation upon Ca2+ influx through NMDA receptor,0.0,1.0
w,RAS and bradykinin pathways in COVID-19,0.0,1.0
r,RAS GTPase cycle mutants,0.0,1.0
r,RAS processing,0.0,1.0
r,RAS signaling downstream of NF1 loss-of-function variants,0.0,1.0
r,Reactions specific to the complex N-glycan synthesis pathway,0.0,1.0
r,Reactions specific to the hybrid N-glycan synthesis pathway,0.0,1.0
r,Receptor Mediated Mitophagy,0.0,1.0
r:w,Receptor-type tyrosine-protein phosphatases,0.0,1.0
r,Recognition and association of DNA glycosylase with site containing an affected purine,0.0,1.0
r,Recognition and association of DNA glycosylase with site containing an affected pyrimidine,0.0,1.0
r,Recognition of DNA damage by PCNA-containing replication complex,0.0,1.0
r,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.0,1.0
r,Recruitment of mitotic centrosome proteins and complexes,0.0,1.0
r,Recruitment of NuMA to mitotic centrosomes,0.0,1.0
r,Recycling of bile acids and salts,0.0,1.0
r,Recycling of eIF2:GDP,0.0,1.0
r,Recycling pathway of L1,0.0,1.0
r,Reduction of cytosolic Ca++ levels,0.0,1.0
w,Reelin signaling,0.0,1.0
r,Reelin signalling pathway,0.0,1.0
r,Regorafenib-resistant KIT mutants,0.0,1.0
r,Regorafenib-resistant PDGFR mutants,0.0,1.0
w,Regucalcin in proximal tubule epithelial kidney cells,0.0,1.0
r,Regulated Necrosis,0.0,1.0
r,Regulated proteolysis of p75NTR,0.0,1.0
r,Regulation by c-FLIP,0.0,1.0
r,Regulation by TREX1,0.0,1.0
r,Regulation of actin dynamics for phagocytic cup formation,0.0,1.0
r,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0,1.0
r,Regulation of APC/C activators between G1/S and early anaphase,0.0,1.0
r:w,Regulation of Apoptosis,0.0,1.0
w,Regulation of apoptosis by parathyroid hormone-related protein,0.0,1.0
r,Regulation of BACH1 activity,0.0,1.0
r:w,Regulation of beta-cell development,0.0,1.0
r,Regulation of CDH11 Expression and Function,0.0,1.0
r,Regulation of CDH11 function,0.0,1.0
r,Regulation of CDH11 gene transcription,0.0,1.0
r,Regulation of CDH11 mRNA translation by microRNAs,0.0,1.0
r,Regulation of CDH19 Expression and Function,0.0,1.0
r:w,Regulation of cholesterol biosynthesis by SREBP (SREBF),0.0,1.0
r,Regulation of commissural axon pathfinding by SLIT and ROBO,0.0,1.0
r,Regulation of cortical dendrite branching,0.0,1.0
r,Regulation of endogenous retroelements,0.0,1.0
r,Regulation of endogenous retroelements by KRAB-ZFP proteins,0.0,1.0
r,Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs),0.0,1.0
r,Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex,0.0,1.0
r,Regulation of Expression and Function of Type II Classical Cadherins,0.0,1.0
r,Regulation of expression of SLITs and ROBOs,0.0,1.0
r,Regulation of FOXO transcriptional activity by acetylation,0.0,1.0
r,Regulation of FZD by ubiquitination,0.0,1.0
r,Regulation of gap junction activity,0.0,1.0
r,Regulation of gene expression by Hypoxia-inducible Factor,0.0,1.0
r,Regulation of gene expression in beta cells,0.0,1.0
r,Regulation of gene expression in early pancreatic precursor cells,0.0,1.0
r,Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells,0.0,1.0
r,Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,0.0,1.0
r,Regulation of Glucokinase by Glucokinase Regulatory Protein,0.0,1.0
r,"Regulation of glycolysis by fructose 2,6-bisphosphate metabolism",0.0,1.0
r,Regulation of HMOX1 expression and activity,0.0,1.0
r,Regulation of Homotypic Cell-Cell Adhesion,0.0,1.0
r,Regulation of IFNA/IFNB signaling,0.0,1.0
r,Regulation of IFNG signaling,0.0,1.0
w,Regulation of IGF transport and uptake by IGF binding proteins,0.0,1.0
r,Regulation of innate immune responses to cytosolic DNA,0.0,1.0
r,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0,1.0
r,Regulation of insulin secretion,0.0,1.0
r,Regulation of KIT signaling,0.0,1.0
k,Regulation of lipolysis in adipocytes,0.0,1.0
r,Regulation of localization of FOXO transcription factors,0.0,1.0
r,Regulation of MECP2 expression and activity,0.0,1.0
r,Regulation of MITF-M-dependent genes involved in apoptosis,0.0,1.0
r,Regulation of MITF-M-dependent genes involved in cell cycle and proliferation,0.0,1.0
r,Regulation of MITF-M-dependent genes involved in DNA damage repair and senescence,0.0,1.0
r,Regulation of MITF-M dependent genes involved in invasion,0.0,1.0
r,Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy,0.0,1.0
r,Regulation of MITF-M dependent genes involved in metabolism,0.0,1.0
r,Regulation of MITF-M-dependent genes involved in pigmentation,0.0,1.0
r:w,Regulation of mitotic cell cycle,0.0,1.0
r:w,Regulation of mRNA stability by proteins that bind AU-rich elements,0.0,1.0
r,Regulation of necroptotic cell death,0.0,1.0
r,Regulation of NFE2L2 gene expression,0.0,1.0
r,Regulation of NF-kappa B signaling,0.0,1.0
r,Regulation of NPAS4 gene expression,0.0,1.0
r,Regulation of NPAS4 gene transcription,0.0,1.0
r,Regulation of NPAS4 mRNA translation,0.0,1.0
r,Regulation of ornithine decarboxylase (ODC),0.0,1.0
r,Regulation of PAK-2p34 activity by PS-GAP/RHG10,0.0,1.0
r,Regulation of PLK1 Activity at G2/M Transition,0.0,1.0
r,Regulation of PTEN gene transcription,0.0,1.0
r,Regulation of PTEN localization,0.0,1.0
r,Regulation of PTEN mRNA translation,0.0,1.0
r,Regulation of PTEN stability and activity,0.0,1.0
r,Regulation of pyruvate dehydrogenase (PDH) complex,0.0,1.0
r,Regulation of pyruvate metabolism,0.0,1.0
r,Regulation of RAS by GAPs,0.0,1.0
r:w,Regulation of RUNX1 Expression and Activity,0.0,1.0
r:w,Regulation of RUNX2 expression and activity,0.0,1.0
r,Regulation of RUNX3 expression and activity,0.0,1.0
r,Regulation of signaling by CBL,0.0,1.0
r,Regulation of signaling by NODAL,0.0,1.0
w,Regulation of sister chromatid separation at the metaphase-anaphase transition,0.0,1.0
r,"Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 ",0.0,1.0
r,"Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation",0.0,1.0
r,Regulation of the apoptosome activity,0.0,1.0
r,Regulation of thyroid hormone activity,0.0,1.0
r:w,Regulation of TLR by endogenous ligand,0.0,1.0
r,Regulation of TNFR1 signaling,0.0,1.0
w,Regulation of toll-like receptor signaling,0.0,1.0
r,Regulation of TP53 Activity,0.0,1.0
r:w,Regulation of TP53 Activity through Acetylation,0.0,1.0
r:w,Regulation of TP53 Activity through Association with Co-factors,0.0,1.0
r:w,Regulation of TP53 Activity through Methylation,0.0,1.0
r:w,Regulation of TP53 Activity through Phosphorylation,0.0,1.0
r,Regulation of TP53 Degradation,0.0,1.0
r,Regulation of TP53 Expression,0.0,1.0
r:w,Regulation of TP53 Expression and Degradation,0.0,1.0
w,Regulation of Wnt / B-catenin signaling by small molecule compounds,0.0,1.0
w,"Relationship between inflammation, COX-2 and EGFR",0.0,1.0
r,Relaxin receptors,0.0,1.0
k,Relaxin signaling pathway,0.0,1.0
r,Release of apoptotic factors from the mitochondria,0.0,1.0
r,Release of Hh-Np from the secreting cell,0.0,1.0
w,Relevant molecular pathways and targeted agents in triple negative breast cancer,0.0,1.0
r,Removal of aminoterminal propeptides from gamma-carboxylated proteins,0.0,1.0
r,Removal of the Flap Intermediate,0.0,1.0
r,Removal of the Flap Intermediate from the C-strand,0.0,1.0
k,Renal cell carcinoma,0.0,1.0
w,Renin-angiotensin-aldosterone system (RAAS),0.0,1.0
k,Renin-angiotensin system,0.0,1.0
k,Renin secretion,0.0,1.0
r,Replacement of protamines by nucleosomes in the male pronucleus,0.0,1.0
r,Replication of the SARS-CoV-1 genome,0.0,1.0
r,Replication of the SARS-CoV-2 genome,0.0,1.0
r,Repression of WNT target genes,0.0,1.0
r,Resistance of ERBB2 KD mutants to AEE788,0.0,1.0
r,Resistance of ERBB2 KD mutants to afatinib,0.0,1.0
r,Resistance of ERBB2 KD mutants to lapatinib,0.0,1.0
r,Resistance of ERBB2 KD mutants to neratinib,0.0,1.0
r,Resistance of ERBB2 KD mutants to osimertinib,0.0,1.0
r,Resistance of ERBB2 KD mutants to sapitinib,0.0,1.0
r,Resistance of ERBB2 KD mutants to tesevatinib,0.0,1.0
r,Resistance of ERBB2 KD mutants to trastuzumab,0.0,1.0
w,Resistin as a regulator of inflammation,0.0,1.0
r:w,Resolution of Abasic Sites (AP sites),0.0,1.0
r,Resolution of AP sites via the multiple-nucleotide patch replacement pathway,0.0,1.0
r,Resolution of AP sites via the single-nucleotide replacement pathway,0.0,1.0
r,Resolution of D-Loop Structures,0.0,1.0
r,Resolution of D-loop Structures through Holliday Junction Intermediates,0.0,1.0
r,Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA),0.0,1.0
r,Resolution of Sister Chromatid Cohesion,0.0,1.0
w,Resolvin E1 and resolvin D1 signaling decrease inflammation,0.0,1.0
r,Respiratory electron transport,0.0,1.0
w,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",0.0,1.0
r,Respiratory syncytial virus genome replication,0.0,1.0
r,Respiratory syncytial virus genome transcription,0.0,1.0
r,Respiratory syncytial virus (RSV) attachment and entry,0.0,1.0
r,"Respiratory syncytial virus (RSV) genome replication, transcription and translation",0.0,1.0
r:w,Response of EIF2AK1 (HRI) to heme deficiency,0.0,1.0
r:w,Response of EIF2AK4 (GCN2) to amino acid deficiency,0.0,1.0
r,Response of Mtb to phagocytosis,0.0,1.0
r,Response to metal ions,0.0,1.0
w,Retinoblastoma gene in cancer,0.0,1.0
r,Retinoid cycle disease events,0.0,1.0
r:w,Retinoid metabolism and transport,0.0,1.0
r,Retinoid metabolism disease events,0.0,1.0
k:w,Retinol metabolism,0.0,1.0
r,Retrograde neurotrophin signalling,0.0,1.0
r,Retrograde transport at the Trans-Golgi-Network,0.0,1.0
r:w,RET signaling,0.0,1.0
w,Rett syndrome,0.0,1.0
r,Reuptake of GABA,0.0,1.0
r,Reversal of alkylation damage by DNA dioxygenases,0.0,1.0
r,Reverse Transcription of HIV RNA,0.0,1.0
r:w,Reversible hydration of carbon dioxide,0.0,1.0
r,Rev-mediated nuclear export of HIV RNA,0.0,1.0
r,Rhesus blood group biosynthesis,0.0,1.0
r,Rhesus glycoproteins mediate ammonium transport.,0.0,1.0
k,Rheumatoid arthritis,0.0,1.0
r,RHOA GTPase cycle,0.0,1.0
r,RHOB GTPase cycle,0.0,1.0
r,RHOBTB1 GTPase cycle,0.0,1.0
r,RHOBTB2 GTPase cycle,0.0,1.0
r,RHOBTB3 ATPase cycle,0.0,1.0
r:w,RHOBTB GTPase Cycle,0.0,1.0
r,RHOC GTPase cycle,0.0,1.0
r,RHOD GTPase cycle,0.0,1.0
r,RHOF GTPase cycle,0.0,1.0
r,RHOG GTPase cycle,0.0,1.0
r:w,RHO GTPases activate CIT,0.0,1.0
r:w,RHO GTPases Activate Formins,0.0,1.0
r:w,RHO GTPases activate IQGAPs,0.0,1.0
r:w,RHO GTPases activate KTN1,0.0,1.0
r:w,RHO GTPases activate PAKs,0.0,1.0
r:w,RHO GTPases activate PKNs,0.0,1.0
r:w,RHO GTPases Activate Rhotekin and Rhophilins,0.0,1.0
r:w,RHO GTPases Activate ROCKs,0.0,1.0
r:w,RHO GTPases Activate WASPs and WAVEs,0.0,1.0
r:w,RHO GTPases regulate CFTR trafficking,0.0,1.0
r,RHOH GTPase cycle,0.0,1.0
r,RHOJ GTPase cycle,0.0,1.0
r,RHOQ GTPase cycle,0.0,1.0
r,RHOT1 GTPase cycle,0.0,1.0
r,RHOT2 GTPase cycle,0.0,1.0
r,RHOV GTPase cycle,0.0,1.0
r,Ribavirin ADME,0.0,1.0
w,Riboflavin and CoQ disorders,0.0,1.0
k,Riboflavin metabolism,0.0,1.0
r,Ribosomal scanning and start codon recognition,0.0,1.0
k,Ribosome,0.0,1.0
k,Ribosome biogenesis in eukaryotes,0.0,1.0
k,RIG-I-like receptor signaling pathway,0.0,1.0
w,RIOK1 and RIOK2 in EGFR- and PI3K-mediated tumorigenesis,0.0,1.0
r:w,RIPK1-mediated regulated necrosis,0.0,1.0
r,RIP-mediated NFkB activation via ZBP1,0.0,1.0
r,RMTs methylate histone arginines,0.0,1.0
k,RNA degradation,0.0,1.0
r,RNA Pol II CTD phosphorylation and interaction with CE,0.0,1.0
r,RNA Pol II CTD phosphorylation and interaction with CE during HIV infection,0.0,1.0
w,RNA pol II transcription - Initiation and elongation,0.0,1.0
k,RNA polymerase,0.0,1.0
r,RNA Polymerase II HIV Promoter Escape,0.0,1.0
r,RNA Polymerase III Abortive And Retractive Initiation,0.0,1.0
r,RNA Polymerase III Chain Elongation,0.0,1.0
r:w,RNA Polymerase III Transcription,0.0,1.0
r,RNA Polymerase III Transcription Initiation,0.0,1.0
r,RNA Polymerase III Transcription Initiation From Type 1 Promoter,0.0,1.0
r,RNA Polymerase III Transcription Initiation From Type 2 Promoter,0.0,1.0
r,RNA Polymerase III Transcription Initiation From Type 3 Promoter,0.0,1.0
r,RNA Polymerase III Transcription Termination,0.0,1.0
r,RNA Polymerase II Pre-transcription Events,0.0,1.0
r,RNA Polymerase II Promoter Escape,0.0,1.0
r:w,RNA polymerase II transcribes snRNA genes,0.0,1.0
r,RNA Polymerase II Transcription Elongation,0.0,1.0
r,RNA Polymerase II Transcription Initiation,0.0,1.0
r,RNA Polymerase II Transcription Initiation And Promoter Clearance,0.0,1.0
r,RNA Polymerase II Transcription Pre-Initiation And Promoter Opening,0.0,1.0
r,RNA Polymerase II Transcription Termination,0.0,1.0
r,RNA Polymerase I Promoter Clearance,0.0,1.0
r,RNA Polymerase I Promoter Escape,0.0,1.0
r,RNA Polymerase I Promoter Opening,0.0,1.0
r:w,RNA Polymerase I Transcription,0.0,1.0
r,RNA Polymerase I Transcription Initiation,0.0,1.0
r,RNA Polymerase I Transcription Termination,0.0,1.0
r,RND1 GTPase cycle,0.0,1.0
r,RND2 GTPase cycle,0.0,1.0
r,RND3 GTPase cycle,0.0,1.0
w,ROBO4 and VEGF signaling crosstalk,0.0,1.0
r,ROBO receptors bind AKAP5,0.0,1.0
r,Role of ABL in ROBO-SLIT signaling,0.0,1.0
r,Role of LAT2/NTAL/LAB on calcium mobilization,0.0,1.0
r,Role of phospholipids in phagocytosis,0.0,1.0
r,Role of second messengers in netrin-1 signaling,0.0,1.0
w,Roles of ceramides in development of insulin resistance,0.0,1.0
r:w,RORA activates gene expression,0.0,1.0
r:w,ROS and RNS production in phagocytes,0.0,1.0
w,ROS in COVID-19 endothelial dysfunction,0.0,1.0
r,RPIA deficiency: failed conversion of R5P to RU5P,0.0,1.0
r,RPIA deficiency: failed conversion of RU5P to R5P,0.0,1.0
r:w,rRNA modification in the mitochondrion,0.0,1.0
r:w,rRNA modification in the nucleus and cytosol,0.0,1.0
r:w,rRNA processing,0.0,1.0
r,rRNA processing in the mitochondrion,0.0,1.0
r,rRNA processing in the nucleus and cytosol,0.0,1.0
r,RSK activation,0.0,1.0
w,Rubinstein-Taybi syndrome 1,0.0,1.0
r:w,RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),0.0,1.0
r,RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,0.0,1.0
r,RUNX1 regulates estrogen receptor mediated transcription,0.0,1.0
r,RUNX1 regulates expression of components of tight junctions,0.0,1.0
r:w,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,0.0,1.0
r,RUNX1 regulates transcription of genes involved in BCR signaling,0.0,1.0
r,RUNX1 regulates transcription of genes involved in differentiation of HSCs,0.0,1.0
r,RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,0.0,1.0
r,RUNX1 regulates transcription of genes involved in interleukin signaling,0.0,1.0
r,RUNX1 regulates transcription of genes involved in WNT signaling,0.0,1.0
r,RUNX2 regulates bone development,0.0,1.0
r,RUNX2 regulates chondrocyte maturation,0.0,1.0
r,RUNX2 regulates genes involved in cell migration,0.0,1.0
r,RUNX2 regulates genes involved in differentiation of myeloid cells,0.0,1.0
r,RUNX2 regulates osteoblast differentiation,0.0,1.0
r,RUNX3 regulates BCL2L11 (BIM) transcription,0.0,1.0
r,RUNX3 regulates CDKN1A transcription,0.0,1.0
r,RUNX3 Regulates Immune Response and Cell Migration,0.0,1.0
r,RUNX3 regulates NOTCH signaling,0.0,1.0
r,RUNX3 regulates p14-ARF,0.0,1.0
r,RUNX3 regulates RUNX1-mediated transcription,0.0,1.0
r,RUNX3 regulates WNT signaling,0.0,1.0
r,RUNX3 regulates YAP1-mediated transcription,0.0,1.0
w,S1P receptor signal transduction,0.0,1.0
k,Salmonella infection,0.0,1.0
w,SALM protein interactions at the synapse,0.0,1.0
w,Sandbox pathway test,0.0,1.0
w,SARS coronavirus and innate immunity,0.0,1.0
r,SARS-CoV-1 activates/modulates innate immune responses,0.0,1.0
r,SARS-CoV-1 Genome Replication and Transcription,0.0,1.0
r,SARS-CoV-1-host interactions,0.0,1.0
r:w,SARS-CoV-1 Infection,0.0,1.0
r,SARS-CoV-1-mediated effects on programmed cell death,0.0,1.0
r,SARS-CoV-1 modulates host translation machinery,0.0,1.0
r,SARS-CoV-1 targets host intracellular signalling and regulatory pathways,0.0,1.0
r,SARS-CoV-1 targets PDZ proteins in cell-cell junction,0.0,1.0
r,SARS-CoV-2 activates/modulates innate and adaptive immune responses,0.0,1.0
w,SARS-CoV-2 altering angiogenesis via NRP1,0.0,1.0
w,SARS-CoV-2 and ACE2 receptor: molecular mechanisms,0.0,1.0
w,SARS-CoV-2 and COVID-19 pathway,0.0,1.0
w,SARS-CoV-2 B.1.1.7 variant antagonises innate immune activation,0.0,1.0
w,SARS-CoV-2 envelope lipid composition and human cell binding,0.0,1.0
r,SARS-CoV-2 Genome Replication and Transcription,0.0,1.0
r,SARS-CoV-2-host interactions,0.0,1.0
r:w,SARS-CoV-2 Infection,0.0,1.0
w,SARS-CoV-2 innate immunity evasion and cell-specific immune response,0.0,1.0
w,SARS-CoV-2 mitochondrial chronic oxidative stress and endothelial dysfunction,0.0,1.0
r,SARS-CoV-2 modulates autophagy,0.0,1.0
r,SARS-CoV-2 modulates host translation machinery,0.0,1.0
w,SARS-CoV-2 replication organelle formation,0.0,1.0
r,SARS-CoV-2 targets host intracellular signalling and regulatory pathways,0.0,1.0
r,SARS-CoV-2 targets PDZ proteins in cell-cell junction,0.0,1.0
r,SARS-CoV Infections,0.0,1.0
r,Scavenging by Class A Receptors,0.0,1.0
r,Scavenging by Class B Receptors,0.0,1.0
r,Scavenging by Class F Receptors,0.0,1.0
r,Scavenging by Class H Receptors,0.0,1.0
r,Scavenging of heme from plasma,0.0,1.0
w,SCFA and skeletal muscle substrate metabolism,0.0,1.0
r,SCF-beta-TrCP mediated degradation of Emi1,0.0,1.0
r,SCF(Skp2)-mediated degradation of p27/p21,0.0,1.0
r,SDK interactions,0.0,1.0
r,Sealing of the nuclear envelope (NE) by ESCRT-III,0.0,1.0
w,Sebaleic acid formation and metabolism,0.0,1.0
w,Secretion of hydrochloric acid in parietal cells,0.0,1.0
r,Selective autophagy,0.0,1.0
w,Selective expression of chemokine receptors during T-cell polarization,0.0,1.0
w,Selenium metabolism and selenoproteins,0.0,1.0
w,Selenium micronutrient network,0.0,1.0
r:w,Selenoamino acid metabolism,0.0,1.0
k,Selenocompound metabolism,0.0,1.0
r,Selenocysteine synthesis,0.0,1.0
r,Sema3A PAK dependent Axon repulsion,0.0,1.0
r,SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,0.0,1.0
r,Sema4D induced cell migration and growth-cone collapse,0.0,1.0
r,Sema4D in semaphorin signaling,0.0,1.0
r,Sema4D mediated inhibition of cell attachment and migration,0.0,1.0
r:w,Semaphorin interactions,0.0,1.0
r,semaxanib-resistant FLT3 mutants,0.0,1.0
w,Senescence and autophagy in cancer,0.0,1.0
r:w,Senescence-Associated Secretory Phenotype (SASP),0.0,1.0
r,Sensing of DNA Double Strand Breaks,0.0,1.0
r,Sensory Perception,0.0,1.0
r,Sensory perception of salty taste,0.0,1.0
r,Sensory perception of sour taste,0.0,1.0
r,"Sensory perception of sweet, bitter, and umami (glutamate) taste",0.0,1.0
r,Sensory perception of taste,0.0,1.0
r,Sensory processing of sound,0.0,1.0
r,Sensory processing of sound by inner hair cells of the cochlea,0.0,1.0
r,Sensory processing of sound by outer hair cells of the cochlea,0.0,1.0
r,Separation of Sister Chromatids,0.0,1.0
r:w,Serine biosynthesis,0.0,1.0
w,Serine metabolism,0.0,1.0
r,Serotonin and melatonin biosynthesis,0.0,1.0
r,Serotonin clearance from the synaptic cleft,0.0,1.0
w,Serotonin HTR1 group and FOS pathway,0.0,1.0
r,Serotonin Neurotransmitter Release Cycle,0.0,1.0
w,Serotonin receptor 2 and ELK-SRF/GATA4 signaling,0.0,1.0
w,Serotonin receptor 4/6/7 and NR3C signaling,0.0,1.0
r,Serotonin receptors,0.0,1.0
w,Serotonin transporter activity,0.0,1.0
r,Severe congenital neutropenia type 4 (G6PC3),0.0,1.0
r,SHC1 events in EGFR signaling,0.0,1.0
r,SHC1 events in ERBB2 signaling,0.0,1.0
r,SHC1 events in ERBB4 signaling,0.0,1.0
r,SHC-mediated cascade:FGFR1,0.0,1.0
r,SHC-mediated cascade:FGFR2,0.0,1.0
r,SHC-mediated cascade:FGFR3,0.0,1.0
r,SHC-mediated cascade:FGFR4,0.0,1.0
r,SHC-related events triggered by IGF1R,0.0,1.0
k,Shigellosis,0.0,1.0
r,SHOC2 M1731 mutant abolishes MRAS complex function,0.0,1.0
r:w,Sialic acid metabolism,0.0,1.0
w,Sialylation ,0.0,1.0
r:w,Signal amplification,0.0,1.0
r,Signal attenuation,0.0,1.0
r,Signaling by activated point mutants of FGFR1,0.0,1.0
r,Signaling by activated point mutants of FGFR3,0.0,1.0
r:w,Signaling by Activin,0.0,1.0
r,Signaling by ALK,0.0,1.0
r,Signaling by ALK fusions and activated point mutants,0.0,1.0
r,Signaling by ALK in cancer,0.0,1.0
r,Signaling by AMER1 mutants,0.0,1.0
r,Signaling by APC mutants,0.0,1.0
r,Signaling by AXIN mutants,0.0,1.0
r:w,Signaling by BMP,0.0,1.0
r,Signaling by BRAF and RAF1 fusions,0.0,1.0
r,Signaling by CSF1 (M-CSF) in myeloid cells,0.0,1.0
r,Signaling by CSF3 (G-CSF),0.0,1.0
r,Signaling by CTNNB1 phospho-site mutants,0.0,1.0
r,Signaling by cytosolic FGFR1 fusion mutants,0.0,1.0
r,Signaling by cytosolic PDGFRA and PDGFRB fusion proteins,0.0,1.0
r:w,Signaling by EGFR,0.0,1.0
r,Signaling by EGFR in Cancer,0.0,1.0
r,Signaling by EGFRvIII in Cancer,0.0,1.0
r:w,Signaling by ERBB2,0.0,1.0
r,Signaling by ERBB2 ECD mutants,0.0,1.0
r,Signaling by ERBB2 in Cancer,0.0,1.0
r,Signaling by ERBB2 KD Mutants,0.0,1.0
r,Signaling by ERBB2 TMD/JMD mutants,0.0,1.0
r:w,Signaling by ERBB4,0.0,1.0
r:w,Signaling by Erythropoietin,0.0,1.0
r,Signaling by extracellular domain mutants of KIT,0.0,1.0
r,Signaling by FGFR,0.0,1.0
r:w,Signaling by FGFR1,0.0,1.0
r,Signaling by FGFR1 amplification mutants,0.0,1.0
r,Signaling by FGFR1 in disease,0.0,1.0
r:w,Signaling by FGFR2,0.0,1.0
r,Signaling by FGFR2 amplification mutants,0.0,1.0
r,Signaling by FGFR2 fusions,0.0,1.0
r,Signaling by FGFR2 IIIa TM,0.0,1.0
r,Signaling by FGFR2 in disease,0.0,1.0
r:w,Signaling by FGFR3,0.0,1.0
r,Signaling by FGFR3 fusions in cancer,0.0,1.0
r,Signaling by FGFR3 in disease,0.0,1.0
r:w,Signaling by FGFR4,0.0,1.0
r,Signaling by FGFR4 in disease,0.0,1.0
r,Signaling by FGFR in disease,0.0,1.0
r,Signaling by FLT3 fusion proteins,0.0,1.0
r,Signaling by FLT3 ITD and TKD mutants,0.0,1.0
r,Signaling by GSK3beta mutants,0.0,1.0
r,Signaling by Hedgehog,0.0,1.0
r,Signaling by high-kinase activity BRAF mutants,0.0,1.0
r:w,Signaling by Hippo,0.0,1.0
r:w,Signaling by Insulin receptor,0.0,1.0
r,Signaling by Interleukins,0.0,1.0
r,Signaling by juxtamembrane domain KIT mutants,0.0,1.0
r,Signaling by kinase domain mutants of KIT,0.0,1.0
r,Signaling by KIT in disease,0.0,1.0
r:w,Signaling by Leptin,0.0,1.0
r,Signaling by Ligand-Responsive EGFR Variants in Cancer,0.0,1.0
r,Signaling by LRP5 mutants ,0.0,1.0
r,Signaling by LTK,0.0,1.0
r,Signaling by LTK in cancer,0.0,1.0
r,Signaling by MAP2K mutants,0.0,1.0
r,Signaling by MAPK mutants,0.0,1.0
r,Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,0.0,1.0
r:w,Signaling by MET,0.0,1.0
r,Signaling by moderate kinase activity BRAF mutants,0.0,1.0
r,Signaling by MRAS-complex mutants,0.0,1.0
r:w,Signaling by MST1,0.0,1.0
r:w,Signaling by NODAL,0.0,1.0
r,Signaling by Non-Receptor Tyrosine Kinases,0.0,1.0
r,Signaling by NOTCH,0.0,1.0
r:w,Signaling by NOTCH1,0.0,1.0
r,Signaling by NOTCH1 HD Domain Mutants in Cancer,0.0,1.0
r,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,0.0,1.0
r,Signaling by NOTCH1 in Cancer,0.0,1.0
r,Signaling by NOTCH1 PEST Domain Mutants in Cancer,0.0,1.0
r,Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,0.0,1.0
r:w,Signaling by NOTCH2,0.0,1.0
r:w,Signaling by NOTCH3,0.0,1.0
r:w,Signaling by NOTCH4,0.0,1.0
w,Signaling by NTRK1,0.0,1.0
r,Signaling by NTRK1 (TRKA),0.0,1.0
r:w,Signaling by NTRK2 (TRKB),0.0,1.0
r:w,Signaling by NTRK3 (TRKC),0.0,1.0
r,Signaling by NTRKs,0.0,1.0
r,Signaling by Nuclear Receptors,0.0,1.0
r,Signaling by Overexpressed Wild-Type EGFR in Cancer,0.0,1.0
r:w,Signaling by PDGF,0.0,1.0
r,Signaling by PDGFRA extracellular domain mutants,0.0,1.0
r,"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",0.0,1.0
r,Signaling by PDGFR in disease,0.0,1.0
r,"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",0.0,1.0
r,Signaling by plasma membrane FGFR1 fusions,0.0,1.0
r:w,Signaling by PTK6,0.0,1.0
r,Signaling by RAF1 mutants,0.0,1.0
r,Signaling by RAS GAP mutants,0.0,1.0
r,Signaling by RAS GTPase mutants,0.0,1.0
r,Signaling by RAS mutants,0.0,1.0
r:w,Signaling by Retinoic Acid,0.0,1.0
r,Signaling by RNF43 mutants,0.0,1.0
r:w,Signaling by ROBO receptors,0.0,1.0
r:w,Signaling by SCF-KIT,0.0,1.0
r,Signaling by TCF7L2 mutants,0.0,1.0
r:w,Signaling by TGF-beta Receptor Complex,0.0,1.0
r,Signaling by TGF-beta Receptor Complex in Cancer,0.0,1.0
r,Signaling by TGFB family members,0.0,1.0
r,Signaling by TGFBR3,0.0,1.0
r:w,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0.0,1.0
r,Signaling by WNT in cancer,0.0,1.0
r,Signaling downstream of RAS mutants,0.0,1.0
k,Signaling pathways regulating pluripotency of stem cells,0.0,1.0
r,Signalling to ERK5,0.0,1.0
r,Signalling to ERKs,0.0,1.0
r,Signalling to p38 via RIT and RIN,0.0,1.0
r,Signalling to RAS,0.0,1.0
r,Signalling to STAT3,0.0,1.0
r:w,Signal regulatory protein family interactions,0.0,1.0
r,Signal transduction by L1,0.0,1.0
w,Signal transduction through IL1R,0.0,1.0
w,Sildenafil treatment,0.0,1.0
r:w,SIRT1 negatively regulates rRNA expression,0.0,1.0
r,SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs,0.0,1.0
r,SLBP independent Processing of Histone Pre-mRNAs,0.0,1.0
r,SLC15A4:TASL-dependent IRF5 activation,0.0,1.0
w,Sleep regulation,0.0,1.0
r,SLIT2:ROBO1 increases RHOA activity,0.0,1.0
r,SMAC (DIABLO) binds to IAPs ,0.0,1.0
r,SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes ,0.0,1.0
r,"SMAC, XIAP-regulated apoptotic response",0.0,1.0
r,SMAD2/3 MH2 Domain Mutants in Cancer,0.0,1.0
r,SMAD2/3 Phosphorylation Motif Mutants in Cancer,0.0,1.0
r,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,0.0,1.0
r,SMAD4 MH2 Domain Mutants in Cancer,0.0,1.0
k:w,Small cell lung cancer,0.0,1.0
r,Small interfering RNA (siRNA) biogenesis,0.0,1.0
w,Small ligand GPCRs,0.0,1.0
w,SMC1/SMC3 role in DNA damage - Cornelia de Lange Syndrome,0.0,1.0
w,Smith-Magenis and Potocki-Lupski syndrome copy number variation,0.0,1.0
r:w,Smooth Muscle Contraction,0.0,1.0
k,SNARE interactions in vesicular transport,0.0,1.0
r,snRNP Assembly,0.0,1.0
r,Sodium/Calcium exchangers,0.0,1.0
r,Sodium-coupled phosphate cotransporters,0.0,1.0
r,"Sodium-coupled sulphate, di- and tri-carboxylate transporters",0.0,1.0
r,Sodium/Proton exchangers,0.0,1.0
w,Soluble ACE2-mediated cell entry of SARS-CoV-2,0.0,1.0
w,Somatic sex determination,0.0,1.0
w,Somatroph axis (GH) and its relationship to dietary restriction and aging,0.0,1.0
r,Somitogenesis,0.0,1.0
w,Somitogenesis in the context of spondylocostal dysostosis,0.0,1.0
r,sorafenib-resistant FLT3 mutants,0.0,1.0
r,Sorafenib-resistant KIT mutants,0.0,1.0
r,Sorafenib-resistant PDGFR mutants,0.0,1.0
r,SOS-mediated signalling,0.0,1.0
r,Specification of primordial germ cells,0.0,1.0
r,Specification of the neural plate border,0.0,1.0
r,Sperm Motility And Taxes,0.0,1.0
r:w,S Phase,0.0,1.0
r,Sphingolipid catabolism,0.0,1.0
r,Sphingolipid de novo biosynthesis,0.0,1.0
k:r:w,Sphingolipid metabolism,0.0,1.0
w,Sphingolipid metabolism: integrated pathway,0.0,1.0
w,Sphingolipid metabolism overview,0.0,1.0
w,Sphingolipid pathway,0.0,1.0
w,Spina bifida,0.0,1.0
w,Spinal cord injury,0.0,1.0
k,Spliceosome,0.0,1.0
w,Splicing factor NOVA regulated synaptic proteins,0.0,1.0
r,Spry regulation of FGF signaling,0.0,1.0
w,SREBF and miR33 in cholesterol and lipid homeostasis,0.0,1.0
w,SRF and miRs in smooth muscle differentiation and proliferation,0.0,1.0
r:w,SRP-dependent cotranslational protein targeting to membrane,0.0,1.0
r,Stabilization of p53,0.0,1.0
k,Starch and sucrose metabolism,0.0,1.0
r,STAT3 nuclear events downstream of ALK signaling,0.0,1.0
r:w,STAT5 Activation,0.0,1.0
r,STAT5 activation downstream of FLT3 ITD mutants,0.0,1.0
r,STAT6-mediated induction of chemokines,0.0,1.0
w,Statin inhibition of cholesterol production,0.0,1.0
k:w,Steroid biosynthesis,0.0,1.0
k,Steroid hormone biosynthesis,0.0,1.0
w,Steroid hormone precursor biosynthesis,0.0,1.0
w,Steroidogenic pathway,0.0,1.0
w,Sterol regulatory element-binding proteins (SREBP) signaling,0.0,1.0
r,Sterols are 12-hydroxylated by CYP8B1,0.0,1.0
r,Stimulation of the cell death response by PAK-2p34,0.0,1.0
r,Stimuli-sensing channels,0.0,1.0
r,STING mediated induction of host immune responses,0.0,1.0
w,STING pathway in Kawasaki-like disease and COVID-19,0.0,1.0
r:w,Striated Muscle Contraction,0.0,1.0
w,Striated muscle contraction pathway,0.0,1.0
w,Sudden infant death syndrome (SIDS) susceptibility pathways,0.0,1.0
w,Sulfatase and aromatase pathway,0.0,1.0
w,Sulfation biotransformation reaction,0.0,1.0
r,Sulfide oxidation to sulfate,0.0,1.0
r:w,Sulfur amino acid metabolism,0.0,1.0
k,Sulfur metabolism,0.0,1.0
k,Sulfur relay system,0.0,1.0
w,Sulindac metabolic pathway,0.0,1.0
r:w,SUMO E3 ligases SUMOylate target proteins,0.0,1.0
r,SUMO is conjugated to E1 (UBA2:SAE1),0.0,1.0
r,SUMO is proteolytically processed,0.0,1.0
r,"SUMO is transferred from E1 to E2 (UBE2I, UBC9)",0.0,1.0
r:w,SUMOylation,0.0,1.0
r:w,SUMOylation of chromatin organization proteins,0.0,1.0
r:w,SUMOylation of DNA damage response and repair proteins,0.0,1.0
r:w,SUMOylation of DNA methylation proteins,0.0,1.0
r:w,SUMOylation of DNA replication proteins,0.0,1.0
r:w,SUMOylation of immune response proteins,0.0,1.0
r:w,SUMOylation of intracellular receptors,0.0,1.0
r,SUMOylation of nuclear envelope proteins,0.0,1.0
r:w,SUMOylation of RNA binding proteins,0.0,1.0
r:w,SUMOylation of SUMOylation proteins,0.0,1.0
r:w,SUMOylation of transcription cofactors,0.0,1.0
r:w,SUMOylation of transcription factors,0.0,1.0
r:w,SUMOylation of ubiquitinylation proteins,0.0,1.0
r,sunitinib-resistant FLT3 mutants,0.0,1.0
r,Sunitinib-resistant KIT mutants,0.0,1.0
r,Sunitinib-resistant PDGFR mutants,0.0,1.0
r,Suppression of apoptosis,0.0,1.0
r,Suppression of autophagy,0.0,1.0
w,Suppression of HMGB1-mediated inflammation by THBD,0.0,1.0
r,Suppression of phagosomal maturation,0.0,1.0
r:w,Surfactant metabolism,0.0,1.0
r,Switching of origins to a post-replicative state,0.0,1.0
r:w,Synaptic adhesion-like molecules,0.0,1.0
w,Synaptic signaling associated with autism spectrum disorder,0.0,1.0
k,Synaptic vesicle cycle,0.0,1.0
w,Synaptic vesicle pathway,0.0,1.0
r:w,Syndecan interactions,0.0,1.0
r,Synthesis and processing of ENV and VPU,0.0,1.0
r,"Synthesis And Processing Of GAG, GAGPOL Polyproteins",0.0,1.0
r,Synthesis of 12-eicosatetraenoic acid derivatives,0.0,1.0
r,Synthesis of 15-eicosatetraenoic acid derivatives,0.0,1.0
r,Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE),0.0,1.0
r,Synthesis of 5-eicosatetraenoic acids,0.0,1.0
r,Synthesis of active ubiquitin: roles of E1 and E2 enzymes,0.0,1.0
r,Synthesis of bile acids and bile salts,0.0,1.0
r,Synthesis of bile acids and bile salts via 24-hydroxycholesterol,0.0,1.0
r,Synthesis of bile acids and bile salts via 27-hydroxycholesterol,0.0,1.0
r,Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol,0.0,1.0
w,Synthesis of ceramides and 1-deoxyceramides,0.0,1.0
r,Synthesis of CL,0.0,1.0
r,Synthesis of diphthamide-EEF2,0.0,1.0
r:w,Synthesis of DNA,0.0,1.0
r,Synthesis of Dolichyl-phosphate,0.0,1.0
r,Synthesis of dolichyl-phosphate-glucose,0.0,1.0
r,Synthesis of dolichyl-phosphate mannose,0.0,1.0
r,Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET),0.0,1.0
r,Synthesis of GDP-mannose,0.0,1.0
r,Synthesis of glycosylphosphatidylinositol (GPI),0.0,1.0
r,Synthesis of Hepoxilins (HX) and Trioxilins (TrX),0.0,1.0
r,"Synthesis of IP2, IP, and Ins in the cytosol",0.0,1.0
r,Synthesis of IP3 and IP4 in the cytosol,0.0,1.0
r,Synthesis of IPs in the ER lumen,0.0,1.0
r,Synthesis of IPs in the nucleus,0.0,1.0
r,Synthesis of Ketone Bodies,0.0,1.0
r,Synthesis of Leukotrienes (LT) and Eoxins (EX),0.0,1.0
r:w,Synthesis of Lipoxins (LX),0.0,1.0
r,Synthesis of PA,0.0,1.0
r,Synthesis of PC,0.0,1.0
r,Synthesis of PE,0.0,1.0
r,Synthesis of PG,0.0,1.0
r,Synthesis of PI,0.0,1.0
r,Synthesis of PIPs at the early endosome membrane,0.0,1.0
r,Synthesis of PIPs at the ER membrane,0.0,1.0
r,Synthesis of PIPs at the Golgi membrane,0.0,1.0
r,Synthesis of PIPs at the late endosome membrane,0.0,1.0
r,Synthesis of PIPs at the plasma membrane,0.0,1.0
r,Synthesis of PIPs in the nucleus,0.0,1.0
r,Synthesis of Prostaglandins (PG) and Thromboxanes (TX),0.0,1.0
r,Synthesis of PS,0.0,1.0
r,Synthesis of pyrophosphates in the cytosol,0.0,1.0
r,Synthesis of UDP-N-acetyl-glucosamine,0.0,1.0
r,Synthesis of very long-chain fatty acyl-CoAs,0.0,1.0
r:w,Synthesis of wybutosine at G37 of tRNA(Phe),0.0,1.0
r:w,"Synthesis, secretion, and deacylation of Ghrelin",0.0,1.0
r,"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",0.0,1.0
r,"Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)",0.0,1.0
k,Systemic lupus erythematosus,0.0,1.0
r,t(4;14) translocations of FGFR3,0.0,1.0
r,Tachykinin receptors bind tachykinins,0.0,1.0
w,TAK1 activates NF-kB by phosphorylation and activation of IKK complex,0.0,1.0
r,TAK1-dependent IKK and NF-kappa-B activation  ,0.0,1.0
r,"TALDO1 deficiency: failed conversion of  Fru(6)P, E4P to SH7P, GA3P",0.0,1.0
r,"TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P",0.0,1.0
r,tamatinib-resistant FLT3 mutants,0.0,1.0
w,Tamoxifen metabolism,0.0,1.0
r,Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK),0.0,1.0
r,Tandem pore domain halothane-inhibited K+ channel (THIK),0.0,1.0
r,Tandem pore domain potassium channels,0.0,1.0
r,tandutinib-resistant FLT3 mutants,0.0,1.0
w,Target of rapamycin signaling,0.0,1.0
w,TAR syndrome,0.0,1.0
k,Taste transduction,0.0,1.0
r,Tat-mediated elongation of the HIV-1 transcript,0.0,1.0
r,Tat-mediated HIV elongation arrest and recovery,0.0,1.0
k,Taurine and hypotaurine metabolism,0.0,1.0
r:w,TBC/RABGAPs,0.0,1.0
w,TCA cycle (aka Krebs or citric acid cycle),0.0,1.0
w,TCA cycle and deficiency of pyruvate dehydrogenase complex (PDHc),0.0,1.0
w,TCA cycle in senescence,0.0,1.0
w,TCA cycle nutrient use and invasiveness of ovarian cancer,0.0,1.0
w,T cell modulation in pancreatic cancer,0.0,1.0
r:w,TCF dependent signaling in response to WNT,0.0,1.0
r,Telomere C-strand (Lagging Strand) Synthesis,0.0,1.0
r,Telomere C-strand synthesis initiation,0.0,1.0
r,Telomere Extension By Telomerase,0.0,1.0
r:w,Telomere Maintenance,0.0,1.0
r,Terminal pathway of complement,0.0,1.0
r,Termination of O-glycan biosynthesis,0.0,1.0
r,Termination of translesion DNA synthesis,0.0,1.0
k,Terpenoid backbone biosynthesis,0.0,1.0
r:w,"TET1,2,3 and TDG demethylate DNA",0.0,1.0
r,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.0,1.0
r,TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation,0.0,1.0
r,TFAP2 (AP-2) family regulates transcription of cell cycle factors,0.0,1.0
r,TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,0.0,1.0
r,TFAP2 (AP-2) family regulates transcription of other transcription factors,0.0,1.0
w,TGF-beta receptor signaling,0.0,1.0
r,TGF-beta receptor signaling activates SMADs,0.0,1.0
r,TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),0.0,1.0
w,TGF-beta receptor signaling in skeletal dysplasias,0.0,1.0
w,TGF-beta signaling,0.0,1.0
w,TGF-beta signaling in thyroid cells for epithelial-mesenchymal transition,0.0,1.0
k,TGF-beta signaling pathway,0.0,1.0
r,TGFBR1 KD Mutants in Cancer,0.0,1.0
r,TGFBR1 LBD Mutants in Cancer,0.0,1.0
r,TGFBR2 Kinase Domain Mutants in Cancer,0.0,1.0
r,TGFBR2 MSI Frameshift Mutants in Cancer,0.0,1.0
r,TGFBR3 expression,0.0,1.0
r,TGFBR3 PTM regulation,0.0,1.0
r,TGFBR3 regulates activin signaling,0.0,1.0
r,TGFBR3 regulates FGF2 signaling,0.0,1.0
r,TGFBR3 regulates TGF-beta signaling,0.0,1.0
w,TGFB / Smad signaling,0.0,1.0
w,Tgif disruption of Shh signaling,0.0,1.0
r,The activation of arylsulfatases,0.0,1.0
r,The AIM2 inflammasome,0.0,1.0
r,The canonical retinoid cycle in rods (twilight vision),0.0,1.0
r,The fatty acid cycling model,0.0,1.0
r,The IPAF inflammasome,0.0,1.0
r,The NLRP1 inflammasome,0.0,1.0
r,The NLRP3 inflammasome,0.0,1.0
r,The phototransduction cascade,0.0,1.0
r,The retinoid cycle in cones (daylight vision),0.0,1.0
k:w,Thermogenesis,0.0,1.0
r,The role of GTSE1 in G2/M progression after G2 checkpoint,0.0,1.0
r,The role of Nef in HIV-1 replication and disease pathogenesis,0.0,1.0
w,Thiamine metabolic pathways,0.0,1.0
k,Thiamine metabolism,0.0,1.0
r:w,Threonine catabolism,0.0,1.0
w,Thrombin signaling through proteinase activated receptors (PARs),0.0,1.0
r,Thrombin signalling through proteinase activated receptors (PARs),0.0,1.0
r,Thromboxane signalling through TP receptor,0.0,1.0
w,Thymic stromal lymphopoietin (TSLP) signaling,0.0,1.0
k,Thyroid cancer,0.0,1.0
w,Thyroid hormones production and peripheral downstream signaling effects,0.0,1.0
w,Thyroid stimulating hormone (TSH) signaling,0.0,1.0
r,Thyroxine biosynthesis,0.0,1.0
w,Thyroxine (thyroid hormone) production,0.0,1.0
r,TICAM1 deficiency - HSE,0.0,1.0
r,TICAM1-dependent activation of IRF3/IRF7,0.0,1.0
r,"TICAM1, RIP1-mediated IKK complex recruitment",0.0,1.0
r,"TICAM1,TRAF6-dependent induction of TAK1 complex",0.0,1.0
r,Tie2 Signaling,0.0,1.0
k,Tight junction,0.0,1.0
r,Tight junction interactions,0.0,1.0
r,TLR3 deficiency - HSE,0.0,1.0
r,TLR3-mediated TICAM1-dependent programmed cell death,0.0,1.0
w,TLR4 signaling and tolerance,0.0,1.0
w,TNF-alpha signaling,0.0,1.0
r,TNFR1-induced NF-kappa-B signaling pathway,0.0,1.0
r,TNFR1-induced proapoptotic signaling,0.0,1.0
r,TNFR1-mediated ceramide production,0.0,1.0
r:w,TNFR2 non-canonical NF-kB pathway,0.0,1.0
r,TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,0.0,1.0
w,TNF-related weak inducer of apoptosis (TWEAK) signaling,0.0,1.0
r:w,TNFs bind their physiological receptors,0.0,1.0
r:w,TNF signaling,0.0,1.0
k,TNF signaling pathway,0.0,1.0
r,Toll Like Receptor 10 (TLR10) Cascade,0.0,1.0
r,Toll Like Receptor 2 (TLR2) Cascade,0.0,1.0
r:w,Toll Like Receptor 3 (TLR3) Cascade,0.0,1.0
r,Toll Like Receptor 4 (TLR4) Cascade,0.0,1.0
r,Toll Like Receptor 5 (TLR5) Cascade,0.0,1.0
r,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0,1.0
r,Toll Like Receptor 9 (TLR9) Cascade,0.0,1.0
r:w,Toll-like Receptor Cascades,0.0,1.0
w,Toll-like receptor signaling,0.0,1.0
k,Toll-like receptor signaling pathway,0.0,1.0
w,Toll-like receptor signaling related to MyD88,0.0,1.0
r,Toll Like Receptor TLR1:TLR2 Cascade,0.0,1.0
r,Toll Like Receptor TLR6:TLR2 Cascade,0.0,1.0
r,Toxicity of botulinum toxin type A (botA),0.0,1.0
r,Toxicity of botulinum toxin type B (botB),0.0,1.0
r,Toxicity of botulinum toxin type C (botC),0.0,1.0
r,Toxicity of botulinum toxin type D (botD),0.0,1.0
r,Toxicity of botulinum toxin type E (botE),0.0,1.0
r,Toxicity of botulinum toxin type F (botF),0.0,1.0
r,Toxicity of botulinum toxin type G (botG),0.0,1.0
r,Toxicity of tetanus toxin (tetX),0.0,1.0
k,Toxoplasmosis,0.0,1.0
w,TP53 network,0.0,1.0
r:w,TP53 Regulates Metabolic Genes,0.0,1.0
r,TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,0.0,1.0
r,TP53 Regulates Transcription of Caspase Activators and Caspases,0.0,1.0
r:w,TP53 Regulates Transcription of Cell Cycle Genes,0.0,1.0
r:w,TP53 Regulates Transcription of Cell Death Genes,0.0,1.0
r,TP53 Regulates Transcription of Death Receptors and Ligands,0.0,1.0
r:w,TP53 Regulates Transcription of DNA Repair Genes,0.0,1.0
r,TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,0.0,1.0
r,TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,0.0,1.0
r,TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,0.0,1.0
r,TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,0.0,1.0
r,TRAF3 deficiency - HSE,0.0,1.0
r,TRAF3-dependent IRF activation pathway,0.0,1.0
r,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,0.0,1.0
r,TRAF6-mediated induction of TAK1 complex within TLR4 complex,0.0,1.0
r,TRAF6 mediated IRF7 activation,0.0,1.0
r,TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,0.0,1.0
r,TRAF6 mediated NF-kB activation,0.0,1.0
r:w,Trafficking and processing of endosomal TLR,0.0,1.0
r,Trafficking of myristoylated proteins to the cilium,0.0,1.0
r:w,TRAIL  signaling,0.0,1.0
w,Transcriptional activation by NRF2 in response to phytochemicals,0.0,1.0
r,Transcriptional  activation of  cell cycle inhibitor p21 ,0.0,1.0
r,Transcriptional activation of mitochondrial biogenesis,0.0,1.0
r,Transcriptional activation of p53 responsive genes  ,0.0,1.0
r:w,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.0,1.0
r,Transcriptional and post-translational regulation of MITF-M expression and activity,0.0,1.0
w,Transcriptional cascade regulating adipogenesis,0.0,1.0
k,Transcriptional misregulation in cancer,0.0,1.0
r:w,Transcriptional Regulation by E2F6,0.0,1.0
r:w,Transcriptional Regulation by MECP2,0.0,1.0
r,Transcriptional Regulation by NPAS4,0.0,1.0
r:w,Transcriptional regulation by RUNX2,0.0,1.0
r:w,Transcriptional regulation by RUNX3,0.0,1.0
r,Transcriptional regulation by small RNAs,0.0,1.0
r:w,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.0,1.0
r,Transcriptional Regulation by TP53,0.0,1.0
r:w,Transcriptional Regulation by VENTX,0.0,1.0
r,Transcriptional regulation of brown and beige adipocyte differentiation,0.0,1.0
r,Transcriptional regulation of brown and beige adipocyte differentiation by EBF2,0.0,1.0
r:w,Transcriptional regulation of granulopoiesis,0.0,1.0
r:w,Transcriptional regulation of pluripotent stem cells,0.0,1.0
r:w,Transcriptional regulation of testis differentiation,0.0,1.0
w,Transcription co-factors SKI and SKIL protein partners,0.0,1.0
r,Transcription-Coupled Nucleotide Excision Repair (TC-NER),0.0,1.0
w,Transcription factor regulation in adipogenesis,0.0,1.0
w,Transcription factors regulate miRNAs related to cardiac hypertrophy,0.0,1.0
r:w,Transcription from mitochondrial promoters,0.0,1.0
r,Transcription of E2F targets under negative control by DREAM complex,0.0,1.0
r,Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1,0.0,1.0
r,Transcription of the HIV genome,0.0,1.0
r,Transfer of LPS from LBP carrier to CD14,0.0,1.0
r,Transferrin endocytosis and recycling,0.0,1.0
r:w,trans-Golgi Network Vesicle Budding,0.0,1.0
r,Translation,0.0,1.0
w,Translation factors,0.0,1.0
w,Translation inhibitors in chronically activated PDGFRA cells,0.0,1.0
r,Translation initiation complex formation,0.0,1.0
r,Translation of Replicase and Assembly of the Replication Transcription Complex,0.0,1.0
r,Translation of Structural Proteins,0.0,1.0
r,Translesion Synthesis by POLH,0.0,1.0
r,Translesion synthesis by POLI,0.0,1.0
r,Translesion synthesis by POLK,0.0,1.0
r,Translesion synthesis by REV1,0.0,1.0
r,Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template,0.0,1.0
r:w,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0,1.0
r,Translocation of ZAP-70 to Immunological synapse,0.0,1.0
r:w,Transmission across Electrical Synapses ,0.0,1.0
r,Transport and synthesis of PAPS,0.0,1.0
r,Transport of connexins along the secretory pathway,0.0,1.0
r,Transport of connexons to the plasma membrane,0.0,1.0
r,Transport of fatty acids,0.0,1.0
r,Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus,0.0,1.0
w,Transport of glycerol from adipocytes to liver by aquaporins,0.0,1.0
r,Transport of glycerol from adipocytes to the liver by Aquaporins,0.0,1.0
r:w,Transport of inorganic cations/anions and amino acids/oligopeptides,0.0,1.0
r,Transport of Mature mRNA derived from an Intron-Containing Transcript,0.0,1.0
r,Transport of Mature mRNA Derived from an Intronless Transcript,0.0,1.0
r,Transport of Mature mRNAs Derived from Intronless Transcripts,0.0,1.0
r,Transport of Mature Transcript to Cytoplasm,0.0,1.0
r,Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane,0.0,1.0
r,Transport of organic anions,0.0,1.0
r,Transport of RCbl within the body,0.0,1.0
r,Transport of Ribonucleoproteins into the Host Nucleus,0.0,1.0
r,Transport of the SLBP Dependant Mature mRNA,0.0,1.0
r,Transport of the SLBP independent Mature mRNA,0.0,1.0
r,Transport to the Golgi and subsequent modification,0.0,1.0
w,"Trans-sulfuration, one-carbon metabolism and related pathways",0.0,1.0
w,Trans-sulfuration pathway,0.0,1.0
w,Triacylglyceride synthesis,0.0,1.0
r,TRIF-mediated programmed cell death,0.0,1.0
r,TRIF (TICAM1)-mediated TLR4 signaling ,0.0,1.0
r,Triglyceride biosynthesis,0.0,1.0
r,Triglyceride catabolism,0.0,1.0
r:w,Triglyceride metabolism,0.0,1.0
r,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.0,1.0
r,TRKA activation by NGF,0.0,1.0
r:w,tRNA Aminoacylation,0.0,1.0
r,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0,1.0
r:w,tRNA modification in the mitochondrion,0.0,1.0
r:w,tRNA modification in the nucleus and cytosol,0.0,1.0
r,tRNA processing,0.0,1.0
r:w,tRNA processing in the mitochondrion,0.0,1.0
r:w,tRNA processing in the nucleus,0.0,1.0
w,TROP2 regulatory signaling,0.0,1.0
r,TRP channels,0.0,1.0
r,Truncations of AMER1 destabilize the destruction complex,0.0,1.0
r:w,Tryptophan catabolism,0.0,1.0
w,Tryptophan catabolism leading to NAD+ production,0.0,1.0
k:w,Tryptophan metabolism,0.0,1.0
k,Tuberculosis,0.0,1.0
w,Tumor suppressor activity of SMARCB1,0.0,1.0
w,Twelve loci associated with ADHD,0.0,1.0
r,TWIK-related alkaline pH activated K+ channel (TALK),0.0,1.0
r,TWIK related potassium channel (TREK),0.0,1.0
r,TWIK-related spinal cord K+ channel (TRESK),0.0,1.0
r,TWIK-releated acid-sensitive K+ channel (TASK),0.0,1.0
w,Type 2 papillary renal cell carcinoma,0.0,1.0
w,Type I collagen synthesis in the context of osteogenesis imperfecta,0.0,1.0
k,Type I diabetes mellitus,0.0,1.0
r,Type I hemidesmosome assembly,0.0,1.0
k:w,Type II diabetes mellitus,0.0,1.0
w,Type III interferon signaling,0.0,1.0
w,Type II interferon signaling,0.0,1.0
r,Type II Na+/Pi cotransporters,0.0,1.0
w,Type I interferon induction and signaling during SARS-CoV-2 infection,0.0,1.0
w,TYROBP causal network in microglia,0.0,1.0
r,Tyrosine catabolism,0.0,1.0
k,Tyrosine metabolism,0.0,1.0
w,Tyrosine metabolism and related disorders,0.0,1.0
r:w,TYSND1 cleaves peroxisomal proteins,0.0,1.0
r,Ubiquinol biosynthesis,0.0,1.0
k,Ubiquinone and other terpenoid-quinone biosynthesis,0.0,1.0
r,Ubiquitin-dependent degradation of Cyclin D,0.0,1.0
r,Ubiquitin Mediated Degradation of Phosphorylated Cdc25A,0.0,1.0
k,Ubiquitin mediated proteolysis,0.0,1.0
r,Ub-specific processing proteases,0.0,1.0
r,UCH proteinases,0.0,1.0
w,UDP-derived sugars synthesis in fibroblasts,0.0,1.0
w,Ultraconserved region 339 modulation of tumor suppressor microRNAs in cancer,0.0,1.0
r,"Unblocking of NMDA receptors, glutamate binding and activation",0.0,1.0
r,UNC93B1 deficiency - HSE,0.0,1.0
r,Uncoating of the HIV Virion,0.0,1.0
w,Unfolded Protein Response,0.0,1.0
r,Unfolded Protein Response (UPR),0.0,1.0
r,Unwinding of DNA,0.0,1.0
r,Uptake and actions of bacterial toxins,0.0,1.0
r:w,Uptake and function of anthrax toxins,0.0,1.0
r:w,Uptake and function of diphtheria toxin,0.0,1.0
r,Uptake of dietary cobalamins into enterocytes,0.0,1.0
r:w,Urea cycle,0.0,1.0
w,Urea cycle and associated pathways,0.0,1.0
w,Urea cycle and metabolism of amino groups,0.0,1.0
w,Urea cycle and related diseases,0.0,1.0
w,Urotensin-II-mediated signaling,0.0,1.0
r,Utilization of Ketone Bodies,0.0,1.0
k,"Valine, leucine and isoleucine biosynthesis",0.0,1.0
k,"Valine, leucine and isoleucine degradation",0.0,1.0
w,Valproic acid pathway,0.0,1.0
r,Variant SLC6A14 may confer susceptibility towards obesity,0.0,1.0
r,Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0
k,Various types of N-glycan biosynthesis,0.0,1.0
r,Vasopressin-like receptors,0.0,1.0
k:w,Vasopressin-regulated water reabsorption,0.0,1.0
r:w,Vasopressin regulates renal water homeostasis via Aquaporins,0.0,1.0
r,VEGF binds to VEGFR leading to receptor dimerization,0.0,1.0
r,VEGF ligand-receptor interactions,0.0,1.0
r,VEGFR2 mediated vascular permeability,0.0,1.0
r,Vesicle-mediated transport,0.0,1.0
k,Vibrio cholerae infection,0.0,1.0
r,Vif-mediated degradation of APOBEC3G,0.0,1.0
k,Viral carcinogenesis,0.0,1.0
k,Viral life cycle - HIV-1,0.0,1.0
r,Viral Messenger RNA Synthesis,0.0,1.0
r,Viral mRNA Translation,0.0,1.0
k,Viral myocarditis,0.0,1.0
k,Viral protein interaction with cytokine and cytokine receptor,0.0,1.0
r,Viral RNP Complexes in the Host Cell Nucleus,0.0,1.0
k,Virion - Adenovirus,0.0,1.0
k,"Virion - Ebolavirus, Lyssavirus and Morbillivirus",0.0,1.0
k,Virion - Flavivirus,0.0,1.0
k,Virion - Herpesvirus,0.0,1.0
k,Virion - Human immunodeficiency virus,0.0,1.0
k,Virion - Rotavirus,0.0,1.0
r,Virus Assembly and Release,0.0,1.0
r:w,Visual phototransduction,0.0,1.0
w,Vitamin A1 and A5/X pathways,0.0,1.0
w,Vitamin A and carotenoid metabolism,0.0,1.0
w,Vitamin B12 disorders,0.0,1.0
w,Vitamin B12 metabolism,0.0,1.0
r,Vitamin B1 (thiamin) metabolism,0.0,1.0
r,Vitamin B2 (riboflavin) metabolism,0.0,1.0
r,Vitamin B5 (pantothenate) metabolism,0.0,1.0
r,Vitamin B6 activation to pyridoxal phosphate,0.0,1.0
w,Vitamin B6-dependent and responsive disorders,0.0,1.0
k,Vitamin B6 metabolism,0.0,1.0
r,Vitamin C (ascorbate) metabolism,0.0,1.0
r:w,Vitamin D (calciferol) metabolism,0.0,1.0
k,Vitamin digestion and absorption,0.0,1.0
w,Vitamin D metabolism,0.0,1.0
w,Vitamin D receptor pathway,0.0,1.0
w,Vitamin D-sensitive calcium signaling in depression,0.0,1.0
r:w,Vitamin E,0.0,1.0
w,Vitamin K metabolism and activation of dependent proteins,0.0,1.0
r,Vitamins,0.0,1.0
w,Vitamins A and D - action mechanisms,0.0,1.0
r,VLDL assembly,0.0,1.0
r,VLDL clearance,0.0,1.0
r,VLDLR internalisation and degradation,0.0,1.0
r,Voltage gated Potassium channels,0.0,1.0
r,Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization,0.0,1.0
r,Vpr-mediated nuclear import of PICs,0.0,1.0
r,Vpu mediated degradation of CD4,0.0,1.0
r,vRNA Synthesis,0.0,1.0
r,vRNP Assembly,0.0,1.0
r,VxPx cargo-targeting to cilium,0.0,1.0
w,Warburg effect modulated by deubiquitinating enzymes and their substrates,0.0,1.0
r:w,Wax and plasmalogen biosynthesis,0.0,1.0
r,Wax biosynthesis,0.0,1.0
w,White fat cell differentiation,0.0,1.0
w,WikiPathways Tutorial: demo_step3,0.0,1.0
r,"WNT5A-dependent internalization of FZD2, FZD5 and ROR2",0.0,1.0
r:w,WNT5:FZD7-mediated leishmania damping,0.0,1.0
w,Wnt/Beta-catenin signaling inhibitors in current and past clinical trials,0.0,1.0
w,Wnt/beta-catenin signaling in leukemia,0.0,1.0
r:w,WNT ligand biogenesis and trafficking,0.0,1.0
r,WNT mediated activation of DVL,0.0,1.0
w,Wnt signaling in kidney disease,0.0,1.0
r,XAV939 stabilizes AXIN,0.0,1.0
r:w,XBP1(S) activates chaperone genes,0.0,1.0
r,Xenobiotics,0.0,1.0
r:w,YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.0,1.0
r,ZBP1(DAI) mediated induction of type I IFNs,0.0,1.0
r,Z-decay: degradation of maternal mRNAs by zygotically expressed factors,0.0,1.0
r,Zinc efflux and compartmentalization by the SLC30 family,0.0,1.0
w,Zinc homeostasis,0.0,1.0
r,Zinc influx into cells by the SLC39 gene family,0.0,1.0
r,Zinc transporters,0.0,1.0
r,Zygotic genome activation (ZGA),0.0,1.0
